[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIXzIIQzd-i0vUgnUht31cqq4xaEWJ1o2BmdsPTrp9u4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":70,"rows":77},"MedImmune LLC",[4],270,false,7,27,764204,17,13,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Healthy",34,{"name":18,"count":19},"Influenza",33,{"name":21,"count":22},"Asthma",22,{"name":24,"count":25},"Cancer",12,{"name":27,"count":28},"Advanced Solid Tumors",11,{"name":30,"count":31},"Respiratory Syncytial Virus Infections",9,{"name":33,"count":8},"Type 2 Diabetes Mellitus",{"name":35,"count":8},"Rheumatoid Arthritis",[37,42,46,51,56,61,66],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01843374","Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","2016-01-24","Tremelimumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":41},"NCT02519348","A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","2020-11-06",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03381274","Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","2021-05-24","Oleclumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT02671435","A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","2021-10-26","Monalizumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04068610","COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","2022-10-10","Durvalumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03530397","A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors","2025-07-14","MEDI5752",{"nctId":67,"briefTitle":68,"date":69,"intervention":65},"NCT04522323","A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma","2025-09-26",[71,72,73,74,75,76],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[78,280,321,419,464,487,505,523,541,559,577,609,641,659,677,695,713,731,764,798,829,856,874,897,920,944,968,990,1015,1033,1174,1210,1258,1302,1328,1363,1396,1418,1448,1470,1494,1512,1530,1548,1572,1596,1614,1740,1827,1880,1947,1998,2054,2102,2146,2196,2228,2254,2297,2338,2384,2419,2455,2477,2520,2552,2585,2616,2638,2660,2693,2715,2742,2775,2799,2817,2843,2861,2879,2903,2921,2939,2957,2975,3002,3020,3045,3068,3093,3111,3129,3147,3165,3191,3209,3227,3250,3268,3291,3309,3334,3360,3378,3396,3414,3432,3456,3474,3492,3510,3528,3553,3571,3592,3615,3640,3658,3681,3699,3717,3735,3753,3771,3789,3812,3834,3859,3886,3904,3922,3940,3965,3983,4001,4024,4042,4066,4089,4107,4125,4150,4168,4186,4204,4222,4250,4268,4286,4310,4328,4346,4374,4392,4410,4428,4455,4473,4491,4509,4531,4553,4571,4598,4616,4634,4657,4683,4701,4725,4743,4761,4788,4806,4824,4842,4860,4878,4896,4914,4937,4955,4979,4997,5030,5067,5089,5111,5133,5161,5200,5230,5256,5286,5317,5348,5372,5390,5408,5426,5444,5462,5484,5509,5534,5552,5575,5597,5623,5641,5659,5686,5704,5722,5740,5765,5783,5801,5819,5845,5863,5881,5899,5925,5943,5961,5979,5997,6022,6040,6058,6076,6106,6124,6142,6160,6178,6196,6214,6238,6256,6274,6292,6316,6337,6360,6387,6405,6423,6441,6464,6482,6503,6532,6550,6568,6586,6604,6622,6640,6664,6694,6712,6730,6748,6766,6784,6802,6825,6843,6870,6888,6906,6924,6949,6971,6997,7015,7033,7051,7069,7087,7112,7130,7152,7170,7188,7206,7224,7249,7267,7285,7303,7321,7342,7360,7383,7466,7539,7565,7602,7624,7647,7671],{"intervention":60,"totalTrials":79,"cells":80},16,{"EARLY_PHASE1":81,"PHASE1":84,"PHASE2":176,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":82,"activeCount":83},[],0,{"trials":85,"activeCount":83},[86,97,108,120,131,143,153,164],{"nctId":87,"briefTitle":88,"status":89,"phases":90,"primaryCompletion":91,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":95},"NCT02900157","Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors","COMPLETED",[72],"2020-01-23","2016-08-09",42,[27],[96,60],"MEDI9090",{"nctId":98,"briefTitle":99,"status":89,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NCT02503774","MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.",[72],"2021-01-22","2023-03-07","2015-07-24",192,[106],"Solid Tumors",[50,60],{"nctId":109,"briefTitle":110,"status":89,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT02027961","Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",[72],"2018-04-24","2013-12-20",68,[116],"Melanoma",[60,118,119],"Dabrafenib","Trametinib",{"nctId":121,"briefTitle":122,"status":89,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT02705482","A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors",[72],"2019-08-07","2016-03-30",58,[128],"Select Advanced Solid Tumors",[130,41,60],"MEDI0562",{"nctId":132,"briefTitle":133,"status":89,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT04261075","IPH5201 as Monotherapy or in Combination With Durvalumab +\u002F- Oleclumab in Subjects With Advanced Solid Tumors.",[72],"2022-06-16","2020-03-03",57,[27],[140,141,142],"IPH5201","durvalumab","oleclumab",{"nctId":144,"briefTitle":145,"status":89,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT03946800","A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors",[72],"2023-08-24","2019-05-08",61,[106,24],[152,60],"MEDI1191",{"nctId":154,"briefTitle":155,"status":89,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT03889275","A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors",[72],"2021-11-19","2022-12-12","2019-10-24",39,[27],[163,60],"MEDI5395",{"nctId":165,"briefTitle":166,"status":167,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT02556463","A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and\u002For Palliative Radiation in Subjects With Solid Tumors","TERMINATED",[72],"2018-10-26","2015-11-04",53,[106,173,24],"CTCL",[175,141],"MEDI9197",{"trials":177,"activeCount":273,"soonestReadout":45},[178,189,197,209,222,235,249,257],{"nctId":52,"briefTitle":53,"status":179,"phases":180,"primaryCompletion":54,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"ACTIVE_NOT_RECRUITING",[72,73],"2025-09-01","2016-02-22",383,[27],[55,60,186,187,188],"Cetuximab","mFOLFOX6","Bevacizumab",{"nctId":57,"briefTitle":58,"status":179,"phases":190,"primaryCompletion":59,"completion":191,"start":192,"enrollment":149,"conditions":193,"interventions":195},[72,73],"2026-11-24","2019-09-13",[194],"Metastatic Microsatellite-stable Colorectal Cancer",[60,50,196,188],"FOLFOX",{"nctId":198,"briefTitle":199,"status":89,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":207},"NCT03162224","Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent\u002FMetastatic Head and Neck Cancer",[72,73],"2021-03-19","2017-06-26",35,[205,206],"Head and Neck Cancer","Human Papilloma Virus",[208,60],"MEDI0457",{"nctId":210,"briefTitle":211,"status":89,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":220},"NCT03794544","Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer",[73],"2021-01-13","2019-03-08",84,[217,218,219],"Resectable","Early-stage","NSCLC",[60,50,55,221],"Danvatirsen",{"nctId":223,"briefTitle":224,"status":89,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":232},"NCT03822351","Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC",[73],"2023-07-18","2018-12-19",189,[230,231],"Stage III Non-small Cell Lung Cancer","Unresectable",[233,60,234],"Durvalumab + Oleclumab","Durvalumab + Monalizumab",{"nctId":236,"briefTitle":237,"status":89,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":246},"NCT02118337","A Phase 1\u002F2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",[72,73],"2020-03-17","2014-05-19",97,[243,244,245],"Select Advanced Malignancies","Kidney Cancer","Clear Cell Renal Cell Carcinoma",[247,60,248],"MEDI0680","Nivolumab",{"nctId":43,"briefTitle":44,"status":179,"phases":250,"primaryCompletion":45,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},[73],"2026-04-01","2015-10-19",433,[255],"Hepatocellular Carcinoma",[41,60,188],{"nctId":258,"briefTitle":259,"status":89,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT03611556","MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.",[72,73],"2022-07-22","2018-06-21",213,[265,266],"Carcinoma","Metastatic Pancreatic Adenocarcinoma",[50,60,268,269,270,271,272],"Gemcitabine","Nab-paclitaxel","Oxaliplatin","Folinic acid","5-FU",3,{"trials":275,"activeCount":83},[],{"trials":277,"activeCount":83},[],{"trials":279,"activeCount":83},[],{"intervention":188,"totalTrials":281,"cells":282},4,{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":301,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":284,"activeCount":83},[],{"trials":286,"activeCount":83},[287],{"nctId":288,"briefTitle":289,"status":89,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT01248949","A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors",[72],"2015-07","2015-10","2010-10",162,[27,296],"Advanced Recurrent Ovarian Tumors",[298,188,299,300],"MEDI3617","Paclitaxel","Carboplatin",{"trials":302,"activeCount":273,"soonestReadout":45},[303,307,311],{"nctId":52,"briefTitle":53,"status":179,"phases":304,"primaryCompletion":54,"completion":181,"start":182,"enrollment":183,"conditions":305,"interventions":306},[72,73],[27],[55,60,186,187,188],{"nctId":57,"briefTitle":58,"status":179,"phases":308,"primaryCompletion":59,"completion":191,"start":192,"enrollment":149,"conditions":309,"interventions":310},[72,73],[194],[60,50,196,188],{"nctId":43,"briefTitle":44,"status":179,"phases":312,"primaryCompletion":45,"completion":251,"start":252,"enrollment":253,"conditions":313,"interventions":314},[73],[255],[41,60,188],{"trials":316,"activeCount":83},[],{"trials":318,"activeCount":83},[],{"trials":320,"activeCount":83},[],{"intervention":41,"totalTrials":31,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":386,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":324,"activeCount":83},[],{"trials":326,"activeCount":83},[327,339,348,352,364,375],{"nctId":328,"briefTitle":329,"status":89,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT02262741","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer",[72],"2017-09-21","2014-10-15",71,[335],"Squamous Cell Carcinoma of the Head and Neck",[337,338],"MEDI4736","tremelimumab",{"nctId":340,"briefTitle":341,"status":89,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT02261220","A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors",[72],"2020-01-27","2014-10-13",380,[27],[337,338],{"nctId":121,"briefTitle":122,"status":89,"phases":349,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":350,"interventions":351},[72],[128],[130,41,60],{"nctId":353,"briefTitle":354,"status":89,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT02117219","Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome",[72],"2019-04-30","2014-05-20",67,[360],"Myelodysplastic Syndrome",[362,363,338],"MEDI4736 Evaluate MEDI4736 in MDS","VIDAZA",{"nctId":365,"briefTitle":366,"status":89,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":373},"NCT02549651","MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed\u002FRefractory DLBCL (D4190C00023)",[72],"2019-02-04","2016-07-13",32,[372],"Diffuse Large B-Cell Lymphoma",[337,338,374],"AZD9150",{"nctId":376,"briefTitle":377,"status":89,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":385},"NCT02000947","A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer",[72],"2019-09-17","2013-10-25",459,[219,383,384],"Non-small Cell Lung Cancer","Lung Cancer",[337,41,338],{"trials":387,"activeCount":412,"soonestReadout":40},[388,400,408],{"nctId":389,"briefTitle":390,"status":89,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT02340975","A Phase 1b\u002F2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",[72,73],"2019-04-29","2015-03-31",114,[396],"Gastric or Gastroesophageal Junction Adenocarcinoma",[398,398,337,41,399,398],"MEDI4736 + tremelimumab","MEDI4736+tremelimumab",{"nctId":38,"briefTitle":39,"status":179,"phases":401,"primaryCompletion":40,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},[73],"2026-06-30","2013-05-17",571,[406],"Unresectable Pleural or Peritoneal Malignant Mesothelioma",[41],{"nctId":43,"briefTitle":44,"status":179,"phases":409,"primaryCompletion":45,"completion":251,"start":252,"enrollment":253,"conditions":410,"interventions":411},[73],[255],[41,60,188],2,{"trials":414,"activeCount":83},[],{"trials":416,"activeCount":83},[],{"trials":418,"activeCount":83},[],{"intervention":50,"totalTrials":420,"cells":421},6,{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":434,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":423,"activeCount":83},[],{"trials":425,"activeCount":83},[426,430],{"nctId":98,"briefTitle":99,"status":89,"phases":427,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":428,"interventions":429},[72],[106],[50,60],{"nctId":132,"briefTitle":133,"status":89,"phases":431,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":432,"interventions":433},[72],[27],[140,141,142],{"trials":435,"activeCount":412,"soonestReadout":49},[436,440,450,454],{"nctId":57,"briefTitle":58,"status":179,"phases":437,"primaryCompletion":59,"completion":191,"start":192,"enrollment":149,"conditions":438,"interventions":439},[72,73],[194],[60,50,196,188],{"nctId":47,"briefTitle":48,"status":179,"phases":441,"primaryCompletion":49,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":447},[72,73],"2026-04-16","2018-05-08",43,[446],"Carcinoma, Non-Small-Cell Lung",[50,448,449],"Osimertinib","AZD4635",{"nctId":210,"briefTitle":211,"status":89,"phases":451,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":452,"interventions":453},[73],[217,218,219],[60,50,55,221],{"nctId":258,"briefTitle":259,"status":89,"phases":455,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":456,"interventions":457},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":459,"activeCount":83},[],{"trials":461,"activeCount":83},[],{"trials":463,"activeCount":83},[],{"intervention":55,"totalTrials":412,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":467,"activeCount":83},[],{"trials":469,"activeCount":83},[],{"trials":471,"activeCount":480,"soonestReadout":54},[472,476],{"nctId":52,"briefTitle":53,"status":179,"phases":473,"primaryCompletion":54,"completion":181,"start":182,"enrollment":183,"conditions":474,"interventions":475},[72,73],[27],[55,60,186,187,188],{"nctId":210,"briefTitle":211,"status":89,"phases":477,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":478,"interventions":479},[73],[217,218,219],[60,50,55,221],1,{"trials":482,"activeCount":83},[],{"trials":484,"activeCount":83},[],{"trials":486,"activeCount":83},[],{"intervention":186,"totalTrials":480,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":83},[],{"trials":492,"activeCount":83},[],{"trials":494,"activeCount":480,"soonestReadout":54},[495],{"nctId":52,"briefTitle":53,"status":179,"phases":496,"primaryCompletion":54,"completion":181,"start":182,"enrollment":183,"conditions":497,"interventions":498},[72,73],[27],[55,60,186,187,188],{"trials":500,"activeCount":83},[],{"trials":502,"activeCount":83},[],{"trials":504,"activeCount":83},[],{"intervention":187,"totalTrials":480,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":83},[],{"trials":510,"activeCount":83},[],{"trials":512,"activeCount":480,"soonestReadout":54},[513],{"nctId":52,"briefTitle":53,"status":179,"phases":514,"primaryCompletion":54,"completion":181,"start":182,"enrollment":183,"conditions":515,"interventions":516},[72,73],[27],[55,60,186,187,188],{"trials":518,"activeCount":83},[],{"trials":520,"activeCount":83},[],{"trials":522,"activeCount":83},[],{"intervention":196,"totalTrials":480,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":526,"activeCount":83},[],{"trials":528,"activeCount":83},[],{"trials":530,"activeCount":480,"soonestReadout":59},[531],{"nctId":57,"briefTitle":58,"status":179,"phases":532,"primaryCompletion":59,"completion":191,"start":192,"enrollment":149,"conditions":533,"interventions":534},[72,73],[194],[60,50,196,188],{"trials":536,"activeCount":83},[],{"trials":538,"activeCount":83},[],{"trials":540,"activeCount":83},[],{"intervention":448,"totalTrials":480,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":544,"activeCount":83},[],{"trials":546,"activeCount":83},[],{"trials":548,"activeCount":480,"soonestReadout":49},[549],{"nctId":47,"briefTitle":48,"status":179,"phases":550,"primaryCompletion":49,"completion":442,"start":443,"enrollment":444,"conditions":551,"interventions":552},[72,73],[446],[50,448,449],{"trials":554,"activeCount":83},[],{"trials":556,"activeCount":83},[],{"trials":558,"activeCount":83},[],{"intervention":449,"totalTrials":480,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":562,"activeCount":83},[],{"trials":564,"activeCount":83},[],{"trials":566,"activeCount":480,"soonestReadout":49},[567],{"nctId":47,"briefTitle":48,"status":179,"phases":568,"primaryCompletion":49,"completion":442,"start":443,"enrollment":444,"conditions":569,"interventions":570},[72,73],[446],[50,448,449],{"trials":572,"activeCount":83},[],{"trials":574,"activeCount":83},[],{"trials":576,"activeCount":83},[],{"intervention":65,"totalTrials":412,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":580,"activeCount":83},[],{"trials":582,"activeCount":412,"soonestReadout":64},[583,591],{"nctId":67,"briefTitle":68,"status":179,"phases":584,"primaryCompletion":69,"completion":69,"start":585,"enrollment":358,"conditions":586,"interventions":588},[72],"2020-08-05",[587],"Advanced Renal Cell Carcinoma",[65,589,590],"Axitinib","Lenvatinib",{"nctId":62,"briefTitle":63,"status":179,"phases":592,"primaryCompletion":64,"completion":593,"start":112,"enrollment":594,"conditions":595,"interventions":597},[72],"2027-11-30",400,[596],"Selected Advanced Solid Tumors",[65,598,300,599,600],"Pemetrexed","Pembrolizumab","Paclitaxel or Nab-Paclitaxel",{"trials":602,"activeCount":83},[],{"trials":604,"activeCount":83},[],{"trials":606,"activeCount":83},[],{"trials":608,"activeCount":83},[],{"intervention":300,"totalTrials":273,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":623,"PHASE3":635,"PHASE4":637,"NA":639},{"trials":612,"activeCount":83},[],{"trials":614,"activeCount":480,"soonestReadout":64},[615,619],{"nctId":288,"briefTitle":289,"status":89,"phases":616,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":617,"interventions":618},[72],[27,296],[298,188,299,300],{"nctId":62,"briefTitle":63,"status":179,"phases":620,"primaryCompletion":64,"completion":593,"start":112,"enrollment":594,"conditions":621,"interventions":622},[72],[596],[65,598,300,599,600],{"trials":624,"activeCount":83},[625],{"nctId":626,"briefTitle":627,"status":167,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":633},"NCT01268059","A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer",[72,73],"2013-09-11","2010-12-16",99,[383],[300,299,634],"MEDI-575",{"trials":636,"activeCount":83},[],{"trials":638,"activeCount":83},[],{"trials":640,"activeCount":83},[],{"intervention":589,"totalTrials":480,"cells":642},{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":644,"activeCount":83},[],{"trials":646,"activeCount":480,"soonestReadout":69},[647],{"nctId":67,"briefTitle":68,"status":179,"phases":648,"primaryCompletion":69,"completion":69,"start":585,"enrollment":358,"conditions":649,"interventions":650},[72],[587],[65,589,590],{"trials":652,"activeCount":83},[],{"trials":654,"activeCount":83},[],{"trials":656,"activeCount":83},[],{"trials":658,"activeCount":83},[],{"intervention":590,"totalTrials":480,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":662,"activeCount":83},[],{"trials":664,"activeCount":480,"soonestReadout":69},[665],{"nctId":67,"briefTitle":68,"status":179,"phases":666,"primaryCompletion":69,"completion":69,"start":585,"enrollment":358,"conditions":667,"interventions":668},[72],[587],[65,589,590],{"trials":670,"activeCount":83},[],{"trials":672,"activeCount":83},[],{"trials":674,"activeCount":83},[],{"trials":676,"activeCount":83},[],{"intervention":598,"totalTrials":480,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":680,"activeCount":83},[],{"trials":682,"activeCount":480,"soonestReadout":64},[683],{"nctId":62,"briefTitle":63,"status":179,"phases":684,"primaryCompletion":64,"completion":593,"start":112,"enrollment":594,"conditions":685,"interventions":686},[72],[596],[65,598,300,599,600],{"trials":688,"activeCount":83},[],{"trials":690,"activeCount":83},[],{"trials":692,"activeCount":83},[],{"trials":694,"activeCount":83},[],{"intervention":599,"totalTrials":480,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":698,"activeCount":83},[],{"trials":700,"activeCount":480,"soonestReadout":64},[701],{"nctId":62,"briefTitle":63,"status":179,"phases":702,"primaryCompletion":64,"completion":593,"start":112,"enrollment":594,"conditions":703,"interventions":704},[72],[596],[65,598,300,599,600],{"trials":706,"activeCount":83},[],{"trials":708,"activeCount":83},[],{"trials":710,"activeCount":83},[],{"trials":712,"activeCount":83},[],{"intervention":600,"totalTrials":480,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":716,"activeCount":83},[],{"trials":718,"activeCount":480,"soonestReadout":64},[719],{"nctId":62,"briefTitle":63,"status":179,"phases":720,"primaryCompletion":64,"completion":593,"start":112,"enrollment":594,"conditions":721,"interventions":722},[72],[596],[65,598,300,599,600],{"trials":724,"activeCount":83},[],{"trials":726,"activeCount":83},[],{"trials":728,"activeCount":83},[],{"trials":730,"activeCount":83},[],{"intervention":732,"totalTrials":412,"cells":733},"Monovalent Influenza Vaccine",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":762},{"trials":735,"activeCount":83},[],{"trials":737,"activeCount":83},[],{"trials":739,"activeCount":83},[],{"trials":741,"activeCount":83},[],{"trials":743,"activeCount":83},[744,753],{"nctId":745,"briefTitle":746,"status":89,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":752},"NCT03158038","Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season",[75],"2017-12-14","2017-05-30",300,[18,15],[732],{"nctId":754,"briefTitle":755,"status":89,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":761},"NCT02743117","Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season",[75],"2016-11-30","2016-05-02",301,[18,15],[732],{"trials":763,"activeCount":83},[],{"intervention":765,"totalTrials":412,"cells":766},"Trivalent Influenza Virus Vaccine",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":796},{"trials":768,"activeCount":83},[],{"trials":770,"activeCount":83},[],{"trials":772,"activeCount":83},[],{"trials":774,"activeCount":83},[],{"trials":776,"activeCount":83},[777,786],{"nctId":778,"briefTitle":779,"status":89,"phases":780,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT01579916","A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults",[75],"2012-11","2012-05",303,[18],[765],{"nctId":787,"briefTitle":788,"status":89,"phases":789,"primaryCompletion":790,"completion":791,"start":792,"enrollment":750,"conditions":793,"interventions":794},"NCT00677820","A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine",[75],"2008-07","2008-12","2008-06",[18],[795],"Trivalent influenza virus vaccine",{"trials":797,"activeCount":83},[],{"intervention":799,"totalTrials":412,"cells":800},"Trivalent Influenza Vaccine",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":827},{"trials":802,"activeCount":83},[],{"trials":804,"activeCount":83},[],{"trials":806,"activeCount":83},[],{"trials":808,"activeCount":83},[],{"trials":810,"activeCount":83},[811,819],{"nctId":812,"briefTitle":813,"status":89,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":750,"conditions":817,"interventions":818},"NCT01859143","Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults",[75],"2013-12","2013-05",[18,15],[799],{"nctId":820,"briefTitle":821,"status":89,"phases":822,"primaryCompletion":823,"completion":823,"start":824,"enrollment":759,"conditions":825,"interventions":826},"NCT02473510","Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season",[75],"2016-01","2015-06",[18,15],[799],{"trials":828,"activeCount":83},[],{"intervention":830,"totalTrials":480,"cells":831},"Lyophilized Palivizumab",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":854},{"trials":833,"activeCount":83},[],{"trials":835,"activeCount":83},[],{"trials":837,"activeCount":83},[],{"trials":839,"activeCount":83},[],{"trials":841,"activeCount":83},[842],{"nctId":843,"briefTitle":844,"status":89,"phases":845,"primaryCompletion":846,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT00233064","Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)",[75],"2007-10","2007-11","2005-10",417,[851],"Chronic Lung Disease",[830,853],"Liquid Palivizumab",{"trials":855,"activeCount":83},[],{"intervention":853,"totalTrials":480,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":872},{"trials":859,"activeCount":83},[],{"trials":861,"activeCount":83},[],{"trials":863,"activeCount":83},[],{"trials":865,"activeCount":83},[],{"trials":867,"activeCount":83},[868],{"nctId":843,"briefTitle":844,"status":89,"phases":869,"primaryCompletion":846,"completion":847,"start":848,"enrollment":849,"conditions":870,"interventions":871},[75],[851],[830,853],{"trials":873,"activeCount":83},[],{"intervention":875,"totalTrials":480,"cells":876},"Bivalent influenza vaccine",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":895},{"trials":878,"activeCount":83},[],{"trials":880,"activeCount":83},[],{"trials":882,"activeCount":83},[],{"trials":884,"activeCount":83},[],{"trials":886,"activeCount":83},[887],{"nctId":888,"briefTitle":889,"status":89,"phases":890,"primaryCompletion":891,"completion":891,"start":892,"enrollment":750,"conditions":893,"interventions":894},"NCT03564444","D2560C00015 FluMist Annual Safety Study 2018",[75],"2018-12-27","2018-06-06",[18,15],[875],{"trials":896,"activeCount":83},[],{"intervention":898,"totalTrials":480,"cells":899},"Monovalent influenza virus vaccine",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":908,"NA":918},{"trials":901,"activeCount":83},[],{"trials":903,"activeCount":83},[],{"trials":905,"activeCount":83},[],{"trials":907,"activeCount":83},[],{"trials":909,"activeCount":83},[910],{"nctId":911,"briefTitle":912,"status":89,"phases":913,"primaryCompletion":914,"completion":915,"start":914,"enrollment":750,"conditions":916,"interventions":917},"NCT00873912","A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine",[75],"2009-05","2009-12",[15],[898],{"trials":919,"activeCount":83},[],{"intervention":921,"totalTrials":480,"cells":922},"Monovalent Frozen FluMist®",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":942},{"trials":924,"activeCount":83},[],{"trials":926,"activeCount":83},[],{"trials":928,"activeCount":83},[],{"trials":930,"activeCount":83},[],{"trials":932,"activeCount":83},[933],{"nctId":934,"briefTitle":935,"status":89,"phases":936,"primaryCompletion":937,"completion":938,"start":939,"enrollment":750,"conditions":940,"interventions":941},"NCT01104493","A Clinical Study to Assess the Safety of a New Influenza Vaccine",[75],"2010-06","2010-12","2010-05",[15],[921],{"trials":943,"activeCount":83},[],{"intervention":945,"totalTrials":480,"cells":946},"MEDI3414 [Influenza A\u002FH1N1 live attenuated, intranasal]",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":966},{"trials":948,"activeCount":83},[],{"trials":950,"activeCount":83},[],{"trials":952,"activeCount":83},[],{"trials":954,"activeCount":83},[],{"trials":956,"activeCount":83},[957],{"nctId":958,"briefTitle":959,"status":89,"phases":960,"primaryCompletion":961,"completion":962,"start":963,"enrollment":750,"conditions":964,"interventions":965},"NCT00945893","A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults",[75],"2009-09","2010-03","2009-08",[15],[945],{"trials":967,"activeCount":83},[],{"intervention":969,"totalTrials":480,"cells":970},"MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":988},{"trials":972,"activeCount":83},[],{"trials":974,"activeCount":83},[],{"trials":976,"activeCount":83},[],{"trials":978,"activeCount":83},[],{"trials":980,"activeCount":83},[981],{"nctId":982,"briefTitle":983,"status":89,"phases":984,"primaryCompletion":961,"completion":962,"start":963,"enrollment":985,"conditions":986,"interventions":987},"NCT00946101","A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age",[75],326,[18],[969],{"trials":989,"activeCount":83},[],{"intervention":991,"totalTrials":480,"cells":992},"FluMist trivalent",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1013},{"trials":994,"activeCount":83},[],{"trials":996,"activeCount":83},[],{"trials":998,"activeCount":83},[],{"trials":1000,"activeCount":83},[],{"trials":1002,"activeCount":83},[1003],{"nctId":1004,"briefTitle":1005,"status":89,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1011},"NCT03143101","Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to \u003C48 Months of Age",[75],"2017-09-29","2017-05-08",200,[18,15],[991,1012,1012],"FluMist Quadrivalent",{"trials":1014,"activeCount":83},[],{"intervention":1012,"totalTrials":480,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1031},{"trials":1018,"activeCount":83},[],{"trials":1020,"activeCount":83},[],{"trials":1022,"activeCount":83},[],{"trials":1024,"activeCount":83},[],{"trials":1026,"activeCount":83},[1027],{"nctId":1004,"briefTitle":1005,"status":89,"phases":1028,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1029,"interventions":1030},[75],[18,15],[991,1012,1012],{"trials":1032,"activeCount":83},[],{"intervention":1034,"totalTrials":1035,"cells":1036},"CAIV-T",14,{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1060,"PHASE3":1100,"PHASE4":1170,"NA":1172},{"trials":1038,"activeCount":83},[],{"trials":1040,"activeCount":83},[1041,1050],{"nctId":1042,"briefTitle":1043,"status":89,"phases":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1049},"NCT00192348","A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants",[72],"2002-12","2002-05",120,[15],[1034],{"nctId":1051,"briefTitle":1052,"status":89,"phases":1053,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT00224783","Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults",[72],"2002-09","2002-08",45,[1058],"Healthy Japanese Male Adults",[1034],{"trials":1061,"activeCount":83},[1062,1071,1081,1091],{"nctId":1063,"briefTitle":1064,"status":89,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1070},"NCT00111579","Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)",[73],"2006-01","2005-05",52,[18],[1034],{"nctId":1072,"briefTitle":1073,"status":89,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT00192166","Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months",[73],"2003-03","2003-05","2002-10",1200,[18],[1034],{"nctId":1082,"briefTitle":1083,"status":89,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT00192309","Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.",[73],"2001-12","2001-09",31,[18],[1034,1090],"TIV",{"nctId":1092,"briefTitle":1093,"status":89,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1099},"NCT00192270","Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children",[73],"2001-01","2000-10",498,[15],[1034],{"trials":1101,"activeCount":83},[1102,1111,1118,1126,1133,1142,1153,1161],{"nctId":1103,"briefTitle":1104,"status":89,"phases":1105,"completion":1106,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1110},"NCT00192400","Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.",[74],"2002-11","2002-03",2160,[15],[1034],{"nctId":1112,"briefTitle":1113,"status":89,"phases":1114,"completion":1085,"start":1086,"enrollment":1115,"conditions":1116,"interventions":1117},"NCT00192426","Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.",[74],2400,[18],[1034],{"nctId":1119,"briefTitle":1120,"status":89,"phases":1121,"completion":1122,"start":1123,"enrollment":1047,"conditions":1124,"interventions":1125},"NCT00192231","Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)",[74],"2001-06","2001-04",[18],[1034],{"nctId":1127,"briefTitle":1128,"status":89,"phases":1129,"start":1130,"enrollment":1009,"conditions":1131,"interventions":1132},"NCT00192361","Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)",[74],"1999-11",[18],[1034],{"nctId":1134,"briefTitle":1135,"status":89,"phases":1136,"completion":1137,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1141},"NCT00192192","Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults",[74],"2000-12","2000-11",20,[18],[1034],{"nctId":1143,"briefTitle":1144,"status":89,"phases":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1150},"NCT00192335","Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants",[74],"2005-02","2004-07",890,[15],[1034,1151,1152],"CAIVT","FluMist",{"nctId":1154,"briefTitle":1155,"status":89,"phases":1156,"completion":1157,"start":1123,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT00217230","Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older",[74],"2001-11",3000,[18],[1034],{"nctId":1162,"briefTitle":1163,"status":89,"phases":1164,"primaryCompletion":1165,"completion":1046,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT00192283","Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers",[74],"2002-04","2000-09",2903,[18],[1034],{"trials":1171,"activeCount":83},[],{"trials":1173,"activeCount":83},[],{"intervention":1175,"totalTrials":273,"cells":1176},"CAIV-T, Liquid",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1190,"PHASE4":1206,"NA":1208},{"trials":1178,"activeCount":83},[],{"trials":1180,"activeCount":83},[],{"trials":1182,"activeCount":83},[1183],{"nctId":1184,"briefTitle":1185,"status":89,"phases":1186,"completion":1085,"start":1086,"enrollment":1187,"conditions":1188,"interventions":1189},"NCT00192387","Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)",[73],60,[18],[1175],{"trials":1191,"activeCount":83},[1192,1198],{"nctId":1193,"briefTitle":1194,"status":89,"phases":1195,"completion":1077,"start":1166,"enrollment":1158,"conditions":1196,"interventions":1197},"NCT00192244","Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children",[74],[15],[1175],{"nctId":1199,"briefTitle":1200,"status":89,"phases":1201,"completion":1106,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT00192374","Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children",[74],"2002-02",1920,[15],[1175],{"trials":1207,"activeCount":83},[],{"trials":1209,"activeCount":83},[],{"intervention":1211,"totalTrials":273,"cells":1212},"Moxetumomab Pasudotox",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1228,"PHASE3":1240,"PHASE4":1254,"NA":1256},{"trials":1214,"activeCount":83},[],{"trials":1216,"activeCount":83},[1217],{"nctId":1218,"briefTitle":1219,"status":89,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT00586924","A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia",[72],"2015-05-06","2007-05-10",49,[1225],"Hairy Cell Leukemia",[1211,1211,1211,1211,1227,1211],"CAT 8015",{"trials":1229,"activeCount":83},[1230],{"nctId":1231,"briefTitle":1232,"status":167,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1239},"NCT02227108","Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma",[73],"2015-11","2014-08",37,[1238],"B-Cell Pediatric ALL",[1211],{"trials":1241,"activeCount":83},[1242],{"nctId":1243,"briefTitle":1244,"status":89,"phases":1245,"primaryCompletion":1246,"completion":392,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1251},"NCT01829711","Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia",[74],"2017-05-24","2013-04-29",80,[1250],"Leukemia, Hairy Cell",[1252,1253],"Moxetumomab pasudotox","IV Bag Protectant for Moxetumomab pasudotox",{"trials":1255,"activeCount":83},[],{"trials":1257,"activeCount":83},[],{"intervention":1259,"totalTrials":273,"cells":1260},"FluMist\u002FB\u002FYamagata",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1298,"NA":1300},{"trials":1262,"activeCount":83},[],{"trials":1264,"activeCount":83},[],{"trials":1266,"activeCount":83},[],{"trials":1268,"activeCount":83},[1269,1280,1290],{"nctId":1270,"briefTitle":1271,"status":89,"phases":1272,"primaryCompletion":1273,"completion":938,"start":962,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT01091246","A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children",[74],"2010-07",2312,[1276],"Healthy or Stable Chronic Illness",[1278,1259,1279],"Q\u002FLAIV","FluMist\u002FB\u002FVictoria",{"nctId":1281,"briefTitle":1282,"status":89,"phases":1283,"primaryCompletion":914,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT00860067","A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age",[73,74],"2009-10","2009-03",1800,[1288],"Healthy or Stable Underlying Chronic Medical Condition",[1278,1259,1279],{"nctId":1291,"briefTitle":1292,"status":89,"phases":1293,"primaryCompletion":1294,"completion":962,"start":963,"enrollment":1286,"conditions":1295,"interventions":1296},"NCT00952705","A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age",[74],"2010-01",[1288],[1297,1259,1279],"Q\u002FLAIV-BFS",{"trials":1299,"activeCount":83},[],{"trials":1301,"activeCount":83},[],{"intervention":1279,"totalTrials":273,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1324,"NA":1326},{"trials":1305,"activeCount":83},[],{"trials":1307,"activeCount":83},[],{"trials":1309,"activeCount":83},[],{"trials":1311,"activeCount":83},[1312,1316,1320],{"nctId":1270,"briefTitle":1271,"status":89,"phases":1313,"primaryCompletion":1273,"completion":938,"start":962,"enrollment":1274,"conditions":1314,"interventions":1315},[74],[1276],[1278,1259,1279],{"nctId":1281,"briefTitle":1282,"status":89,"phases":1317,"primaryCompletion":914,"completion":1284,"start":1285,"enrollment":1286,"conditions":1318,"interventions":1319},[73,74],[1288],[1278,1259,1279],{"nctId":1291,"briefTitle":1292,"status":89,"phases":1321,"primaryCompletion":1294,"completion":962,"start":963,"enrollment":1286,"conditions":1322,"interventions":1323},[74],[1288],[1297,1259,1279],{"trials":1325,"activeCount":83},[],{"trials":1327,"activeCount":83},[],{"intervention":1329,"totalTrials":412,"cells":1330},"palivizumab",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1347,"PHASE4":1359,"NA":1361},{"trials":1332,"activeCount":83},[],{"trials":1334,"activeCount":83},[],{"trials":1336,"activeCount":83},[1337],{"nctId":1338,"briefTitle":1339,"status":89,"phases":1340,"primaryCompletion":792,"completion":792,"start":848,"enrollment":1341,"conditions":1342,"interventions":1344},"NCT00538785","A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease",[73],1236,[1343],"Congenital Heart Disease",[1345,1346],"Motavizumab","Palivizumab",{"trials":1348,"activeCount":83},[1349],{"nctId":1350,"briefTitle":1351,"status":89,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":1355,"conditions":1356,"interventions":1357},"NCT00129766","Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children",[74],"2006-05","2004-11",6635,[30],[1358,1329],"motavizumab",{"trials":1360,"activeCount":83},[],{"trials":1362,"activeCount":83},[],{"intervention":1364,"totalTrials":412,"cells":1365},"CAIV-T or TIV",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1381,"PHASE4":1392,"NA":1394},{"trials":1367,"activeCount":83},[],{"trials":1369,"activeCount":83},[],{"trials":1371,"activeCount":83},[1372],{"nctId":1373,"briefTitle":1374,"status":89,"phases":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1380},"NCT00192153","Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older",[73],"2001-10","2001-07",240,[18],[1364],{"trials":1382,"activeCount":83},[1383],{"nctId":1384,"briefTitle":1385,"status":89,"phases":1386,"completion":1387,"start":1077,"enrollment":1388,"conditions":1389,"interventions":1391},"NCT00192205","Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children",[74],"2003-06",2200,[1390],"Respiratory Tract Infections",[1364],{"trials":1393,"activeCount":83},[],{"trials":1395,"activeCount":83},[],{"intervention":1278,"totalTrials":412,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1414,"NA":1416},{"trials":1399,"activeCount":83},[],{"trials":1401,"activeCount":83},[],{"trials":1403,"activeCount":83},[],{"trials":1405,"activeCount":83},[1406,1410],{"nctId":1270,"briefTitle":1271,"status":89,"phases":1407,"primaryCompletion":1273,"completion":938,"start":962,"enrollment":1274,"conditions":1408,"interventions":1409},[74],[1276],[1278,1259,1279],{"nctId":1281,"briefTitle":1282,"status":89,"phases":1411,"primaryCompletion":914,"completion":1284,"start":1285,"enrollment":1286,"conditions":1412,"interventions":1413},[73,74],[1288],[1278,1259,1279],{"trials":1415,"activeCount":83},[],{"trials":1417,"activeCount":83},[],{"intervention":1419,"totalTrials":412,"cells":1420},"Cold-adapted influenza vaccine trivalent",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1434,"PHASE4":1444,"NA":1446},{"trials":1422,"activeCount":83},[],{"trials":1424,"activeCount":83},[],{"trials":1426,"activeCount":83},[1427],{"nctId":1428,"briefTitle":1429,"status":89,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1387,"enrollment":1378,"conditions":1432,"interventions":1433},"NCT00192179","A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.",[73],"2003-07",[18],[1419],{"trials":1435,"activeCount":83},[1436],{"nctId":1437,"briefTitle":1438,"status":89,"phases":1439,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":1440,"conditions":1441,"interventions":1442},"NCT00192413","Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza",[74],3009,[18],[1419,1443],"Trivalent Inactivated Vaccine",{"trials":1445,"activeCount":83},[],{"trials":1447,"activeCount":83},[],{"intervention":1449,"totalTrials":480,"cells":1450},"CAIV-T and TIV",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1466,"NA":1468},{"trials":1452,"activeCount":83},[],{"trials":1454,"activeCount":83},[],{"trials":1456,"activeCount":83},[],{"trials":1458,"activeCount":83},[1459],{"nctId":1460,"briefTitle":1461,"status":89,"phases":1462,"completion":1076,"start":1077,"enrollment":1463,"conditions":1464,"interventions":1465},"NCT00192257","Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma",[74],2229,[21],[1449],{"trials":1467,"activeCount":83},[],{"trials":1469,"activeCount":83},[],{"intervention":1471,"totalTrials":480,"cells":1472},"Liquid CAIV-T",{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1490,"NA":1492},{"trials":1474,"activeCount":83},[],{"trials":1476,"activeCount":83},[],{"trials":1478,"activeCount":83},[],{"trials":1480,"activeCount":83},[1481],{"nctId":1482,"briefTitle":1483,"status":89,"phases":1484,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1489},"NCT00128167","Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age",[74],"2005-12","2004-10",8500,[18],[1471],{"trials":1491,"activeCount":83},[],{"trials":1493,"activeCount":83},[],{"intervention":1253,"totalTrials":480,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1502,"PHASE4":1508,"NA":1510},{"trials":1497,"activeCount":83},[],{"trials":1499,"activeCount":83},[],{"trials":1501,"activeCount":83},[],{"trials":1503,"activeCount":83},[1504],{"nctId":1243,"briefTitle":1244,"status":89,"phases":1505,"primaryCompletion":1246,"completion":392,"start":1247,"enrollment":1248,"conditions":1506,"interventions":1507},[74],[1250],[1252,1253],{"trials":1509,"activeCount":83},[],{"trials":1511,"activeCount":83},[],{"intervention":1443,"totalTrials":480,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1526,"NA":1528},{"trials":1515,"activeCount":83},[],{"trials":1517,"activeCount":83},[],{"trials":1519,"activeCount":83},[],{"trials":1521,"activeCount":83},[1522],{"nctId":1437,"briefTitle":1438,"status":89,"phases":1523,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":1440,"conditions":1524,"interventions":1525},[74],[18],[1419,1443],{"trials":1527,"activeCount":83},[],{"trials":1529,"activeCount":83},[],{"intervention":1151,"totalTrials":480,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1544,"NA":1546},{"trials":1533,"activeCount":83},[],{"trials":1535,"activeCount":83},[],{"trials":1537,"activeCount":83},[],{"trials":1539,"activeCount":83},[1540],{"nctId":1143,"briefTitle":1144,"status":89,"phases":1541,"completion":1146,"start":1147,"enrollment":1148,"conditions":1542,"interventions":1543},[74],[15],[1034,1151,1152],{"trials":1545,"activeCount":83},[],{"trials":1547,"activeCount":83},[],{"intervention":1549,"totalTrials":480,"cells":1550},"AV024",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1568,"NA":1570},{"trials":1552,"activeCount":83},[],{"trials":1554,"activeCount":83},[],{"trials":1556,"activeCount":83},[],{"trials":1558,"activeCount":83},[1559],{"nctId":1560,"briefTitle":1561,"status":89,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1055,"enrollment":1565,"conditions":1566,"interventions":1567},"NCT00240877","Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)",[74],"2003-08","2004-04",330,[18],[1549],{"trials":1569,"activeCount":83},[],{"trials":1571,"activeCount":83},[],{"intervention":1573,"totalTrials":480,"cells":1574},"Inebilizumab",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1592,"NA":1594},{"trials":1576,"activeCount":83},[],{"trials":1578,"activeCount":83},[],{"trials":1580,"activeCount":83},[],{"trials":1582,"activeCount":83},[1583],{"nctId":1584,"briefTitle":1585,"status":89,"phases":1586,"primaryCompletion":169,"completion":45,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1591},"NCT02200770","N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders",[73,74],"2015-04-01",231,[1590],"Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders",[1573],{"trials":1593,"activeCount":83},[],{"trials":1595,"activeCount":83},[],{"intervention":1297,"totalTrials":480,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":83},[],{"trials":1601,"activeCount":83},[],{"trials":1603,"activeCount":83},[],{"trials":1605,"activeCount":83},[1606],{"nctId":1291,"briefTitle":1292,"status":89,"phases":1607,"primaryCompletion":1294,"completion":962,"start":963,"enrollment":1286,"conditions":1608,"interventions":1609},[74],[1288],[1297,1259,1279],{"trials":1611,"activeCount":83},[],{"trials":1613,"activeCount":83},[],{"intervention":1615,"totalTrials":25,"cells":1616},"MEDI0382",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1669,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1618,"activeCount":83},[],{"trials":1620,"activeCount":83},[1621,1631,1641,1649,1659],{"nctId":1622,"briefTitle":1623,"status":89,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":370,"conditions":1627,"interventions":1630},"NCT03385369","A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight\u002FObese Subjects of Japanese or Chinese Descent",[72],"2018-04-12","2018-01-05",[1628,1629],"Safety","Healthy Subjects",[1615],{"nctId":1632,"briefTitle":1633,"status":89,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1640},"NCT02394314","A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers",[72],"2015-08","2015-02",362,[1639],"Healthy Volunteers",[1615],{"nctId":1642,"briefTitle":1643,"status":89,"phases":1644,"primaryCompletion":112,"completion":112,"start":1645,"enrollment":1236,"conditions":1646,"interventions":1648},"NCT03235375","A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects",[72],"2017-10-27",[1647],"Renal Insufficiency",[1615],{"nctId":1650,"briefTitle":1651,"status":89,"phases":1652,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1658},"NCT03625778","A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants",[72],"2019-08-25","2018-08-14",51,[1657],"Obesity",[1615],{"nctId":1660,"briefTitle":1661,"status":89,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":22,"conditions":1665,"interventions":1666},"NCT03347968","Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382",[72],"2018-04-09","2017-11-27",[1639],[1615,1667,1668],"Warfarin","Esmolol",{"trials":1670,"activeCount":83},[1671,1680,1688,1697,1706,1715,1725],{"nctId":1672,"briefTitle":1673,"status":89,"phases":1674,"primaryCompletion":368,"completion":368,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1679},"NCT03550378","A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated",[73],"2018-06-29",41,[1678,1647],"Type II Diabetes Mellitus",[1615],{"nctId":1681,"briefTitle":1682,"status":89,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":1685,"enrollment":1139,"conditions":1686,"interventions":1687},"NCT03745937","A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",[73],"2019-05-28","2019-01-07",[33],[1615],{"nctId":1689,"briefTitle":1690,"status":89,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1696},"NCT03244800","A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.",[73],"2018-01-23","2017-09-04",65,[33],[1615],{"nctId":1698,"briefTitle":1699,"status":89,"phases":1700,"primaryCompletion":1701,"completion":1701,"start":443,"enrollment":1223,"conditions":1702,"interventions":1703},"NCT03444584","Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight\u002FObese Participants With Type 2 Diabetes",[73],"2018-12-06",[33],[1615,1704,1705],"Dapaglifozin","Metformin",{"nctId":1707,"briefTitle":1708,"status":89,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":1655,"conditions":1712,"interventions":1713},"NCT03555994","A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.",[73],"2021-04-14","2018-05-31",[33],[1615,1714],"Liraglutide",{"nctId":1716,"briefTitle":1717,"status":89,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1724},"NCT03596177","A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus",[73],"2019-12-22","2018-09-26",28,[1723,1657],"Diabetes Mellitus, Type II",[1615],{"nctId":1726,"briefTitle":1727,"status":89,"phases":1728,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":1731,"conditions":1732,"interventions":1733},"NCT02548585","A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",[72,73],"2017-02-24","2015-12-09",113,[33],[1615],{"trials":1735,"activeCount":83},[],{"trials":1737,"activeCount":83},[],{"trials":1739,"activeCount":83},[],{"intervention":1741,"totalTrials":1742,"cells":1743},"MEDI-507",8,{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1803,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1745,"activeCount":83},[],{"trials":1747,"activeCount":83},[1748,1756,1763,1773,1782,1792],{"nctId":1749,"briefTitle":1750,"status":167,"phases":1751,"start":1146,"enrollment":1248,"conditions":1752,"interventions":1755},"NCT00105313","Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma\u002FLeukemia",[72],[1753,1754,24],"Lymphoma","Leukemia",[1741],{"nctId":1757,"briefTitle":1758,"status":167,"phases":1759,"start":1564,"enrollment":1087,"conditions":1760,"interventions":1762},"NCT00123942","Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease",[72],[1761],"Lymphoproliferative Disorders",[1741],{"nctId":1764,"briefTitle":1765,"status":89,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":16,"conditions":1770,"interventions":1772},"NCT00806208","Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)",[72],"2000-01","2000-03","1999-01",[1771],"Graft-Versus-Host Disease",[1741,1741,1741,1741],{"nctId":1774,"briefTitle":1775,"status":89,"phases":1776,"primaryCompletion":1777,"completion":1778,"start":1779,"enrollment":11,"conditions":1780,"interventions":1781},"NCT00806728","Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease",[72],"1998-11","1998-12","1998-05",[24,1771],[1741,1741],{"nctId":1783,"briefTitle":1784,"status":89,"phases":1785,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":12,"conditions":1789,"interventions":1791},"NCT00807794","A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection",[72],"1997-11","1998-01","1997-02",[1790],"Kidney Diseases",[1741,1741,1741,1741,1741],{"nctId":1793,"briefTitle":1794,"status":89,"phases":1795,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":1799,"conditions":1800,"interventions":1802},"NCT00813618","Study of MEDI 507 in the Treatment of Pediatric Patients",[72],"2004-06","2004-08","1999-09",10,[1801],"Graft Versus Host Disease",[1741,1741,1741],{"trials":1804,"activeCount":83},[1805,1813],{"nctId":1806,"briefTitle":1807,"status":89,"phases":1808,"completion":1085,"start":1809,"enrollment":1047,"conditions":1810,"interventions":1812},"NCT00192452","Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis",[73],"2001-03",[1811],"Psoriasis",[1741],{"nctId":1814,"briefTitle":1815,"status":89,"phases":1816,"completion":1431,"start":1086,"enrollment":1817,"conditions":1818,"interventions":1820},"NCT00540618","A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis",[73],420,[1819],"Plaque Psoriasis",[1741,1741,1741],{"trials":1822,"activeCount":83},[],{"trials":1824,"activeCount":83},[],{"trials":1826,"activeCount":83},[],{"intervention":337,"totalTrials":8,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1859,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1830,"activeCount":83},[],{"trials":1832,"activeCount":83},[1833,1837,1841,1845,1855],{"nctId":328,"briefTitle":329,"status":89,"phases":1834,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":1835,"interventions":1836},[72],[335],[337,338],{"nctId":340,"briefTitle":341,"status":89,"phases":1838,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":1839,"interventions":1840},[72],[27],[337,338],{"nctId":365,"briefTitle":366,"status":89,"phases":1842,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":1843,"interventions":1844},[72],[372],[337,338,374],{"nctId":1846,"briefTitle":1847,"status":89,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1853},"NCT02088112","MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).",[72],"2021-03-09","2014-03-24",56,[446],[1854,337],"Gefitinib",{"nctId":376,"briefTitle":377,"status":89,"phases":1856,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":1857,"interventions":1858},[72],[219,383,384],[337,41,338],{"trials":1860,"activeCount":83},[1861,1870],{"nctId":1862,"briefTitle":1863,"status":89,"phases":1864,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":1867,"conditions":1868,"interventions":1869},"NCT01693562","A Phase 1\u002F2 Study to Evaluate MEDI4736",[72,73],"2020-02-28","2012-09-05",1022,[27],[337],{"nctId":389,"briefTitle":390,"status":89,"phases":1871,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":1872,"interventions":1873},[72,73],[396],[398,398,337,41,399,398],{"trials":1875,"activeCount":83},[],{"trials":1877,"activeCount":83},[],{"trials":1879,"activeCount":83},[],{"intervention":1881,"totalTrials":420,"cells":1882},"MEDI-522",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1904,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1884,"activeCount":83},[],{"trials":1886,"activeCount":83},[1887,1895],{"nctId":1888,"briefTitle":1889,"status":89,"phases":1890,"primaryCompletion":1165,"completion":1891,"start":1809,"enrollment":1892,"conditions":1893,"interventions":1894},"NCT00263783","Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors",[72],"2002-06",24,[24],[1881],{"nctId":1896,"briefTitle":1897,"status":89,"phases":1898,"primaryCompletion":1899,"completion":847,"start":1067,"enrollment":1900,"conditions":1901,"interventions":1903},"NCT00111696","Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma",[72],"2007-08",18,[1902],"Malignant Melanoma",[1881],{"trials":1905,"activeCount":83},[1906,1913,1925,1933],{"nctId":1907,"briefTitle":1908,"status":89,"phases":1909,"primaryCompletion":1910,"completion":1067,"start":1377,"enrollment":11,"conditions":1911,"interventions":1912},"NCT00284817","Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer",[72,73],"2005-01",[24],[1881,1881,1881,1881,1881],{"nctId":1914,"briefTitle":1915,"status":89,"phases":1916,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1923},"NCT00072930","MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer",[73],"2007-04","2007-06","2003-12",150,[1922],"Prostate Cancer",[1881,1924],"Docetaxel + Prednisone* + Zoledronic Acid",{"nctId":1926,"briefTitle":1927,"status":89,"phases":1928,"completion":1929,"start":1930,"enrollment":750,"conditions":1931,"interventions":1932},"NCT00069017","Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate",[73],"2006-04","2003-09",[35],[1881],{"nctId":1934,"briefTitle":1935,"status":89,"phases":1936,"primaryCompletion":1797,"completion":1937,"start":1919,"enrollment":1938,"conditions":1939,"interventions":1940},"NCT00192517","Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis",[73],"2004-09",44,[1811],[1881],{"trials":1942,"activeCount":83},[],{"trials":1944,"activeCount":83},[],{"trials":1946,"activeCount":83},[],{"intervention":1948,"totalTrials":281,"cells":1949},"MEDI8852",{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1962,"PHASE3":1992,"PHASE4":1994,"NA":1996},{"trials":1951,"activeCount":83},[],{"trials":1953,"activeCount":83},[1954],{"nctId":1955,"briefTitle":1956,"status":89,"phases":1957,"primaryCompletion":824,"completion":824,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1961},"NCT02350751","Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults",[72],"2015-01",94,[18],[1948],{"trials":1963,"activeCount":83},[1964,1974,1984],{"nctId":1965,"briefTitle":1966,"status":89,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1972},"NCT02603952","A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza",[72,73],"2016-12-09","2015-12-07",126,[18],[1973,1948],"Oseltamivir",{"nctId":1975,"briefTitle":1976,"status":1977,"phases":1978,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":83,"conditions":1981,"interventions":1983},"NCT03028909","Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.","WITHDRAWN",[73],"2019-07-26","2017-07-24",[1982],"Influenza - Type A Strains",[1973,1948],{"nctId":1985,"briefTitle":1986,"status":1977,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":83,"conditions":1990,"interventions":1991},"NCT03903718","Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza",[73],"2020-10-09","2020-04-03",[18],[1973,1948],{"trials":1993,"activeCount":83},[],{"trials":1995,"activeCount":83},[],{"trials":1997,"activeCount":83},[],{"intervention":1999,"totalTrials":281,"cells":2000},"Mavrilimumab 100 mg",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2002,"activeCount":83},[],{"trials":2004,"activeCount":83},[],{"trials":2006,"activeCount":83},[2007,2017,2027,2039],{"nctId":2008,"briefTitle":2009,"status":89,"phases":2010,"primaryCompletion":815,"completion":2011,"start":2012,"enrollment":1817,"conditions":2013,"interventions":2014},"NCT01706926","A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis",[73],"2014-01","2012-08",[35],[2015,1999,2016],"Mavrilimumab 30 mg","Mavrilimumab 150 mg",{"nctId":2018,"briefTitle":2019,"status":89,"phases":2020,"primaryCompletion":2021,"completion":1636,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2025},"NCT01715896","A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis",[73],"2014-11","2013-03",215,[35],[2026,1999],"Golimumab 50 mg",{"nctId":2028,"briefTitle":2029,"status":89,"phases":2030,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":2035,"interventions":2036},"NCT01050998","A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis",[73],"2011-06-09","2012-07-27","2010-01-05",516,[35],[2037,2015,2038,1999],"Mavrilimumab 10 mg","Mavrilimumab 50 mg",{"nctId":2040,"briefTitle":2041,"status":167,"phases":2042,"primaryCompletion":2043,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2047},"NCT01712399","A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis",[73],"2015-12-30","2013-01-28",409,[35],[1999],{"trials":2049,"activeCount":83},[],{"trials":2051,"activeCount":83},[],{"trials":2053,"activeCount":83},[],{"intervention":2055,"totalTrials":273,"cells":2056},"MEDI7510",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2083,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2058,"activeCount":83},[],{"trials":2060,"activeCount":83},[2061,2073],{"nctId":2062,"briefTitle":2063,"status":89,"phases":2064,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT02115815","A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults",[72],"2014-04",246,[2068],"Respiratory Syncytial Virus (RSV)",[2070,2055,2071,2055,2072,2055],"RSV sF 20 mcg","RSV sF 50 mcg","RSV sF 80 mcg",{"nctId":2074,"briefTitle":2075,"status":89,"phases":2076,"primaryCompletion":2077,"completion":2077,"start":2078,"enrollment":2079,"conditions":2080,"interventions":2081},"NCT02289820","A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults",[72],"2016-02-24","2015-01-05",363,[2068],[2055,2082],"IIV",{"trials":2084,"activeCount":83},[2085],{"nctId":2086,"briefTitle":2087,"status":167,"phases":2088,"primaryCompletion":2089,"completion":2090,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2095},"NCT02508194","A Study to Evaluate the Efficacy of MEDI7510 in Older Adults",[73],"2016-09-09","2016-11-07","2015-09-29",1900,[2094],"Respiratory Syncytial Virus",[2055,2082],{"trials":2097,"activeCount":83},[],{"trials":2099,"activeCount":83},[],{"trials":2101,"activeCount":83},[],{"intervention":2103,"totalTrials":273,"cells":2104},"MEDI-573",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2127,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2106,"activeCount":83},[],{"trials":2108,"activeCount":83},[2109,2119],{"nctId":2110,"briefTitle":2111,"status":89,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":420,"conditions":2115,"interventions":2117},"NCT01498952","MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.",[72],"2013-04-09","2012-01-17",[2116],"Unresectable or Metastatic Hepatocellular Carcinoma (HCC)",[2103,2118],"Sorafenib",{"nctId":2120,"briefTitle":2121,"status":89,"phases":2122,"primaryCompletion":2123,"completion":2123,"start":2124,"enrollment":444,"conditions":2125,"interventions":2126},"NCT00816361","A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors",[72],"2012-09-11","2009-03-09",[24],[2103],{"trials":2128,"activeCount":83},[2129],{"nctId":2130,"briefTitle":2131,"status":89,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2138},"NCT01446159","Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer",[73],"2019-06-28","2011-06-13",188,[2137],"Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer",[2103,2139],"Aromatase Inhibitor",{"trials":2141,"activeCount":83},[],{"trials":2143,"activeCount":83},[],{"trials":2145,"activeCount":83},[],{"intervention":2147,"totalTrials":273,"cells":2148},"Rituximab",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2150,"activeCount":83},[],{"trials":2152,"activeCount":83},[],{"trials":2154,"activeCount":83},[2155,2167,2177],{"nctId":2156,"briefTitle":2157,"status":89,"phases":2158,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":2161,"conditions":2162,"interventions":2164},"NCT01466153","A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[73],"2016-01-08","2012-02-07",183,[2163],"Chronic Lymphocytic Leukemia (CLL)",[2147,2165,2166],"Bendamustine","MEDI-551",{"nctId":2168,"briefTitle":2169,"status":89,"phases":2170,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":2173,"conditions":2174,"interventions":2176},"NCT00983619","A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies",[72,73],"2019-03-21","2010-04-16",136,[2175,24],"B-cell Malignancies",[2166,2147],{"nctId":2178,"briefTitle":2179,"status":89,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2185},"NCT01453205","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",[73],"2016-07-11","2012-02-27",187,[372],[2186,2147,2187,2188,2189],"MEDI-551 2 mg\u002Fkg","ICE","DHAP","MEDI-551 4 mg\u002Fkg",{"trials":2191,"activeCount":83},[],{"trials":2193,"activeCount":83},[],{"trials":2195,"activeCount":83},[],{"intervention":2166,"totalTrials":273,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2212,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2199,"activeCount":83},[],{"trials":2201,"activeCount":83},[2202],{"nctId":2203,"briefTitle":2204,"status":89,"phases":2205,"primaryCompletion":2206,"completion":2207,"start":962,"enrollment":2208,"conditions":2209,"interventions":2211},"NCT00946699","A Study of the Safety and Tolerability of MEDI-551 in Scleroderma",[72],"2012-03","2014-03",50,[2210],"Scleroderma",[2166,2166,2166,2166],{"trials":2213,"activeCount":83},[2214,2218],{"nctId":2156,"briefTitle":2157,"status":89,"phases":2215,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":2161,"conditions":2216,"interventions":2217},[73],[2163],[2147,2165,2166],{"nctId":2168,"briefTitle":2169,"status":89,"phases":2219,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":2173,"conditions":2220,"interventions":2221},[72,73],[2175,24],[2166,2147],{"trials":2223,"activeCount":83},[],{"trials":2225,"activeCount":83},[],{"trials":2227,"activeCount":83},[],{"intervention":1973,"totalTrials":273,"cells":2229},{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2231,"activeCount":83},[],{"trials":2233,"activeCount":83},[],{"trials":2235,"activeCount":83},[2236,2240,2244],{"nctId":1965,"briefTitle":1966,"status":89,"phases":2237,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":1970,"conditions":2238,"interventions":2239},[72,73],[18],[1973,1948],{"nctId":1975,"briefTitle":1976,"status":1977,"phases":2241,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":83,"conditions":2242,"interventions":2243},[73],[1982],[1973,1948],{"nctId":1985,"briefTitle":1986,"status":1977,"phases":2245,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":83,"conditions":2246,"interventions":2247},[73],[18],[1973,1948],{"trials":2249,"activeCount":83},[],{"trials":2251,"activeCount":83},[],{"trials":2253,"activeCount":83},[],{"intervention":2255,"totalTrials":273,"cells":2256},"MEDI-528 9 mg\u002Fkg",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2280,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2258,"activeCount":83},[],{"trials":2260,"activeCount":83},[2261,2271],{"nctId":2262,"briefTitle":2263,"status":89,"phases":2264,"primaryCompletion":1146,"completion":2265,"start":1797,"enrollment":1892,"conditions":2266,"interventions":2267},"NCT00192296","Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers",[72],"2005-03",[21],[2268,2269,2270,2255],"MEDI-528 0.3 mg\u002Fkg","MEDI-528 1 mg\u002Fkg","MEDI-528 3 mg\u002Fkg",{"nctId":2272,"briefTitle":2273,"status":89,"phases":2274,"primaryCompletion":1929,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT00116168","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528",[72],"2006-07","2005-06",29,[15],[2268,2269,2270,2255],{"trials":2281,"activeCount":83},[2282],{"nctId":2283,"briefTitle":2284,"status":89,"phases":2285,"primaryCompletion":1899,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2290},"NCT00394654","A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma",[73],"2008-01","2006-11",30,[21],[2255],{"trials":2292,"activeCount":83},[],{"trials":2294,"activeCount":83},[],{"trials":2296,"activeCount":83},[],{"intervention":2298,"totalTrials":273,"cells":2299},"MEDI-545",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2322,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2301,"activeCount":83},[],{"trials":2303,"activeCount":83},[2304,2313],{"nctId":2305,"briefTitle":2306,"status":89,"phases":2307,"completion":846,"start":2308,"enrollment":1056,"conditions":2309,"interventions":2311},"NCT00299819","Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)",[72],"2006-03",[2310],"Lupus",[2298,2312,2298,2298,2298],"MEDI 545",{"nctId":2314,"briefTitle":2315,"status":89,"phases":2316,"primaryCompletion":2317,"completion":293,"start":2318,"enrollment":1655,"conditions":2319,"interventions":2321},"NCT00533091","A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis",[72],"2010-08","2008-04",[2320],"DERMATOMYOSITIS OR POLYMYOSITIS",[2298],{"trials":2323,"activeCount":83},[2324],{"nctId":2325,"briefTitle":2326,"status":89,"phases":2327,"primaryCompletion":939,"completion":939,"start":790,"enrollment":2328,"conditions":2329,"interventions":2331},"NCT00657189","A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus",[73],87,[2330,2310],"Lupus Erythematosus, Systemic",[2298,2298,2298,2298],{"trials":2333,"activeCount":83},[],{"trials":2335,"activeCount":83},[],{"trials":2337,"activeCount":83},[],{"intervention":2339,"totalTrials":273,"cells":2340},"Benralizumab 100 mg",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2342,"activeCount":83},[],{"trials":2344,"activeCount":83},[],{"trials":2346,"activeCount":83},[2347,2357,2367],{"nctId":2348,"briefTitle":2349,"status":89,"phases":2350,"primaryCompletion":2022,"completion":2351,"start":938,"enrollment":2352,"conditions":2353,"interventions":2354},"NCT01238861","Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma",[73],"2013-08",964,[21],[2355,2356,2339],"Benralizumab 2 mg","Benralizumab 20 mg",{"nctId":2358,"briefTitle":2359,"status":89,"phases":2360,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":203,"conditions":2363,"interventions":2364},"NCT00783289","A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma",[73],"2009-11-17","2008-11-14",[21],[2365,2339,2366],"Benralizumab 25 mg","Benralizumab 200 mg",{"nctId":2368,"briefTitle":2369,"status":89,"phases":2370,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":2374,"conditions":2375,"interventions":2377},"NCT01227278","A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[73],"2013-01","2013-07","2010-11",421,[2376],"Pulmonary Disease, Chronic Obstructive",[2339],{"trials":2379,"activeCount":83},[],{"trials":2381,"activeCount":83},[],{"trials":2383,"activeCount":83},[],{"intervention":634,"totalTrials":273,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2398,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2387,"activeCount":83},[],{"trials":2389,"activeCount":83},[2390],{"nctId":2391,"briefTitle":2392,"status":89,"phases":2393,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":1223,"conditions":2396,"interventions":2397},"NCT00816400","A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.",[72],"2012-01-19","2009-03-02",[24],[634],{"trials":2399,"activeCount":83},[2400,2404],{"nctId":626,"briefTitle":627,"status":167,"phases":2401,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":2402,"interventions":2403},[72,73],[383],[300,299,634],{"nctId":2405,"briefTitle":2406,"status":89,"phases":2407,"primaryCompletion":781,"completion":781,"start":2408,"enrollment":2409,"conditions":2410,"interventions":2412},"NCT01268566","A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme",[73],"2011-01",62,[2411],"Glioblastoma Multiforme",[634],{"trials":2414,"activeCount":83},[],{"trials":2416,"activeCount":83},[],{"trials":2418,"activeCount":83},[],{"intervention":2420,"totalTrials":412,"cells":2421},"MEDI6012",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2423,"activeCount":83},[],{"trials":2425,"activeCount":83},[],{"trials":2427,"activeCount":83},[2428,2438],{"nctId":2429,"briefTitle":2430,"status":89,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":2435,"interventions":2437},"NCT03578809","A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction",[73],"2021-01-18","2018-06-05",593,[2436],"ST Elevation Myocardial Infarction",[2420],{"nctId":2439,"briefTitle":2440,"status":89,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":2445,"conditions":2446,"interventions":2448},"NCT02601560","To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease",[73],"2016-08-20","2016-11-03","2015-12-03",48,[2447],"Coronary Artery Disease",[2420],{"trials":2450,"activeCount":83},[],{"trials":2452,"activeCount":83},[],{"trials":2454,"activeCount":83},[],{"intervention":2082,"totalTrials":412,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2465,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2458,"activeCount":83},[],{"trials":2460,"activeCount":83},[2461],{"nctId":2074,"briefTitle":2075,"status":89,"phases":2462,"primaryCompletion":2077,"completion":2077,"start":2078,"enrollment":2079,"conditions":2463,"interventions":2464},[72],[2068],[2055,2082],{"trials":2466,"activeCount":83},[2467],{"nctId":2086,"briefTitle":2087,"status":167,"phases":2468,"primaryCompletion":2089,"completion":2090,"start":2091,"enrollment":2092,"conditions":2469,"interventions":2470},[73],[2094],[2055,2082],{"trials":2472,"activeCount":83},[],{"trials":2474,"activeCount":83},[],{"trials":2476,"activeCount":83},[],{"intervention":2478,"totalTrials":412,"cells":2479},"CAT-8015 20 mcg\u002Fkg",{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2497,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2481,"activeCount":83},[],{"trials":2483,"activeCount":83},[2484],{"nctId":2485,"briefTitle":2486,"status":167,"phases":2487,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":28,"conditions":2490,"interventions":2494},"NCT00587457","A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia",[72],"2008-04-07","2007-03-07",[2491,2492,2493],"Leukemia, Lymphoma, Chronic Lymphocytic","Leukemia, Prolymphocytic Leukemia, Small","Lymphocytic Lymphoma, Moxetumomab Pasudotox",[2495,2496,2478],"CAT-8015 5 mcg\u002Fkg","CAT-8015 10 mcg\u002Fkg",{"trials":2498,"activeCount":83},[2499],{"nctId":2500,"briefTitle":2501,"status":89,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":2505,"conditions":2506,"interventions":2509},"NCT01030536","Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)",[72,73],"2013-03-04","2010-02-15",23,[2507,2508],"Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[2478,2510,2511,2512,2513],"CAT-8015 30 mcg\u002Fkg","CAT-8015 40 mcg\u002Fkg","CAT-8015 50 mcg\u002Fkg","CAT-8015 60 mcg\u002Fkg",{"trials":2515,"activeCount":83},[],{"trials":2517,"activeCount":83},[],{"trials":2519,"activeCount":83},[],{"intervention":2521,"totalTrials":412,"cells":2522},"MEDI-524",{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2534,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2524,"activeCount":83},[],{"trials":2526,"activeCount":83},[2527],{"nctId":2528,"briefTitle":2529,"status":89,"phases":2530,"primaryCompletion":1564,"completion":1354,"start":2531,"enrollment":2288,"conditions":2532,"interventions":2533},"NCT00192465","Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults",[72],"2003-11",[30],[2521,2521,2521,2521,2521],{"trials":2535,"activeCount":83},[2536],{"nctId":2537,"briefTitle":2538,"status":89,"phases":2539,"primaryCompletion":1353,"completion":2540,"start":2541,"enrollment":2542,"conditions":2543,"interventions":2544},"NCT00192478","Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg\u002Fkg or 15 mg\u002Fkg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524",[72,73],"2006-08","2004-02",217,[30],[2545],"Medi-524",{"trials":2547,"activeCount":83},[],{"trials":2549,"activeCount":83},[],{"trials":2551,"activeCount":83},[],{"intervention":2553,"totalTrials":412,"cells":2554},"MEDI4893",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2568,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2556,"activeCount":83},[],{"trials":2558,"activeCount":83},[2559],{"nctId":2560,"briefTitle":2561,"status":89,"phases":2562,"primaryCompletion":2563,"completion":2563,"start":2371,"enrollment":2564,"conditions":2565,"interventions":2567},"NCT01769417","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects",[72],"2014-05",85,[2566],"Staphylococcus Aureus",[2553],{"trials":2569,"activeCount":83},[2570],{"nctId":2571,"briefTitle":2572,"status":89,"phases":2573,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":263,"conditions":2576,"interventions":2578},"NCT02296320","Study of the Efficacy and Safety of MEDI4893",[73],"2018-10-02","2014-10-10",[2577],"Staphylococcus Aureus Pneumonia",[2553],{"trials":2580,"activeCount":83},[],{"trials":2582,"activeCount":83},[],{"trials":2584,"activeCount":83},[],{"intervention":2586,"totalTrials":412,"cells":2587},"MEDI-538",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2601,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2589,"activeCount":83},[],{"trials":2591,"activeCount":83},[2592],{"nctId":2593,"briefTitle":2594,"status":1977,"phases":2595,"primaryCompletion":962,"completion":939,"start":2596,"enrollment":1900,"conditions":2597,"interventions":2600},"NCT00538096","A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma",[72],"2007-09",[2598,2599],"Lymphoma, B-Cell","Lymphoma, Non-Hodgkin",[2586,2586,2586],{"trials":2602,"activeCount":83},[2603],{"nctId":2604,"briefTitle":2605,"status":1977,"phases":2606,"primaryCompletion":962,"completion":2607,"start":792,"enrollment":2288,"conditions":2608,"interventions":2609},"NCT00676871","A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)",[72,73],"2011-06",[2508],[2586,2586,2586,2586,2586,2586,2586],{"trials":2611,"activeCount":83},[],{"trials":2613,"activeCount":83},[],{"trials":2615,"activeCount":83},[],{"intervention":299,"totalTrials":412,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2626,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2619,"activeCount":83},[],{"trials":2621,"activeCount":83},[2622],{"nctId":288,"briefTitle":289,"status":89,"phases":2623,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":2624,"interventions":2625},[72],[27,296],[298,188,299,300],{"trials":2627,"activeCount":83},[2628],{"nctId":626,"briefTitle":627,"status":167,"phases":2629,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":2630,"interventions":2631},[72,73],[383],[300,299,634],{"trials":2633,"activeCount":83},[],{"trials":2635,"activeCount":83},[],{"trials":2637,"activeCount":83},[],{"intervention":2015,"totalTrials":412,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2641,"activeCount":83},[],{"trials":2643,"activeCount":83},[],{"trials":2645,"activeCount":83},[2646,2650],{"nctId":2008,"briefTitle":2009,"status":89,"phases":2647,"primaryCompletion":815,"completion":2011,"start":2012,"enrollment":1817,"conditions":2648,"interventions":2649},[73],[35],[2015,1999,2016],{"nctId":2028,"briefTitle":2029,"status":89,"phases":2651,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":2652,"interventions":2653},[73],[35],[2037,2015,2038,1999],{"trials":2655,"activeCount":83},[],{"trials":2657,"activeCount":83},[],{"trials":2659,"activeCount":83},[],{"intervention":2661,"totalTrials":412,"cells":2662},"CAT-354 150 mg",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2676,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2664,"activeCount":83},[],{"trials":2666,"activeCount":83},[2667],{"nctId":2668,"briefTitle":2669,"status":89,"phases":2670,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2288,"conditions":2673,"interventions":2674},"NCT00638989","A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354",[72],"2008-06-07","2008-04-11",[21,15],[2661,2661,2675],"CAT-354 300 mg",{"trials":2677,"activeCount":83},[2678],{"nctId":2679,"briefTitle":2680,"status":89,"phases":2681,"primaryCompletion":2317,"completion":2317,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2685},"NCT00873860","Study to Evaluate the Safety and Efficacy of CAT-354",[73],"2009-06",357,[21],[2661,2675,2686],"CAT-354 600 mg",{"trials":2688,"activeCount":83},[],{"trials":2690,"activeCount":83},[],{"trials":2692,"activeCount":83},[],{"intervention":2675,"totalTrials":412,"cells":2694},{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2703,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2696,"activeCount":83},[],{"trials":2698,"activeCount":83},[2699],{"nctId":2668,"briefTitle":2669,"status":89,"phases":2700,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2288,"conditions":2701,"interventions":2702},[72],[21,15],[2661,2661,2675],{"trials":2704,"activeCount":83},[2705],{"nctId":2679,"briefTitle":2680,"status":89,"phases":2706,"primaryCompletion":2317,"completion":2317,"start":2682,"enrollment":2683,"conditions":2707,"interventions":2708},[73],[21],[2661,2675,2686],{"trials":2710,"activeCount":83},[],{"trials":2712,"activeCount":83},[],{"trials":2714,"activeCount":83},[],{"intervention":247,"totalTrials":412,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2730,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2718,"activeCount":83},[],{"trials":2720,"activeCount":83},[2721],{"nctId":2722,"briefTitle":2723,"status":89,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":126,"conditions":2727,"interventions":2729},"NCT02013804","A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies",[72],"2017-05-18","2013-12-19",[2728],"Advanced Malignancies",[247],{"trials":2731,"activeCount":83},[2732],{"nctId":236,"briefTitle":237,"status":89,"phases":2733,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":2734,"interventions":2735},[72,73],[243,244,245],[247,60,248],{"trials":2737,"activeCount":83},[],{"trials":2739,"activeCount":83},[],{"trials":2741,"activeCount":83},[],{"intervention":2743,"totalTrials":412,"cells":2744},"CAT-354 5 mg\u002Fkg",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2760,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2746,"activeCount":83},[],{"trials":2748,"activeCount":83},[2749],{"nctId":2750,"briefTitle":2751,"status":167,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":2754,"enrollment":2505,"conditions":2755,"interventions":2757},"NCT00974675","A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma",[72],"2007-08-03","2006-09-29",[2756],"Moderate Asthma",[2758,2743,2759],"CAT-354 1mg\u002Fkg","CAT-354 10mg\u002Fkg",{"trials":2761,"activeCount":83},[2762],{"nctId":2763,"briefTitle":2764,"status":167,"phases":2765,"primaryCompletion":790,"completion":790,"start":2286,"enrollment":1035,"conditions":2766,"interventions":2767},"NCT00640016","A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma",[73],[21],[2768,2743],"CAT-354 1 mg\u002Fkg",{"trials":2770,"activeCount":83},[],{"trials":2772,"activeCount":83},[],{"trials":2774,"activeCount":83},[],{"intervention":2776,"totalTrials":480,"cells":2777},"Anifrolumab",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2793,"PHASE4":2795,"NA":2797},{"trials":2779,"activeCount":83},[],{"trials":2781,"activeCount":83},[],{"trials":2783,"activeCount":83},[2784],{"nctId":2785,"briefTitle":2786,"status":89,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2792},"NCT01753193","An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults",[73],"2018-07-18","2013-03-28",218,[2330],[2776],{"trials":2794,"activeCount":83},[],{"trials":2796,"activeCount":83},[],{"trials":2798,"activeCount":83},[],{"intervention":2165,"totalTrials":480,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2802,"activeCount":83},[],{"trials":2804,"activeCount":83},[],{"trials":2806,"activeCount":83},[2807],{"nctId":2156,"briefTitle":2157,"status":89,"phases":2808,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":2161,"conditions":2809,"interventions":2810},[73],[2163],[2147,2165,2166],{"trials":2812,"activeCount":83},[],{"trials":2814,"activeCount":83},[],{"trials":2816,"activeCount":83},[],{"intervention":2818,"totalTrials":480,"cells":2819},"MEDI-551 12 mg\u002Fkg",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2821,"activeCount":83},[],{"trials":2823,"activeCount":83},[],{"trials":2825,"activeCount":83},[2826],{"nctId":2827,"briefTitle":2828,"status":89,"phases":2829,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":1799,"conditions":2832,"interventions":2834},"NCT02271945","Safety\u002FEfficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas",[72,73],"2016-05-24","2014-12-01",[2833],"Relapsed\u002FRefractory Aggressive B-cell Lymphomas",[2818,2835,2836],"MEDI0680 2.5 mg\u002Fkg","MEDI0680 10 mg\u002Fkg",{"trials":2838,"activeCount":83},[],{"trials":2840,"activeCount":83},[],{"trials":2842,"activeCount":83},[],{"intervention":2835,"totalTrials":480,"cells":2844},{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2846,"activeCount":83},[],{"trials":2848,"activeCount":83},[],{"trials":2850,"activeCount":83},[2851],{"nctId":2827,"briefTitle":2828,"status":89,"phases":2852,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":1799,"conditions":2853,"interventions":2854},[72,73],[2833],[2818,2835,2836],{"trials":2856,"activeCount":83},[],{"trials":2858,"activeCount":83},[],{"trials":2860,"activeCount":83},[],{"intervention":2836,"totalTrials":480,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2864,"activeCount":83},[],{"trials":2866,"activeCount":83},[],{"trials":2868,"activeCount":83},[2869],{"nctId":2827,"briefTitle":2828,"status":89,"phases":2870,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":1799,"conditions":2871,"interventions":2872},[72,73],[2833],[2818,2835,2836],{"trials":2874,"activeCount":83},[],{"trials":2876,"activeCount":83},[],{"trials":2878,"activeCount":83},[],{"intervention":2880,"totalTrials":480,"cells":2881},"Tralokinumab",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2883,"activeCount":83},[],{"trials":2885,"activeCount":83},[],{"trials":2887,"activeCount":83},[2888],{"nctId":2889,"briefTitle":2890,"status":167,"phases":2891,"primaryCompletion":2892,"completion":823,"start":2893,"enrollment":2045,"conditions":2894,"interventions":2896},"NCT01629667","A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis",[73],"2015-05","2012-10",[2895],"Idiopathic Pulmonary Fibrosis",[2880,2880],{"trials":2898,"activeCount":83},[],{"trials":2900,"activeCount":83},[],{"trials":2902,"activeCount":83},[],{"intervention":2510,"totalTrials":480,"cells":2904},{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2906,"activeCount":83},[],{"trials":2908,"activeCount":83},[],{"trials":2910,"activeCount":83},[2911],{"nctId":2500,"briefTitle":2501,"status":89,"phases":2912,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":2505,"conditions":2913,"interventions":2914},[72,73],[2507,2508],[2478,2510,2511,2512,2513],{"trials":2916,"activeCount":83},[],{"trials":2918,"activeCount":83},[],{"trials":2920,"activeCount":83},[],{"intervention":2511,"totalTrials":480,"cells":2922},{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2924,"activeCount":83},[],{"trials":2926,"activeCount":83},[],{"trials":2928,"activeCount":83},[2929],{"nctId":2500,"briefTitle":2501,"status":89,"phases":2930,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":2505,"conditions":2931,"interventions":2932},[72,73],[2507,2508],[2478,2510,2511,2512,2513],{"trials":2934,"activeCount":83},[],{"trials":2936,"activeCount":83},[],{"trials":2938,"activeCount":83},[],{"intervention":2512,"totalTrials":480,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2942,"activeCount":83},[],{"trials":2944,"activeCount":83},[],{"trials":2946,"activeCount":83},[2947],{"nctId":2500,"briefTitle":2501,"status":89,"phases":2948,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":2505,"conditions":2949,"interventions":2950},[72,73],[2507,2508],[2478,2510,2511,2512,2513],{"trials":2952,"activeCount":83},[],{"trials":2954,"activeCount":83},[],{"trials":2956,"activeCount":83},[],{"intervention":2513,"totalTrials":480,"cells":2958},{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2960,"activeCount":83},[],{"trials":2962,"activeCount":83},[],{"trials":2964,"activeCount":83},[2965],{"nctId":2500,"briefTitle":2501,"status":89,"phases":2966,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":2505,"conditions":2967,"interventions":2968},[72,73],[2507,2508],[2478,2510,2511,2512,2513],{"trials":2970,"activeCount":83},[],{"trials":2972,"activeCount":83},[],{"trials":2974,"activeCount":83},[],{"intervention":2976,"totalTrials":480,"cells":2977},"MEDI0382 high dose",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2979,"activeCount":83},[],{"trials":2981,"activeCount":83},[],{"trials":2983,"activeCount":83},[2984],{"nctId":2985,"briefTitle":2986,"status":89,"phases":2987,"primaryCompletion":2988,"completion":2988,"start":2989,"enrollment":2990,"conditions":2991,"interventions":2994},"NCT04019561","A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD\u002FNASH.",[73],"2021-05-06","2019-09-23",74,[2992,2993],"Non-alcoholic Fatty Liver Disease (NAFLD)","Non-alcoholic Steatohepatitis (NASH)",[2976,2995],"MEDI0382 low dose",{"trials":2997,"activeCount":83},[],{"trials":2999,"activeCount":83},[],{"trials":3001,"activeCount":83},[],{"intervention":2995,"totalTrials":480,"cells":3003},{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":3005,"activeCount":83},[],{"trials":3007,"activeCount":83},[],{"trials":3009,"activeCount":83},[3010],{"nctId":2985,"briefTitle":2986,"status":89,"phases":3011,"primaryCompletion":2988,"completion":2988,"start":2989,"enrollment":2990,"conditions":3012,"interventions":3013},[73],[2992,2993],[2976,2995],{"trials":3015,"activeCount":83},[],{"trials":3017,"activeCount":83},[],{"trials":3019,"activeCount":83},[],{"intervention":3021,"totalTrials":480,"cells":3022},"Amifostine",{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3024,"activeCount":83},[],{"trials":3026,"activeCount":83},[],{"trials":3028,"activeCount":83},[3029],{"nctId":3030,"briefTitle":3031,"status":89,"phases":3032,"completion":2540,"start":2531,"enrollment":3033,"conditions":3034,"interventions":3038},"NCT00081315","Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer",[73],130,[3035,3036,3037],"Esophagitis","Pneumonitis","Non-Small Cell Lung Carcinoma",[3021],{"trials":3040,"activeCount":83},[],{"trials":3042,"activeCount":83},[],{"trials":3044,"activeCount":83},[],{"intervention":3046,"totalTrials":480,"cells":3047},"Frozen FluMist®",{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3049,"activeCount":83},[],{"trials":3051,"activeCount":83},[],{"trials":3053,"activeCount":83},[3054],{"nctId":3055,"briefTitle":3056,"status":89,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":750,"conditions":3060,"interventions":3061},"NCT00480155","A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults",[73],"2007-12","2007-05",[15],[3046],{"trials":3063,"activeCount":83},[],{"trials":3065,"activeCount":83},[],{"trials":3067,"activeCount":83},[],{"intervention":3069,"totalTrials":480,"cells":3070},"TIV, Trivalent Inactivated Influenza Virus Vaccine",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3072,"activeCount":83},[],{"trials":3074,"activeCount":83},[],{"trials":3076,"activeCount":83},[3077],{"nctId":3078,"briefTitle":3079,"status":89,"phases":3080,"primaryCompletion":3058,"completion":3081,"start":3059,"enrollment":3082,"conditions":3083,"interventions":3085},"NCT00461981","A Phase 2 Study to Evaluate Immune Responses of FluMist®",[73],"2008-02",101,[3084],"Influenza Vaccine",[3069,3086],"FluMist, Influenza Virus Vaccine Live",{"trials":3088,"activeCount":83},[],{"trials":3090,"activeCount":83},[],{"trials":3092,"activeCount":83},[],{"intervention":3086,"totalTrials":480,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3105,"PHASE4":3107,"NA":3109},{"trials":3096,"activeCount":83},[],{"trials":3098,"activeCount":83},[],{"trials":3100,"activeCount":83},[3101],{"nctId":3078,"briefTitle":3079,"status":89,"phases":3102,"primaryCompletion":3058,"completion":3081,"start":3059,"enrollment":3082,"conditions":3103,"interventions":3104},[73],[3084],[3069,3086],{"trials":3106,"activeCount":83},[],{"trials":3108,"activeCount":83},[],{"trials":3110,"activeCount":83},[],{"intervention":1924,"totalTrials":480,"cells":3112},{"EARLY_PHASE1":3113,"PHASE1":3115,"PHASE2":3117,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3114,"activeCount":83},[],{"trials":3116,"activeCount":83},[],{"trials":3118,"activeCount":83},[3119],{"nctId":1914,"briefTitle":1915,"status":89,"phases":3120,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":3121,"interventions":3122},[73],[1922],[1881,1924],{"trials":3124,"activeCount":83},[],{"trials":3126,"activeCount":83},[],{"trials":3128,"activeCount":83},[],{"intervention":398,"totalTrials":480,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":83},[],{"trials":3134,"activeCount":83},[],{"trials":3136,"activeCount":83},[3137],{"nctId":389,"briefTitle":390,"status":89,"phases":3138,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":3139,"interventions":3140},[72,73],[396],[398,398,337,41,399,398],{"trials":3142,"activeCount":83},[],{"trials":3144,"activeCount":83},[],{"trials":3146,"activeCount":83},[],{"intervention":399,"totalTrials":480,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":83},[],{"trials":3152,"activeCount":83},[],{"trials":3154,"activeCount":83},[3155],{"nctId":389,"briefTitle":390,"status":89,"phases":3156,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":3157,"interventions":3158},[72,73],[396],[398,398,337,41,399,398],{"trials":3160,"activeCount":83},[],{"trials":3162,"activeCount":83},[],{"trials":3164,"activeCount":83},[],{"intervention":3166,"totalTrials":480,"cells":3167},"MEDI528 30 mg",{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3169,"activeCount":83},[],{"trials":3171,"activeCount":83},[],{"trials":3173,"activeCount":83},[3174],{"nctId":3175,"briefTitle":3176,"status":89,"phases":3177,"primaryCompletion":3178,"completion":3179,"start":915,"enrollment":3180,"conditions":3181,"interventions":3182},"NCT00968669","A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults",[73],"2011-11","2012-01",329,[21],[3166,3183,3184],"MEDI528 100 mg","MEDI528 300 mg",{"trials":3186,"activeCount":83},[],{"trials":3188,"activeCount":83},[],{"trials":3190,"activeCount":83},[],{"intervention":3183,"totalTrials":480,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":83},[],{"trials":3196,"activeCount":83},[],{"trials":3198,"activeCount":83},[3199],{"nctId":3175,"briefTitle":3176,"status":89,"phases":3200,"primaryCompletion":3178,"completion":3179,"start":915,"enrollment":3180,"conditions":3201,"interventions":3202},[73],[21],[3166,3183,3184],{"trials":3204,"activeCount":83},[],{"trials":3206,"activeCount":83},[],{"trials":3208,"activeCount":83},[],{"intervention":3184,"totalTrials":480,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3212,"activeCount":83},[],{"trials":3214,"activeCount":83},[],{"trials":3216,"activeCount":83},[3217],{"nctId":3175,"briefTitle":3176,"status":89,"phases":3218,"primaryCompletion":3178,"completion":3179,"start":915,"enrollment":3180,"conditions":3219,"interventions":3220},[73],[21],[3166,3183,3184],{"trials":3222,"activeCount":83},[],{"trials":3224,"activeCount":83},[],{"trials":3226,"activeCount":83},[],{"intervention":3228,"totalTrials":480,"cells":3229},"CAIV-T 10^7",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3244,"PHASE4":3246,"NA":3248},{"trials":3231,"activeCount":83},[],{"trials":3233,"activeCount":83},[],{"trials":3235,"activeCount":83},[3236],{"nctId":3237,"briefTitle":3238,"status":89,"phases":3239,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":3240,"conditions":3241,"interventions":3242},"NCT00192322","Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children",[73],173,[18],[3228,3243,1090],"CAIVT 10^5",{"trials":3245,"activeCount":83},[],{"trials":3247,"activeCount":83},[],{"trials":3249,"activeCount":83},[],{"intervention":3243,"totalTrials":480,"cells":3251},{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3253,"activeCount":83},[],{"trials":3255,"activeCount":83},[],{"trials":3257,"activeCount":83},[3258],{"nctId":3237,"briefTitle":3238,"status":89,"phases":3259,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":3240,"conditions":3260,"interventions":3261},[73],[18],[3228,3243,1090],{"trials":3263,"activeCount":83},[],{"trials":3265,"activeCount":83},[],{"trials":3267,"activeCount":83},[],{"intervention":3269,"totalTrials":480,"cells":3270},"MEDI528 9 mg\u002Fkg",{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3272,"activeCount":83},[],{"trials":3274,"activeCount":83},[],{"trials":3276,"activeCount":83},[3277],{"nctId":3278,"briefTitle":3279,"status":167,"phases":3280,"primaryCompletion":3281,"completion":2682,"start":3282,"enrollment":28,"conditions":3283,"interventions":3284},"NCT00483041","A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528",[73],"2008-10","2007-07",[21],[3269],{"trials":3286,"activeCount":83},[],{"trials":3288,"activeCount":83},[],{"trials":3290,"activeCount":83},[],{"intervention":208,"totalTrials":480,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":83},[],{"trials":3296,"activeCount":83},[],{"trials":3298,"activeCount":83},[3299],{"nctId":198,"briefTitle":199,"status":89,"phases":3300,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":3301,"interventions":3302},[72,73],[205,206],[208,60],{"trials":3304,"activeCount":83},[],{"trials":3306,"activeCount":83},[],{"trials":3308,"activeCount":83},[],{"intervention":3310,"totalTrials":480,"cells":3311},"Benralizumab",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3313,"activeCount":83},[],{"trials":3315,"activeCount":83},[],{"trials":3317,"activeCount":83},[3318],{"nctId":3319,"briefTitle":3320,"status":89,"phases":3321,"primaryCompletion":3322,"completion":3323,"start":3324,"enrollment":3325,"conditions":3326,"interventions":3327},"NCT00768079","A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).",[73],"2010-12-17","2011-03-10","2009-02-02",110,[21],[3310],{"trials":3329,"activeCount":83},[],{"trials":3331,"activeCount":83},[],{"trials":3333,"activeCount":83},[],{"intervention":3335,"totalTrials":480,"cells":3336},"MEDI-534, Cohort 1",{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3354,"PHASE4":3356,"NA":3358},{"trials":3338,"activeCount":83},[],{"trials":3340,"activeCount":83},[],{"trials":3342,"activeCount":83},[3343],{"nctId":3344,"briefTitle":3345,"status":89,"phases":3346,"primaryCompletion":2012,"completion":2012,"start":792,"enrollment":3347,"conditions":3348,"interventions":3349},"NCT00686075","A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to \u003C24 Month-old Children and in 2 Month-old Infants",[72,73],1338,[15],[3335,3350,3351,3352,3353],"MEDI-534, Cohort 2","MEDI-534, Cohort 3","MEDI-534, Cohort 4","MEDI-534, Cohort 5",{"trials":3355,"activeCount":83},[],{"trials":3357,"activeCount":83},[],{"trials":3359,"activeCount":83},[],{"intervention":3350,"totalTrials":480,"cells":3361},{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3372,"PHASE4":3374,"NA":3376},{"trials":3363,"activeCount":83},[],{"trials":3365,"activeCount":83},[],{"trials":3367,"activeCount":83},[3368],{"nctId":3344,"briefTitle":3345,"status":89,"phases":3369,"primaryCompletion":2012,"completion":2012,"start":792,"enrollment":3347,"conditions":3370,"interventions":3371},[72,73],[15],[3335,3350,3351,3352,3353],{"trials":3373,"activeCount":83},[],{"trials":3375,"activeCount":83},[],{"trials":3377,"activeCount":83},[],{"intervention":3351,"totalTrials":480,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3381,"activeCount":83},[],{"trials":3383,"activeCount":83},[],{"trials":3385,"activeCount":83},[3386],{"nctId":3344,"briefTitle":3345,"status":89,"phases":3387,"primaryCompletion":2012,"completion":2012,"start":792,"enrollment":3347,"conditions":3388,"interventions":3389},[72,73],[15],[3335,3350,3351,3352,3353],{"trials":3391,"activeCount":83},[],{"trials":3393,"activeCount":83},[],{"trials":3395,"activeCount":83},[],{"intervention":3352,"totalTrials":480,"cells":3397},{"EARLY_PHASE1":3398,"PHASE1":3400,"PHASE2":3402,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3399,"activeCount":83},[],{"trials":3401,"activeCount":83},[],{"trials":3403,"activeCount":83},[3404],{"nctId":3344,"briefTitle":3345,"status":89,"phases":3405,"primaryCompletion":2012,"completion":2012,"start":792,"enrollment":3347,"conditions":3406,"interventions":3407},[72,73],[15],[3335,3350,3351,3352,3353],{"trials":3409,"activeCount":83},[],{"trials":3411,"activeCount":83},[],{"trials":3413,"activeCount":83},[],{"intervention":3353,"totalTrials":480,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3417,"activeCount":83},[],{"trials":3419,"activeCount":83},[],{"trials":3421,"activeCount":83},[3422],{"nctId":3344,"briefTitle":3345,"status":89,"phases":3423,"primaryCompletion":2012,"completion":2012,"start":792,"enrollment":3347,"conditions":3424,"interventions":3425},[72,73],[15],[3335,3350,3351,3352,3353],{"trials":3427,"activeCount":83},[],{"trials":3429,"activeCount":83},[],{"trials":3431,"activeCount":83},[],{"intervention":3433,"totalTrials":480,"cells":3434},"MEDI8968 600 mg IV, 300 mg SC",{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3450,"PHASE4":3452,"NA":3454},{"trials":3436,"activeCount":83},[],{"trials":3438,"activeCount":83},[],{"trials":3440,"activeCount":83},[3441],{"nctId":3442,"briefTitle":3443,"status":89,"phases":3444,"primaryCompletion":3445,"completion":3445,"start":3178,"enrollment":3446,"conditions":3447,"interventions":3449},"NCT01448850","A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease",[73],"2014-02",464,[3448],"Chronic Obstructive Pulmonary Disease",[3433],{"trials":3451,"activeCount":83},[],{"trials":3453,"activeCount":83},[],{"trials":3455,"activeCount":83},[],{"intervention":221,"totalTrials":480,"cells":3457},{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3459,"activeCount":83},[],{"trials":3461,"activeCount":83},[],{"trials":3463,"activeCount":83},[3464],{"nctId":210,"briefTitle":211,"status":89,"phases":3465,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":3466,"interventions":3467},[73],[217,218,219],[60,50,55,221],{"trials":3469,"activeCount":83},[],{"trials":3471,"activeCount":83},[],{"trials":3473,"activeCount":83},[],{"intervention":2355,"totalTrials":480,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3486,"PHASE4":3488,"NA":3490},{"trials":3477,"activeCount":83},[],{"trials":3479,"activeCount":83},[],{"trials":3481,"activeCount":83},[3482],{"nctId":2348,"briefTitle":2349,"status":89,"phases":3483,"primaryCompletion":2022,"completion":2351,"start":938,"enrollment":2352,"conditions":3484,"interventions":3485},[73],[21],[2355,2356,2339],{"trials":3487,"activeCount":83},[],{"trials":3489,"activeCount":83},[],{"trials":3491,"activeCount":83},[],{"intervention":2356,"totalTrials":480,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3495,"activeCount":83},[],{"trials":3497,"activeCount":83},[],{"trials":3499,"activeCount":83},[3500],{"nctId":2348,"briefTitle":2349,"status":89,"phases":3501,"primaryCompletion":2022,"completion":2351,"start":938,"enrollment":2352,"conditions":3502,"interventions":3503},[73],[21],[2355,2356,2339],{"trials":3505,"activeCount":83},[],{"trials":3507,"activeCount":83},[],{"trials":3509,"activeCount":83},[],{"intervention":2016,"totalTrials":480,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3513,"activeCount":83},[],{"trials":3515,"activeCount":83},[],{"trials":3517,"activeCount":83},[3518],{"nctId":2008,"briefTitle":2009,"status":89,"phases":3519,"primaryCompletion":815,"completion":2011,"start":2012,"enrollment":1817,"conditions":3520,"interventions":3521},[73],[35],[2015,1999,2016],{"trials":3523,"activeCount":83},[],{"trials":3525,"activeCount":83},[],{"trials":3527,"activeCount":83},[],{"intervention":3529,"totalTrials":480,"cells":3530},"Anifrolumab 300 mg",{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3532,"activeCount":83},[],{"trials":3534,"activeCount":83},[],{"trials":3536,"activeCount":83},[3537],{"nctId":3538,"briefTitle":3539,"status":89,"phases":3540,"primaryCompletion":3541,"completion":3541,"start":3179,"enrollment":3542,"conditions":3543,"interventions":3545},"NCT01438489","A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus",[73],"2015-04",626,[3544],"Systemic Lupus Erythematosus",[3529,3546],"Anifrolumab 1000 mg",{"trials":3548,"activeCount":83},[],{"trials":3550,"activeCount":83},[],{"trials":3552,"activeCount":83},[],{"intervention":3546,"totalTrials":480,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3556,"activeCount":83},[],{"trials":3558,"activeCount":83},[],{"trials":3560,"activeCount":83},[3561],{"nctId":3538,"briefTitle":3539,"status":89,"phases":3562,"primaryCompletion":3541,"completion":3541,"start":3179,"enrollment":3542,"conditions":3563,"interventions":3564},[73],[3544],[3529,3546],{"trials":3566,"activeCount":83},[],{"trials":3568,"activeCount":83},[],{"trials":3570,"activeCount":83},[],{"intervention":3572,"totalTrials":480,"cells":3573},"MEDI 517",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3575,"activeCount":83},[],{"trials":3577,"activeCount":83},[],{"trials":3579,"activeCount":83},[3580],{"nctId":3581,"briefTitle":3582,"status":89,"phases":3583,"primaryCompletion":1123,"completion":1122,"start":1130,"enrollment":1187,"conditions":3584,"interventions":3585},"NCT00263744","Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive",[72,73],[15],[3572],{"trials":3587,"activeCount":83},[],{"trials":3589,"activeCount":83},[],{"trials":3591,"activeCount":83},[],{"intervention":3593,"totalTrials":480,"cells":3594},"MEDI8897",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3596,"activeCount":83},[],{"trials":3598,"activeCount":83},[],{"trials":3600,"activeCount":83},[3601],{"nctId":3602,"briefTitle":3603,"status":89,"phases":3604,"primaryCompletion":3605,"completion":1701,"start":2443,"enrollment":3606,"conditions":3607,"interventions":3608},"NCT02878330","A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.",[73],"2018-07-17",1453,[30],[3593],{"trials":3610,"activeCount":83},[],{"trials":3612,"activeCount":83},[],{"trials":3614,"activeCount":83},[],{"intervention":3616,"totalTrials":480,"cells":3617},"Tralokinumab 300 mg, Q2W",{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3634,"PHASE4":3636,"NA":3638},{"trials":3619,"activeCount":83},[],{"trials":3621,"activeCount":83},[],{"trials":3623,"activeCount":83},[3624],{"nctId":3625,"briefTitle":3626,"status":89,"phases":3627,"primaryCompletion":3628,"completion":3445,"start":3629,"enrollment":3630,"conditions":3631,"interventions":3632},"NCT01402986","A Safety and Efficacy Study of Tralokinumab in Adults With Asthma",[73],"2013-06","2011-08",689,[21],[3616,3633],"Tralokinumab 300 mg, Q2\u002F4W",{"trials":3635,"activeCount":83},[],{"trials":3637,"activeCount":83},[],{"trials":3639,"activeCount":83},[],{"intervention":3633,"totalTrials":480,"cells":3641},{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3646,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3643,"activeCount":83},[],{"trials":3645,"activeCount":83},[],{"trials":3647,"activeCount":83},[3648],{"nctId":3625,"briefTitle":3626,"status":89,"phases":3649,"primaryCompletion":3628,"completion":3445,"start":3629,"enrollment":3630,"conditions":3650,"interventions":3651},[73],[21],[3616,3633],{"trials":3653,"activeCount":83},[],{"trials":3655,"activeCount":83},[],{"trials":3657,"activeCount":83},[],{"intervention":3659,"totalTrials":480,"cells":3660},"MEDI-493",{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3662,"activeCount":83},[],{"trials":3664,"activeCount":83},[],{"trials":3666,"activeCount":83},[3667],{"nctId":3668,"briefTitle":3669,"status":89,"phases":3670,"completion":3671,"start":1054,"enrollment":1920,"conditions":3672,"interventions":3674},"NCT00240929","A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)",[73],"2003-04",[3673],"-Unhealthy Children With a History of Prematurity",[3659],{"trials":3676,"activeCount":83},[],{"trials":3678,"activeCount":83},[],{"trials":3680,"activeCount":83},[],{"intervention":233,"totalTrials":480,"cells":3682},{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3684,"activeCount":83},[],{"trials":3686,"activeCount":83},[],{"trials":3688,"activeCount":83},[3689],{"nctId":223,"briefTitle":224,"status":89,"phases":3690,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":3691,"interventions":3692},[73],[230,231],[233,60,234],{"trials":3694,"activeCount":83},[],{"trials":3696,"activeCount":83},[],{"trials":3698,"activeCount":83},[],{"intervention":234,"totalTrials":480,"cells":3700},{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3705,"PHASE3":3711,"PHASE4":3713,"NA":3715},{"trials":3702,"activeCount":83},[],{"trials":3704,"activeCount":83},[],{"trials":3706,"activeCount":83},[3707],{"nctId":223,"briefTitle":224,"status":89,"phases":3708,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":3709,"interventions":3710},[73],[230,231],[233,60,234],{"trials":3712,"activeCount":83},[],{"trials":3714,"activeCount":83},[],{"trials":3716,"activeCount":83},[],{"intervention":1704,"totalTrials":480,"cells":3718},{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3720,"activeCount":83},[],{"trials":3722,"activeCount":83},[],{"trials":3724,"activeCount":83},[3725],{"nctId":1698,"briefTitle":1699,"status":89,"phases":3726,"primaryCompletion":1701,"completion":1701,"start":443,"enrollment":1223,"conditions":3727,"interventions":3728},[73],[33],[1615,1704,1705],{"trials":3730,"activeCount":83},[],{"trials":3732,"activeCount":83},[],{"trials":3734,"activeCount":83},[],{"intervention":1705,"totalTrials":480,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3738,"activeCount":83},[],{"trials":3740,"activeCount":83},[],{"trials":3742,"activeCount":83},[3743],{"nctId":1698,"briefTitle":1699,"status":89,"phases":3744,"primaryCompletion":1701,"completion":1701,"start":443,"enrollment":1223,"conditions":3745,"interventions":3746},[73],[33],[1615,1704,1705],{"trials":3748,"activeCount":83},[],{"trials":3750,"activeCount":83},[],{"trials":3752,"activeCount":83},[],{"intervention":1714,"totalTrials":480,"cells":3754},{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3756,"activeCount":83},[],{"trials":3758,"activeCount":83},[],{"trials":3760,"activeCount":83},[3761],{"nctId":1707,"briefTitle":1708,"status":89,"phases":3762,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":1655,"conditions":3763,"interventions":3764},[73],[33],[1615,1714],{"trials":3766,"activeCount":83},[],{"trials":3768,"activeCount":83},[],{"trials":3770,"activeCount":83},[],{"intervention":2026,"totalTrials":480,"cells":3772},{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3774,"activeCount":83},[],{"trials":3776,"activeCount":83},[],{"trials":3778,"activeCount":83},[3779],{"nctId":2018,"briefTitle":2019,"status":89,"phases":3780,"primaryCompletion":2021,"completion":1636,"start":2022,"enrollment":2023,"conditions":3781,"interventions":3782},[73],[35],[2026,1999],{"trials":3784,"activeCount":83},[],{"trials":3786,"activeCount":83},[],{"trials":3788,"activeCount":83},[],{"intervention":3790,"totalTrials":480,"cells":3791},"MEDI-559",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3793,"activeCount":83},[],{"trials":3795,"activeCount":83},[],{"trials":3797,"activeCount":83},[3798],{"nctId":3799,"briefTitle":3800,"status":89,"phases":3801,"primaryCompletion":3802,"completion":3802,"start":3281,"enrollment":3803,"conditions":3804,"interventions":3805},"NCT00767416","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to \u003C24 Month-Old Children",[72,73],"2011-12",116,[15],[3790],{"trials":3807,"activeCount":83},[],{"trials":3809,"activeCount":83},[],{"trials":3811,"activeCount":83},[],{"intervention":3813,"totalTrials":480,"cells":3814},"MEDI-560",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3828,"PHASE4":3830,"NA":3832},{"trials":3816,"activeCount":83},[],{"trials":3818,"activeCount":83},[],{"trials":3820,"activeCount":83},[3821],{"nctId":3822,"briefTitle":3823,"status":167,"phases":3824,"primaryCompletion":3825,"completion":3825,"start":846,"enrollment":2288,"conditions":3826,"interventions":3827},"NCT00508651","A Phase 1\u002F2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to \u003C 12 Months of Age",[72,73],"2009-04",[15],[3813],{"trials":3829,"activeCount":83},[],{"trials":3831,"activeCount":83},[],{"trials":3833,"activeCount":83},[],{"intervention":3835,"totalTrials":480,"cells":3836},"AMG 557\u002FMEDI5872",{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3838,"activeCount":83},[],{"trials":3840,"activeCount":83},[],{"trials":3842,"activeCount":83},[3843],{"nctId":3844,"briefTitle":3845,"status":89,"phases":3846,"primaryCompletion":3847,"completion":3848,"start":3849,"enrollment":370,"conditions":3850,"interventions":3852},"NCT02334306","A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557\u002FMEDI5872 in Primary Sjögren's Syndrome",[73],"2018-01-16","2018-08-13","2015-06-08",[3851],"Primary Sjögren's Syndrome",[3835],{"trials":3854,"activeCount":83},[],{"trials":3856,"activeCount":83},[],{"trials":3858,"activeCount":83},[],{"intervention":3860,"totalTrials":480,"cells":3861},"MEDI6469 Monotherapy",{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3880,"PHASE4":3882,"NA":3884},{"trials":3863,"activeCount":83},[],{"trials":3865,"activeCount":83},[],{"trials":3867,"activeCount":83},[3868],{"nctId":3869,"briefTitle":3870,"status":167,"phases":3871,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":2445,"conditions":3874,"interventions":3876},"NCT02205333","A Phase 1b\u002F2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies",[72,73],"2016-04-08","2014-08-13",[27,3875],"Aggressive B-cell Lymphomas",[3860,3877,3878,3879],"MEDI6469 Plus Tremelimumab","MEDI6469 Plus Durvalumab","MEDI6469 plus Rituximab",{"trials":3881,"activeCount":83},[],{"trials":3883,"activeCount":83},[],{"trials":3885,"activeCount":83},[],{"intervention":3877,"totalTrials":480,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3889,"activeCount":83},[],{"trials":3891,"activeCount":83},[],{"trials":3893,"activeCount":83},[3894],{"nctId":3869,"briefTitle":3870,"status":167,"phases":3895,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":2445,"conditions":3896,"interventions":3897},[72,73],[27,3875],[3860,3877,3878,3879],{"trials":3899,"activeCount":83},[],{"trials":3901,"activeCount":83},[],{"trials":3903,"activeCount":83},[],{"intervention":3878,"totalTrials":480,"cells":3905},{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3907,"activeCount":83},[],{"trials":3909,"activeCount":83},[],{"trials":3911,"activeCount":83},[3912],{"nctId":3869,"briefTitle":3870,"status":167,"phases":3913,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":2445,"conditions":3914,"interventions":3915},[72,73],[27,3875],[3860,3877,3878,3879],{"trials":3917,"activeCount":83},[],{"trials":3919,"activeCount":83},[],{"trials":3921,"activeCount":83},[],{"intervention":3879,"totalTrials":480,"cells":3923},{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3925,"activeCount":83},[],{"trials":3927,"activeCount":83},[],{"trials":3929,"activeCount":83},[3930],{"nctId":3869,"briefTitle":3870,"status":167,"phases":3931,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":2445,"conditions":3932,"interventions":3933},[72,73],[27,3875],[3860,3877,3878,3879],{"trials":3935,"activeCount":83},[],{"trials":3937,"activeCount":83},[],{"trials":3939,"activeCount":83},[],{"intervention":3941,"totalTrials":480,"cells":3942},"Idarubincin and Amufostine",{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3947,"PHASE3":3959,"PHASE4":3961,"NA":3963},{"trials":3944,"activeCount":83},[],{"trials":3946,"activeCount":83},[],{"trials":3948,"activeCount":83},[3949],{"nctId":3950,"briefTitle":3951,"status":89,"phases":3952,"primaryCompletion":1485,"completion":3953,"start":1147,"enrollment":3954,"conditions":3955,"interventions":3957},"NCT00086099","Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia",[72,73],"2006-02",54,[1754,3956],"Acute Myeloid Leukemia",[3941,3958],"Idarubincin",{"trials":3960,"activeCount":83},[],{"trials":3962,"activeCount":83},[],{"trials":3964,"activeCount":83},[],{"intervention":3958,"totalTrials":480,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3971,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3968,"activeCount":83},[],{"trials":3970,"activeCount":83},[],{"trials":3972,"activeCount":83},[3973],{"nctId":3950,"briefTitle":3951,"status":89,"phases":3974,"primaryCompletion":1485,"completion":3953,"start":1147,"enrollment":3954,"conditions":3975,"interventions":3976},[72,73],[1754,3956],[3941,3958],{"trials":3978,"activeCount":83},[],{"trials":3980,"activeCount":83},[],{"trials":3982,"activeCount":83},[],{"intervention":2139,"totalTrials":480,"cells":3984},{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3995,"PHASE4":3997,"NA":3999},{"trials":3986,"activeCount":83},[],{"trials":3988,"activeCount":83},[],{"trials":3990,"activeCount":83},[3991],{"nctId":2130,"briefTitle":2131,"status":89,"phases":3992,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":3993,"interventions":3994},[73],[2137],[2103,2139],{"trials":3996,"activeCount":83},[],{"trials":3998,"activeCount":83},[],{"trials":4000,"activeCount":83},[],{"intervention":4002,"totalTrials":480,"cells":4003},"IPI-504",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4018,"PHASE4":4020,"NA":4022},{"trials":4005,"activeCount":83},[],{"trials":4007,"activeCount":83},[],{"trials":4009,"activeCount":83},[4010],{"nctId":4011,"briefTitle":4012,"status":1977,"phases":4013,"primaryCompletion":4014,"start":2318,"enrollment":1851,"conditions":4015,"interventions":4017},"NCT00627627","A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer",[72,73],"2010-02",[4016],"Breast Cancer",[4002],{"trials":4019,"activeCount":83},[],{"trials":4021,"activeCount":83},[],{"trials":4023,"activeCount":83},[],{"intervention":248,"totalTrials":480,"cells":4025},{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4036,"PHASE4":4038,"NA":4040},{"trials":4027,"activeCount":83},[],{"trials":4029,"activeCount":83},[],{"trials":4031,"activeCount":83},[4032],{"nctId":236,"briefTitle":237,"status":89,"phases":4033,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":4034,"interventions":4035},[72,73],[243,244,245],[247,60,248],{"trials":4037,"activeCount":83},[],{"trials":4039,"activeCount":83},[],{"trials":4041,"activeCount":83},[],{"intervention":4043,"totalTrials":480,"cells":4044},"Trivalent influenza virus vaccine live, intranasal",{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4046,"activeCount":83},[],{"trials":4048,"activeCount":83},[],{"trials":4050,"activeCount":83},[4051],{"nctId":4052,"briefTitle":4053,"status":89,"phases":4054,"primaryCompletion":4055,"completion":4056,"start":4057,"enrollment":1009,"conditions":4058,"interventions":4059},"NCT00344305","A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children",[73],"2006-07-01","2006-12-01","2006-05-01",[15],[4043],{"trials":4061,"activeCount":83},[],{"trials":4063,"activeCount":83},[],{"trials":4065,"activeCount":83},[],{"intervention":4067,"totalTrials":480,"cells":4068},"BL22",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4083,"PHASE4":4085,"NA":4087},{"trials":4070,"activeCount":83},[],{"trials":4072,"activeCount":83},[],{"trials":4074,"activeCount":83},[4075],{"nctId":4076,"briefTitle":4077,"status":89,"phases":4078,"primaryCompletion":1917,"completion":790,"start":4079,"enrollment":4080,"conditions":4081,"interventions":4082},"NCT00074048","BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia",[73],"2003-10",36,[1754],[4067],{"trials":4084,"activeCount":83},[],{"trials":4086,"activeCount":83},[],{"trials":4088,"activeCount":83},[],{"intervention":2365,"totalTrials":480,"cells":4090},{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4101,"PHASE4":4103,"NA":4105},{"trials":4092,"activeCount":83},[],{"trials":4094,"activeCount":83},[],{"trials":4096,"activeCount":83},[4097],{"nctId":2358,"briefTitle":2359,"status":89,"phases":4098,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":203,"conditions":4099,"interventions":4100},[73],[21],[2365,2339,2366],{"trials":4102,"activeCount":83},[],{"trials":4104,"activeCount":83},[],{"trials":4106,"activeCount":83},[],{"intervention":2366,"totalTrials":480,"cells":4108},{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4110,"activeCount":83},[],{"trials":4112,"activeCount":83},[],{"trials":4114,"activeCount":83},[4115],{"nctId":2358,"briefTitle":2359,"status":89,"phases":4116,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":203,"conditions":4117,"interventions":4118},[73],[21],[2365,2339,2366],{"trials":4120,"activeCount":83},[],{"trials":4122,"activeCount":83},[],{"trials":4124,"activeCount":83},[],{"intervention":4126,"totalTrials":480,"cells":4127},"MEDI5884",{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4132,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4129,"activeCount":83},[],{"trials":4131,"activeCount":83},[],{"trials":4133,"activeCount":83},[4134],{"nctId":4135,"briefTitle":4136,"status":89,"phases":4137,"primaryCompletion":4138,"completion":4138,"start":4139,"enrollment":4140,"conditions":4141,"interventions":4143},"NCT03351738","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease",[73],"2018-11-09","2017-12-13",133,[4142],"Stable Coronary Heart Disease",[4126],{"trials":4145,"activeCount":83},[],{"trials":4147,"activeCount":83},[],{"trials":4149,"activeCount":83},[],{"intervention":2186,"totalTrials":480,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4153,"activeCount":83},[],{"trials":4155,"activeCount":83},[],{"trials":4157,"activeCount":83},[4158],{"nctId":2178,"briefTitle":2179,"status":89,"phases":4159,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":4160,"interventions":4161},[73],[372],[2186,2147,2187,2188,2189],{"trials":4163,"activeCount":83},[],{"trials":4165,"activeCount":83},[],{"trials":4167,"activeCount":83},[],{"intervention":2187,"totalTrials":480,"cells":4169},{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4180,"PHASE4":4182,"NA":4184},{"trials":4171,"activeCount":83},[],{"trials":4173,"activeCount":83},[],{"trials":4175,"activeCount":83},[4176],{"nctId":2178,"briefTitle":2179,"status":89,"phases":4177,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":4178,"interventions":4179},[73],[372],[2186,2147,2187,2188,2189],{"trials":4181,"activeCount":83},[],{"trials":4183,"activeCount":83},[],{"trials":4185,"activeCount":83},[],{"intervention":2188,"totalTrials":480,"cells":4187},{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4189,"activeCount":83},[],{"trials":4191,"activeCount":83},[],{"trials":4193,"activeCount":83},[4194],{"nctId":2178,"briefTitle":2179,"status":89,"phases":4195,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":4196,"interventions":4197},[73],[372],[2186,2147,2187,2188,2189],{"trials":4199,"activeCount":83},[],{"trials":4201,"activeCount":83},[],{"trials":4203,"activeCount":83},[],{"intervention":2189,"totalTrials":480,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4216,"PHASE4":4218,"NA":4220},{"trials":4207,"activeCount":83},[],{"trials":4209,"activeCount":83},[],{"trials":4211,"activeCount":83},[4212],{"nctId":2178,"briefTitle":2179,"status":89,"phases":4213,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":4214,"interventions":4215},[73],[372],[2186,2147,2187,2188,2189],{"trials":4217,"activeCount":83},[],{"trials":4219,"activeCount":83},[],{"trials":4221,"activeCount":83},[],{"intervention":4223,"totalTrials":480,"cells":4224},"Tralokinumab Dose 1",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4244,"PHASE4":4246,"NA":4248},{"trials":4226,"activeCount":83},[],{"trials":4228,"activeCount":83},[],{"trials":4230,"activeCount":83},[4231],{"nctId":4232,"briefTitle":4233,"status":89,"phases":4234,"primaryCompletion":4235,"completion":4236,"start":4237,"enrollment":4238,"conditions":4239,"interventions":4241},"NCT02347176","Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis",[73],"2015-11-27","2016-02-05","2015-01-23",204,[4240],"Atopic Dermatitis",[4223,4242,4243],"Tralokinumab Dose 2","Tralokinumab Dose 3",{"trials":4245,"activeCount":83},[],{"trials":4247,"activeCount":83},[],{"trials":4249,"activeCount":83},[],{"intervention":4242,"totalTrials":480,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4253,"activeCount":83},[],{"trials":4255,"activeCount":83},[],{"trials":4257,"activeCount":83},[4258],{"nctId":4232,"briefTitle":4233,"status":89,"phases":4259,"primaryCompletion":4235,"completion":4236,"start":4237,"enrollment":4238,"conditions":4260,"interventions":4261},[73],[4240],[4223,4242,4243],{"trials":4263,"activeCount":83},[],{"trials":4265,"activeCount":83},[],{"trials":4267,"activeCount":83},[],{"intervention":4243,"totalTrials":480,"cells":4269},{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4280,"PHASE4":4282,"NA":4284},{"trials":4271,"activeCount":83},[],{"trials":4273,"activeCount":83},[],{"trials":4275,"activeCount":83},[4276],{"nctId":4232,"briefTitle":4233,"status":89,"phases":4277,"primaryCompletion":4235,"completion":4236,"start":4237,"enrollment":4238,"conditions":4278,"interventions":4279},[73],[4240],[4223,4242,4243],{"trials":4281,"activeCount":83},[],{"trials":4283,"activeCount":83},[],{"trials":4285,"activeCount":83},[],{"intervention":4287,"totalTrials":480,"cells":4288},"MEDI528 0.3 mg\u002Fkg",{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4293,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4290,"activeCount":83},[],{"trials":4292,"activeCount":83},[],{"trials":4294,"activeCount":83},[4295],{"nctId":4296,"briefTitle":4297,"status":89,"phases":4298,"primaryCompletion":790,"completion":4299,"start":3282,"enrollment":4080,"conditions":4300,"interventions":4301},"NCT00507130","A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma",[73],"2008-09",[21],[4287,4302,4303],"MEDI528 1 mg\u002Fkg","MEDI528 3 mg\u002Fkg",{"trials":4305,"activeCount":83},[],{"trials":4307,"activeCount":83},[],{"trials":4309,"activeCount":83},[],{"intervention":4302,"totalTrials":480,"cells":4311},{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4313,"activeCount":83},[],{"trials":4315,"activeCount":83},[],{"trials":4317,"activeCount":83},[4318],{"nctId":4296,"briefTitle":4297,"status":89,"phases":4319,"primaryCompletion":790,"completion":4299,"start":3282,"enrollment":4080,"conditions":4320,"interventions":4321},[73],[21],[4287,4302,4303],{"trials":4323,"activeCount":83},[],{"trials":4325,"activeCount":83},[],{"trials":4327,"activeCount":83},[],{"intervention":4303,"totalTrials":480,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4331,"activeCount":83},[],{"trials":4333,"activeCount":83},[],{"trials":4335,"activeCount":83},[4336],{"nctId":4296,"briefTitle":4297,"status":89,"phases":4337,"primaryCompletion":790,"completion":4299,"start":3282,"enrollment":4080,"conditions":4338,"interventions":4339},[73],[21],[4287,4302,4303],{"trials":4341,"activeCount":83},[],{"trials":4343,"activeCount":83},[],{"trials":4345,"activeCount":83},[],{"intervention":4347,"totalTrials":480,"cells":4348},"MEDI6012 40 mg",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4350,"activeCount":83},[],{"trials":4352,"activeCount":83},[],{"trials":4354,"activeCount":83},[4355],{"nctId":4356,"briefTitle":4357,"status":89,"phases":4358,"primaryCompletion":4359,"completion":4359,"start":4360,"enrollment":370,"conditions":4361,"interventions":4364},"NCT03004638","Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease",[73],"2017-11-02","2017-01-23",[4362,4363],"Atherosclerosis","Cardiovascular Disease",[4347,4365,4366,4367],"MEDI6012 120 mg","MEDI6012 300 mg","MEDI6012 IV Push",{"trials":4369,"activeCount":83},[],{"trials":4371,"activeCount":83},[],{"trials":4373,"activeCount":83},[],{"intervention":4365,"totalTrials":480,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4386,"PHASE4":4388,"NA":4390},{"trials":4377,"activeCount":83},[],{"trials":4379,"activeCount":83},[],{"trials":4381,"activeCount":83},[4382],{"nctId":4356,"briefTitle":4357,"status":89,"phases":4383,"primaryCompletion":4359,"completion":4359,"start":4360,"enrollment":370,"conditions":4384,"interventions":4385},[73],[4362,4363],[4347,4365,4366,4367],{"trials":4387,"activeCount":83},[],{"trials":4389,"activeCount":83},[],{"trials":4391,"activeCount":83},[],{"intervention":4366,"totalTrials":480,"cells":4393},{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4404,"PHASE4":4406,"NA":4408},{"trials":4395,"activeCount":83},[],{"trials":4397,"activeCount":83},[],{"trials":4399,"activeCount":83},[4400],{"nctId":4356,"briefTitle":4357,"status":89,"phases":4401,"primaryCompletion":4359,"completion":4359,"start":4360,"enrollment":370,"conditions":4402,"interventions":4403},[73],[4362,4363],[4347,4365,4366,4367],{"trials":4405,"activeCount":83},[],{"trials":4407,"activeCount":83},[],{"trials":4409,"activeCount":83},[],{"intervention":4367,"totalTrials":480,"cells":4411},{"EARLY_PHASE1":4412,"PHASE1":4414,"PHASE2":4416,"PHASE3":4422,"PHASE4":4424,"NA":4426},{"trials":4413,"activeCount":83},[],{"trials":4415,"activeCount":83},[],{"trials":4417,"activeCount":83},[4418],{"nctId":4356,"briefTitle":4357,"status":89,"phases":4419,"primaryCompletion":4359,"completion":4359,"start":4360,"enrollment":370,"conditions":4420,"interventions":4421},[73],[4362,4363],[4347,4365,4366,4367],{"trials":4423,"activeCount":83},[],{"trials":4425,"activeCount":83},[],{"trials":4427,"activeCount":83},[],{"intervention":4429,"totalTrials":480,"cells":4430},"Standard of Care - mFOLFOX6",{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4432,"activeCount":83},[],{"trials":4434,"activeCount":83},[],{"trials":4436,"activeCount":83},[4437],{"nctId":4438,"briefTitle":4439,"status":1977,"phases":4440,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":83,"conditions":4443,"interventions":4445},"NCT04145193","Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC",[73],"2024-03-19","2020-10-01",[4444],"Microsatellite-stable Colorectal Cancer",[4429,4446,4447,4448],"E1 - mFOLFOX and durvalumab","E2 - mFOLFOX6, durvalumab and oleclumab","E3 - mFOLFOX6, durvalumab and monalizumab",{"trials":4450,"activeCount":83},[],{"trials":4452,"activeCount":83},[],{"trials":4454,"activeCount":83},[],{"intervention":4446,"totalTrials":480,"cells":4456},{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4467,"PHASE4":4469,"NA":4471},{"trials":4458,"activeCount":83},[],{"trials":4460,"activeCount":83},[],{"trials":4462,"activeCount":83},[4463],{"nctId":4438,"briefTitle":4439,"status":1977,"phases":4464,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":83,"conditions":4465,"interventions":4466},[73],[4444],[4429,4446,4447,4448],{"trials":4468,"activeCount":83},[],{"trials":4470,"activeCount":83},[],{"trials":4472,"activeCount":83},[],{"intervention":4447,"totalTrials":480,"cells":4474},{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4476,"activeCount":83},[],{"trials":4478,"activeCount":83},[],{"trials":4480,"activeCount":83},[4481],{"nctId":4438,"briefTitle":4439,"status":1977,"phases":4482,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":83,"conditions":4483,"interventions":4484},[73],[4444],[4429,4446,4447,4448],{"trials":4486,"activeCount":83},[],{"trials":4488,"activeCount":83},[],{"trials":4490,"activeCount":83},[],{"intervention":4448,"totalTrials":480,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4503,"PHASE4":4505,"NA":4507},{"trials":4494,"activeCount":83},[],{"trials":4496,"activeCount":83},[],{"trials":4498,"activeCount":83},[4499],{"nctId":4438,"briefTitle":4439,"status":1977,"phases":4500,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":83,"conditions":4501,"interventions":4502},[73],[4444],[4429,4446,4447,4448],{"trials":4504,"activeCount":83},[],{"trials":4506,"activeCount":83},[],{"trials":4508,"activeCount":83},[],{"intervention":4510,"totalTrials":480,"cells":4511},"MEDI528 50 mg",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4525,"PHASE4":4527,"NA":4529},{"trials":4513,"activeCount":83},[],{"trials":4515,"activeCount":83},[],{"trials":4517,"activeCount":83},[4518],{"nctId":4519,"briefTitle":4520,"status":167,"phases":4521,"primaryCompletion":791,"completion":1284,"start":4522,"enrollment":28,"conditions":4523,"interventions":4524},"NCT00590720","A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma",[73],"2008-03",[21],[4510],{"trials":4526,"activeCount":83},[],{"trials":4528,"activeCount":83},[],{"trials":4530,"activeCount":83},[],{"intervention":4532,"totalTrials":480,"cells":4533},"palivizumab 15 mg\u002Fkg",{"EARLY_PHASE1":4534,"PHASE1":4536,"PHASE2":4538,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4535,"activeCount":83},[],{"trials":4537,"activeCount":83},[],{"trials":4539,"activeCount":83},[4540],{"nctId":4541,"briefTitle":4542,"status":89,"phases":4543,"primaryCompletion":3953,"completion":3953,"start":1067,"enrollment":2173,"conditions":4544,"interventions":4546},"NCT00113490","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children",[72,73],[4545],"Motavizumab Administration for a Second Season for RSV Prophylaxis",[1358,4532],{"trials":4548,"activeCount":83},[],{"trials":4550,"activeCount":83},[],{"trials":4552,"activeCount":83},[],{"intervention":2686,"totalTrials":480,"cells":4554},{"EARLY_PHASE1":4555,"PHASE1":4557,"PHASE2":4559,"PHASE3":4565,"PHASE4":4567,"NA":4569},{"trials":4556,"activeCount":83},[],{"trials":4558,"activeCount":83},[],{"trials":4560,"activeCount":83},[4561],{"nctId":2679,"briefTitle":2680,"status":89,"phases":4562,"primaryCompletion":2317,"completion":2317,"start":2682,"enrollment":2683,"conditions":4563,"interventions":4564},[73],[21],[2661,2675,2686],{"trials":4566,"activeCount":83},[],{"trials":4568,"activeCount":83},[],{"trials":4570,"activeCount":83},[],{"intervention":4572,"totalTrials":480,"cells":4573},"MEDI9929 70 mg",{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4592,"PHASE4":4594,"NA":4596},{"trials":4575,"activeCount":83},[],{"trials":4577,"activeCount":83},[],{"trials":4579,"activeCount":83},[4580],{"nctId":4581,"briefTitle":4582,"status":89,"phases":4583,"primaryCompletion":4584,"completion":4585,"start":4586,"enrollment":4587,"conditions":4588,"interventions":4589},"NCT02054130","Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma",[73],"2016-12-12","2017-03-01","2013-12-13",584,[21],[4572,4590,4591],"MEDI9929 210 mg","MEDI9929 280 mg",{"trials":4593,"activeCount":83},[],{"trials":4595,"activeCount":83},[],{"trials":4597,"activeCount":83},[],{"intervention":4590,"totalTrials":480,"cells":4599},{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4610,"PHASE4":4612,"NA":4614},{"trials":4601,"activeCount":83},[],{"trials":4603,"activeCount":83},[],{"trials":4605,"activeCount":83},[4606],{"nctId":4581,"briefTitle":4582,"status":89,"phases":4607,"primaryCompletion":4584,"completion":4585,"start":4586,"enrollment":4587,"conditions":4608,"interventions":4609},[73],[21],[4572,4590,4591],{"trials":4611,"activeCount":83},[],{"trials":4613,"activeCount":83},[],{"trials":4615,"activeCount":83},[],{"intervention":4591,"totalTrials":480,"cells":4617},{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4622,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4619,"activeCount":83},[],{"trials":4621,"activeCount":83},[],{"trials":4623,"activeCount":83},[4624],{"nctId":4581,"briefTitle":4582,"status":89,"phases":4625,"primaryCompletion":4584,"completion":4585,"start":4586,"enrollment":4587,"conditions":4626,"interventions":4627},[73],[21],[4572,4590,4591],{"trials":4629,"activeCount":83},[],{"trials":4631,"activeCount":83},[],{"trials":4633,"activeCount":83},[],{"intervention":4635,"totalTrials":480,"cells":4636},"Sifalimumab",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4638,"activeCount":83},[],{"trials":4640,"activeCount":83},[],{"trials":4642,"activeCount":83},[4643],{"nctId":4644,"briefTitle":4645,"status":89,"phases":4646,"primaryCompletion":4647,"completion":4647,"start":2317,"enrollment":4648,"conditions":4649,"interventions":4650},"NCT00979654","A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis",[73],"2015-03",118,[3544],[4635],{"trials":4652,"activeCount":83},[],{"trials":4654,"activeCount":83},[],{"trials":4656,"activeCount":83},[],{"intervention":4658,"totalTrials":480,"cells":4659},"Motavizumab, palivizumab",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4677,"PHASE4":4679,"NA":4681},{"trials":4661,"activeCount":83},[],{"trials":4663,"activeCount":83},[],{"trials":4665,"activeCount":83},[4666],{"nctId":4667,"briefTitle":4668,"status":89,"phases":4669,"primaryCompletion":4670,"completion":4670,"start":1929,"enrollment":4671,"conditions":4672,"interventions":4675},"NCT00316264","Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season",[73],"2007-02",260,[30,4673,4674],"Chronic Lung Disease and \u003C= 24 Months of Age or","Premature With Gestational Age \u003C=35 Weeks and \u003C=6 Months of Age",[4658,4676,1345],"Palivizumab, motavizumab",{"trials":4678,"activeCount":83},[],{"trials":4680,"activeCount":83},[],{"trials":4682,"activeCount":83},[],{"intervention":4676,"totalTrials":480,"cells":4684},{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4695,"PHASE4":4697,"NA":4699},{"trials":4686,"activeCount":83},[],{"trials":4688,"activeCount":83},[],{"trials":4690,"activeCount":83},[4691],{"nctId":4667,"briefTitle":4668,"status":89,"phases":4692,"primaryCompletion":4670,"completion":4670,"start":1929,"enrollment":4671,"conditions":4693,"interventions":4694},[73],[30,4673,4674],[4658,4676,1345],{"trials":4696,"activeCount":83},[],{"trials":4698,"activeCount":83},[],{"trials":4700,"activeCount":83},[],{"intervention":4702,"totalTrials":480,"cells":4703},"MEDI9929",{"EARLY_PHASE1":4704,"PHASE1":4706,"PHASE2":4708,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4705,"activeCount":83},[],{"trials":4707,"activeCount":83},[],{"trials":4709,"activeCount":83},[4710],{"nctId":4711,"briefTitle":4712,"status":89,"phases":4713,"primaryCompletion":4714,"completion":4715,"start":4716,"enrollment":1731,"conditions":4717,"interventions":4718},"NCT02525094","Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis",[73],"2016-05-09","2016-07-15","2015-08-15",[4240],[4702],{"trials":4720,"activeCount":83},[],{"trials":4722,"activeCount":83},[],{"trials":4724,"activeCount":83},[],{"intervention":2037,"totalTrials":480,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4737,"PHASE4":4739,"NA":4741},{"trials":4728,"activeCount":83},[],{"trials":4730,"activeCount":83},[],{"trials":4732,"activeCount":83},[4733],{"nctId":2028,"briefTitle":2029,"status":89,"phases":4734,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":4735,"interventions":4736},[73],[35],[2037,2015,2038,1999],{"trials":4738,"activeCount":83},[],{"trials":4740,"activeCount":83},[],{"trials":4742,"activeCount":83},[],{"intervention":2038,"totalTrials":480,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4749,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4746,"activeCount":83},[],{"trials":4748,"activeCount":83},[],{"trials":4750,"activeCount":83},[4751],{"nctId":2028,"briefTitle":2029,"status":89,"phases":4752,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":4753,"interventions":4754},[73],[35],[2037,2015,2038,1999],{"trials":4756,"activeCount":83},[],{"trials":4758,"activeCount":83},[],{"trials":4760,"activeCount":83},[],{"intervention":4762,"totalTrials":480,"cells":4763},"Sifalimumab 200 mg",{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4782,"PHASE4":4784,"NA":4786},{"trials":4765,"activeCount":83},[],{"trials":4767,"activeCount":83},[],{"trials":4769,"activeCount":83},[4770],{"nctId":4771,"briefTitle":4772,"status":89,"phases":4773,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":4777,"conditions":4778,"interventions":4779},"NCT01283139","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",[73],"2013-11-14","2014-04-17","2011-03-31",834,[3544],[4762,4780,4781],"Sifalimumab 600 mg","Sifalimumab 1,200 mg",{"trials":4783,"activeCount":83},[],{"trials":4785,"activeCount":83},[],{"trials":4787,"activeCount":83},[],{"intervention":4780,"totalTrials":480,"cells":4789},{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4794,"PHASE3":4800,"PHASE4":4802,"NA":4804},{"trials":4791,"activeCount":83},[],{"trials":4793,"activeCount":83},[],{"trials":4795,"activeCount":83},[4796],{"nctId":4771,"briefTitle":4772,"status":89,"phases":4797,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":4777,"conditions":4798,"interventions":4799},[73],[3544],[4762,4780,4781],{"trials":4801,"activeCount":83},[],{"trials":4803,"activeCount":83},[],{"trials":4805,"activeCount":83},[],{"intervention":4781,"totalTrials":480,"cells":4807},{"EARLY_PHASE1":4808,"PHASE1":4810,"PHASE2":4812,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4809,"activeCount":83},[],{"trials":4811,"activeCount":83},[],{"trials":4813,"activeCount":83},[4814],{"nctId":4771,"briefTitle":4772,"status":89,"phases":4815,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":4777,"conditions":4816,"interventions":4817},[73],[3544],[4762,4780,4781],{"trials":4819,"activeCount":83},[],{"trials":4821,"activeCount":83},[],{"trials":4823,"activeCount":83},[],{"intervention":268,"totalTrials":480,"cells":4825},{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4830,"PHASE3":4836,"PHASE4":4838,"NA":4840},{"trials":4827,"activeCount":83},[],{"trials":4829,"activeCount":83},[],{"trials":4831,"activeCount":83},[4832],{"nctId":258,"briefTitle":259,"status":89,"phases":4833,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":4834,"interventions":4835},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":4837,"activeCount":83},[],{"trials":4839,"activeCount":83},[],{"trials":4841,"activeCount":83},[],{"intervention":269,"totalTrials":480,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4854,"PHASE4":4856,"NA":4858},{"trials":4845,"activeCount":83},[],{"trials":4847,"activeCount":83},[],{"trials":4849,"activeCount":83},[4850],{"nctId":258,"briefTitle":259,"status":89,"phases":4851,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":4852,"interventions":4853},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":4855,"activeCount":83},[],{"trials":4857,"activeCount":83},[],{"trials":4859,"activeCount":83},[],{"intervention":270,"totalTrials":480,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4872,"PHASE4":4874,"NA":4876},{"trials":4863,"activeCount":83},[],{"trials":4865,"activeCount":83},[],{"trials":4867,"activeCount":83},[4868],{"nctId":258,"briefTitle":259,"status":89,"phases":4869,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":4870,"interventions":4871},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":4873,"activeCount":83},[],{"trials":4875,"activeCount":83},[],{"trials":4877,"activeCount":83},[],{"intervention":271,"totalTrials":480,"cells":4879},{"EARLY_PHASE1":4880,"PHASE1":4882,"PHASE2":4884,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4881,"activeCount":83},[],{"trials":4883,"activeCount":83},[],{"trials":4885,"activeCount":83},[4886],{"nctId":258,"briefTitle":259,"status":89,"phases":4887,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":4888,"interventions":4889},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":4891,"activeCount":83},[],{"trials":4893,"activeCount":83},[],{"trials":4895,"activeCount":83},[],{"intervention":272,"totalTrials":480,"cells":4897},{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4902,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4899,"activeCount":83},[],{"trials":4901,"activeCount":83},[],{"trials":4903,"activeCount":83},[4904],{"nctId":258,"briefTitle":259,"status":89,"phases":4905,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":4906,"interventions":4907},[72,73],[265,266],[50,60,268,269,270,271,272],{"trials":4909,"activeCount":83},[],{"trials":4911,"activeCount":83},[],{"trials":4913,"activeCount":83},[],{"intervention":4915,"totalTrials":480,"cells":4916},"MEDI--522",{"EARLY_PHASE1":4917,"PHASE1":4919,"PHASE2":4921,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4918,"activeCount":83},[],{"trials":4920,"activeCount":83},[],{"trials":4922,"activeCount":83},[4923],{"nctId":4924,"briefTitle":4925,"status":89,"phases":4926,"primaryCompletion":1917,"completion":1918,"start":1563,"enrollment":3325,"conditions":4927,"interventions":4929},"NCT00066196","Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma",[73],[116,4928],"Malignant Metastatic Melanoma",[4915,4930],"Integrin + Dacarbazine",{"trials":4932,"activeCount":83},[],{"trials":4934,"activeCount":83},[],{"trials":4936,"activeCount":83},[],{"intervention":4930,"totalTrials":480,"cells":4938},{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4949,"PHASE4":4951,"NA":4953},{"trials":4940,"activeCount":83},[],{"trials":4942,"activeCount":83},[],{"trials":4944,"activeCount":83},[4945],{"nctId":4924,"briefTitle":4925,"status":89,"phases":4946,"primaryCompletion":1917,"completion":1918,"start":1563,"enrollment":3325,"conditions":4947,"interventions":4948},[73],[116,4928],[4915,4930],{"trials":4950,"activeCount":83},[],{"trials":4952,"activeCount":83},[],{"trials":4954,"activeCount":83},[],{"intervention":4956,"totalTrials":480,"cells":4957},"MEDI3902",{"EARLY_PHASE1":4958,"PHASE1":4960,"PHASE2":4962,"PHASE3":4973,"PHASE4":4975,"NA":4977},{"trials":4959,"activeCount":83},[],{"trials":4961,"activeCount":83},[],{"trials":4963,"activeCount":83},[4964],{"nctId":4965,"briefTitle":4966,"status":89,"phases":4967,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":2135,"conditions":4970,"interventions":4972},"NCT02696902","Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects",[73],"2019-12-04","2016-03-25",[4971],"Pseudomonas Aeruginosa",[4956],{"trials":4974,"activeCount":83},[],{"trials":4976,"activeCount":83},[],{"trials":4978,"activeCount":83},[],{"intervention":2768,"totalTrials":480,"cells":4980},{"EARLY_PHASE1":4981,"PHASE1":4983,"PHASE2":4985,"PHASE3":4991,"PHASE4":4993,"NA":4995},{"trials":4982,"activeCount":83},[],{"trials":4984,"activeCount":83},[],{"trials":4986,"activeCount":83},[4987],{"nctId":2763,"briefTitle":2764,"status":167,"phases":4988,"primaryCompletion":790,"completion":790,"start":2286,"enrollment":1035,"conditions":4989,"interventions":4990},[73],[21],[2768,2743],{"trials":4992,"activeCount":83},[],{"trials":4994,"activeCount":83},[],{"trials":4996,"activeCount":83},[],{"intervention":2312,"totalTrials":273,"cells":4998},{"EARLY_PHASE1":4999,"PHASE1":5001,"PHASE2":5022,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5000,"activeCount":83},[],{"trials":5002,"activeCount":83},[5003,5010,5014],{"nctId":5004,"briefTitle":5005,"status":89,"phases":5006,"primaryCompletion":1273,"completion":5007,"start":1918,"enrollment":2161,"conditions":5008,"interventions":5009},"NCT00482989","A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus",[72],"2010-09",[2310],[2312],{"nctId":2305,"briefTitle":2306,"status":89,"phases":5011,"completion":846,"start":2308,"enrollment":1056,"conditions":5012,"interventions":5013},[72],[2310],[2298,2312,2298,2298,2298],{"nctId":5015,"briefTitle":5016,"status":89,"phases":5017,"primaryCompletion":3081,"completion":4522,"start":4670,"enrollment":5018,"conditions":5019,"interventions":5021},"NCT00472758","A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545",[72],40,[5020],"Chronic Plaque Psoriasis",[2312],{"trials":5023,"activeCount":83},[],{"trials":5025,"activeCount":83},[],{"trials":5027,"activeCount":83},[],{"trials":5029,"activeCount":83},[],{"intervention":5031,"totalTrials":273,"cells":5032},"MEDI-557",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5059,"PHASE3":5061,"PHASE4":5063,"NA":5065},{"trials":5034,"activeCount":83},[],{"trials":5036,"activeCount":83},[5037,5043,5053],{"nctId":5038,"briefTitle":5039,"status":89,"phases":5040,"primaryCompletion":293,"completion":2373,"start":3058,"enrollment":1087,"conditions":5041,"interventions":5042},"NCT00578682","A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557",[72],[15],[5031,5031,5031,5031],{"nctId":5044,"briefTitle":5045,"status":167,"phases":5046,"primaryCompletion":5047,"completion":5048,"start":5049,"enrollment":8,"conditions":5050,"interventions":5052},"NCT01475305","Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)",[72],"2011-12-03","2012-12-13","2011-10-20",[5051],"RSV Infection",[5031],{"nctId":5054,"briefTitle":5055,"status":89,"phases":5056,"primaryCompletion":816,"completion":2372,"start":2206,"enrollment":93,"conditions":5057,"interventions":5058},"NCT01562938","MEDI-557 Adult Dosing",[72],[2094],[5031,5031],{"trials":5060,"activeCount":83},[],{"trials":5062,"activeCount":83},[],{"trials":5064,"activeCount":83},[],{"trials":5066,"activeCount":83},[],{"intervention":2268,"totalTrials":412,"cells":5068},{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5081,"PHASE3":5083,"PHASE4":5085,"NA":5087},{"trials":5070,"activeCount":83},[],{"trials":5072,"activeCount":83},[5073,5077],{"nctId":2262,"briefTitle":2263,"status":89,"phases":5074,"primaryCompletion":1146,"completion":2265,"start":1797,"enrollment":1892,"conditions":5075,"interventions":5076},[72],[21],[2268,2269,2270,2255],{"nctId":2272,"briefTitle":2273,"status":89,"phases":5078,"primaryCompletion":1929,"completion":2275,"start":2276,"enrollment":2277,"conditions":5079,"interventions":5080},[72],[15],[2268,2269,2270,2255],{"trials":5082,"activeCount":83},[],{"trials":5084,"activeCount":83},[],{"trials":5086,"activeCount":83},[],{"trials":5088,"activeCount":83},[],{"intervention":2269,"totalTrials":412,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5103,"PHASE3":5105,"PHASE4":5107,"NA":5109},{"trials":5092,"activeCount":83},[],{"trials":5094,"activeCount":83},[5095,5099],{"nctId":2262,"briefTitle":2263,"status":89,"phases":5096,"primaryCompletion":1146,"completion":2265,"start":1797,"enrollment":1892,"conditions":5097,"interventions":5098},[72],[21],[2268,2269,2270,2255],{"nctId":2272,"briefTitle":2273,"status":89,"phases":5100,"primaryCompletion":1929,"completion":2275,"start":2276,"enrollment":2277,"conditions":5101,"interventions":5102},[72],[15],[2268,2269,2270,2255],{"trials":5104,"activeCount":83},[],{"trials":5106,"activeCount":83},[],{"trials":5108,"activeCount":83},[],{"trials":5110,"activeCount":83},[],{"intervention":2270,"totalTrials":412,"cells":5112},{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5125,"PHASE3":5127,"PHASE4":5129,"NA":5131},{"trials":5114,"activeCount":83},[],{"trials":5116,"activeCount":83},[5117,5121],{"nctId":2262,"briefTitle":2263,"status":89,"phases":5118,"primaryCompletion":1146,"completion":2265,"start":1797,"enrollment":1892,"conditions":5119,"interventions":5120},[72],[21],[2268,2269,2270,2255],{"nctId":2272,"briefTitle":2273,"status":89,"phases":5122,"primaryCompletion":1929,"completion":2275,"start":2276,"enrollment":2277,"conditions":5123,"interventions":5124},[72],[15],[2268,2269,2270,2255],{"trials":5126,"activeCount":83},[],{"trials":5128,"activeCount":83},[],{"trials":5130,"activeCount":83},[],{"trials":5132,"activeCount":83},[],{"intervention":5134,"totalTrials":412,"cells":5135},"MEDI-563",{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5153,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5137,"activeCount":83},[],{"trials":5139,"activeCount":83},[5140,5146],{"nctId":5141,"briefTitle":5142,"status":89,"phases":5143,"primaryCompletion":4299,"completion":3281,"start":2287,"enrollment":93,"conditions":5144,"interventions":5145},"NCT00512486","A Sequential Dose-Escalation Study in Subjects With Mild Asthma",[72],[21],[5134],{"nctId":5147,"briefTitle":5148,"status":89,"phases":5149,"primaryCompletion":2408,"completion":5150,"start":2286,"enrollment":9,"conditions":5151,"interventions":5152},"NCT00659659","A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma",[72],"2011-03",[21],[5134,5134],{"trials":5154,"activeCount":83},[],{"trials":5156,"activeCount":83},[],{"trials":5158,"activeCount":83},[],{"trials":5160,"activeCount":83},[],{"intervention":5162,"totalTrials":412,"cells":5163},"MEDI7247",{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5192,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5165,"activeCount":83},[],{"trials":5167,"activeCount":83},[5168,5182],{"nctId":5169,"briefTitle":5170,"status":89,"phases":5171,"primaryCompletion":5172,"completion":5172,"start":5173,"enrollment":1742,"conditions":5174,"interventions":5181},"NCT03811652","A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",[72],"2019-12-10","2018-12-20",[5175,5176,5177,5178,5179,5180],"Non Small Cell Lung Cancer Squamous (NSCLC-Sq)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Small Cell Lung Cancer (SCLC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Colorectal Cancer (CRC)","Metastatic Castration-resistant Prostate Cancer (mCRPC)",[5162],{"nctId":5183,"briefTitle":5184,"status":89,"phases":5185,"primaryCompletion":5186,"completion":5186,"start":5187,"enrollment":358,"conditions":5188,"interventions":5191},"NCT03106428","A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed\u002FRefractory Hematological Malignancies",[72],"2020-01-03","2017-03-29",[3956,5189,5190],"Multiple Myeloma","Diffuse Large B-cell Lymphoma",[5162],{"trials":5193,"activeCount":83},[],{"trials":5195,"activeCount":83},[],{"trials":5197,"activeCount":83},[],{"trials":5199,"activeCount":83},[],{"intervention":5201,"totalTrials":412,"cells":5202},"BL22 immunotoxin",{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5222,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5204,"activeCount":83},[],{"trials":5206,"activeCount":83},[5207,5213],{"nctId":5208,"briefTitle":5209,"status":89,"phases":5210,"primaryCompletion":1285,"completion":2682,"start":2276,"enrollment":1892,"conditions":5211,"interventions":5212},"NCT00126646","BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma",[72],[1754,1753],[5201],{"nctId":5214,"briefTitle":5215,"status":5216,"phases":5217,"primaryCompletion":3281,"completion":3281,"start":5218,"enrollment":5219,"conditions":5220,"interventions":5221},"NCT00077493","BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","SUSPENDED",[72],"2004-01",95,[1754,1753],[5201],{"trials":5223,"activeCount":83},[],{"trials":5225,"activeCount":83},[],{"trials":5227,"activeCount":83},[],{"trials":5229,"activeCount":83},[],{"intervention":130,"totalTrials":412,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5233,"activeCount":83},[],{"trials":5235,"activeCount":83},[5236,5240],{"nctId":121,"briefTitle":122,"status":89,"phases":5237,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":5238,"interventions":5239},[72],[128],[130,41,60],{"nctId":5241,"briefTitle":5242,"status":89,"phases":5243,"primaryCompletion":5244,"completion":5244,"start":5245,"enrollment":1851,"conditions":5246,"interventions":5247},"NCT02318394","A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors",[72],"2018-01-09","2015-03-02",[27],[130],{"trials":5249,"activeCount":83},[],{"trials":5251,"activeCount":83},[],{"trials":5253,"activeCount":83},[],{"trials":5255,"activeCount":83},[],{"intervention":5257,"totalTrials":412,"cells":5258},"CAT-8015",{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5278,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5260,"activeCount":83},[],{"trials":5262,"activeCount":83},[5263,5269],{"nctId":5264,"briefTitle":5265,"status":167,"phases":5266,"primaryCompletion":4522,"completion":1284,"start":1899,"enrollment":2208,"conditions":5267,"interventions":5268},"NCT00587015","A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)",[72],[1753],[5257],{"nctId":5270,"briefTitle":5271,"status":89,"phases":5272,"primaryCompletion":5273,"completion":5273,"start":4299,"enrollment":137,"conditions":5274,"interventions":5277},"NCT00659425","CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",[72],"2014-12",[5275,5276],"Acute Lymphoblastic Leukemia","Non-Hodgkin's Lymphoma",[5257,5257,5257,5257,5257,5257,5257,5257,5257,5257],{"trials":5279,"activeCount":83},[],{"trials":5281,"activeCount":83},[],{"trials":5283,"activeCount":83},[],{"trials":5285,"activeCount":83},[],{"intervention":5287,"totalTrials":412,"cells":5288},"Tralokinumab 300 mg",{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5309,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5290,"activeCount":83},[],{"trials":5292,"activeCount":83},[5293,5302],{"nctId":5294,"briefTitle":5295,"status":89,"phases":5296,"primaryCompletion":5297,"completion":5297,"start":5298,"enrollment":1187,"conditions":5299,"interventions":5301},"NCT02085473","A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers",[72],"2014-07-10","2014-03-19",[21,5300],"Healthy Subjects or Volunteers",[5287],{"nctId":5303,"briefTitle":5304,"status":89,"phases":5305,"primaryCompletion":2371,"completion":2371,"start":5306,"enrollment":2288,"conditions":5307,"interventions":5308},"NCT01592396","A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma",[72],"2012-06",[21],[5287],{"trials":5310,"activeCount":83},[],{"trials":5312,"activeCount":83},[],{"trials":5314,"activeCount":83},[],{"trials":5316,"activeCount":83},[],{"intervention":5318,"totalTrials":412,"cells":5319},"AMP-110",{"EARLY_PHASE1":5320,"PHASE1":5322,"PHASE2":5340,"PHASE3":5342,"PHASE4":5344,"NA":5346},{"trials":5321,"activeCount":83},[],{"trials":5323,"activeCount":83},[5324,5333],{"nctId":5325,"briefTitle":5326,"status":89,"phases":5327,"primaryCompletion":5328,"completion":5328,"start":5329,"enrollment":5330,"conditions":5331,"interventions":5332},"NCT01878123","Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis",[72],"2014-07","2013-04",26,[35],[5318],{"nctId":5334,"briefTitle":5335,"status":89,"phases":5336,"primaryCompletion":1958,"completion":291,"start":5337,"enrollment":2277,"conditions":5338,"interventions":5339},"NCT02277574","Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis",[72],"2014-06",[35],[5318],{"trials":5341,"activeCount":83},[],{"trials":5343,"activeCount":83},[],{"trials":5345,"activeCount":83},[],{"trials":5347,"activeCount":83},[],{"intervention":5349,"totalTrials":480,"cells":5350},"MEDI0382 Formulation 2",{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5364,"PHASE3":5366,"PHASE4":5368,"NA":5370},{"trials":5352,"activeCount":83},[],{"trials":5354,"activeCount":83},[5355],{"nctId":5356,"briefTitle":5357,"status":89,"phases":5358,"primaryCompletion":5359,"completion":5359,"start":5360,"enrollment":1892,"conditions":5361,"interventions":5362},"NCT03341013","A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382",[72],"2018-01-29","2017-11-30",[33],[5349,5363],"MEDI0382 Formulation 3",{"trials":5365,"activeCount":83},[],{"trials":5367,"activeCount":83},[],{"trials":5369,"activeCount":83},[],{"trials":5371,"activeCount":83},[],{"intervention":5363,"totalTrials":480,"cells":5373},{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5382,"PHASE3":5384,"PHASE4":5386,"NA":5388},{"trials":5375,"activeCount":83},[],{"trials":5377,"activeCount":83},[5378],{"nctId":5356,"briefTitle":5357,"status":89,"phases":5379,"primaryCompletion":5359,"completion":5359,"start":5360,"enrollment":1892,"conditions":5380,"interventions":5381},[72],[33],[5349,5363],{"trials":5383,"activeCount":83},[],{"trials":5385,"activeCount":83},[],{"trials":5387,"activeCount":83},[],{"trials":5389,"activeCount":83},[],{"intervention":2070,"totalTrials":480,"cells":5391},{"EARLY_PHASE1":5392,"PHASE1":5394,"PHASE2":5400,"PHASE3":5402,"PHASE4":5404,"NA":5406},{"trials":5393,"activeCount":83},[],{"trials":5395,"activeCount":83},[5396],{"nctId":2062,"briefTitle":2063,"status":89,"phases":5397,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":2066,"conditions":5398,"interventions":5399},[72],[2068],[2070,2055,2071,2055,2072,2055],{"trials":5401,"activeCount":83},[],{"trials":5403,"activeCount":83},[],{"trials":5405,"activeCount":83},[],{"trials":5407,"activeCount":83},[],{"intervention":2071,"totalTrials":480,"cells":5409},{"EARLY_PHASE1":5410,"PHASE1":5412,"PHASE2":5418,"PHASE3":5420,"PHASE4":5422,"NA":5424},{"trials":5411,"activeCount":83},[],{"trials":5413,"activeCount":83},[5414],{"nctId":2062,"briefTitle":2063,"status":89,"phases":5415,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":2066,"conditions":5416,"interventions":5417},[72],[2068],[2070,2055,2071,2055,2072,2055],{"trials":5419,"activeCount":83},[],{"trials":5421,"activeCount":83},[],{"trials":5423,"activeCount":83},[],{"trials":5425,"activeCount":83},[],{"intervention":2072,"totalTrials":480,"cells":5427},{"EARLY_PHASE1":5428,"PHASE1":5430,"PHASE2":5436,"PHASE3":5438,"PHASE4":5440,"NA":5442},{"trials":5429,"activeCount":83},[],{"trials":5431,"activeCount":83},[5432],{"nctId":2062,"briefTitle":2063,"status":89,"phases":5433,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":2066,"conditions":5434,"interventions":5435},[72],[2068],[2070,2055,2071,2055,2072,2055],{"trials":5437,"activeCount":83},[],{"trials":5439,"activeCount":83},[],{"trials":5441,"activeCount":83},[],{"trials":5443,"activeCount":83},[],{"intervention":2118,"totalTrials":480,"cells":5445},{"EARLY_PHASE1":5446,"PHASE1":5448,"PHASE2":5454,"PHASE3":5456,"PHASE4":5458,"NA":5460},{"trials":5447,"activeCount":83},[],{"trials":5449,"activeCount":83},[5450],{"nctId":2110,"briefTitle":2111,"status":89,"phases":5451,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":420,"conditions":5452,"interventions":5453},[72],[2116],[2103,2118],{"trials":5455,"activeCount":83},[],{"trials":5457,"activeCount":83},[],{"trials":5459,"activeCount":83},[],{"trials":5461,"activeCount":83},[],{"intervention":5463,"totalTrials":480,"cells":5464},"MEDI1873",{"EARLY_PHASE1":5465,"PHASE1":5467,"PHASE2":5476,"PHASE3":5478,"PHASE4":5480,"NA":5482},{"trials":5466,"activeCount":83},[],{"trials":5468,"activeCount":83},[5469],{"nctId":5470,"briefTitle":5471,"status":89,"phases":5472,"primaryCompletion":227,"completion":227,"start":5473,"enrollment":5018,"conditions":5474,"interventions":5475},"NCT02583165","A Study in Adult Subjects With Select Advanced Solid Tumors",[72],"2015-11-09",[27],[5463],{"trials":5477,"activeCount":83},[],{"trials":5479,"activeCount":83},[],{"trials":5481,"activeCount":83},[],{"trials":5483,"activeCount":83},[],{"intervention":5485,"totalTrials":480,"cells":5486},"MEDI-4166",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5501,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5488,"activeCount":83},[],{"trials":5490,"activeCount":83},[5491],{"nctId":5492,"briefTitle":5493,"status":89,"phases":5494,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":5497,"conditions":5498,"interventions":5500},"NCT02524782","A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes",[72],"2017-04-14","2015-10-07",103,[5499],"Type 2 Diabetes",[5485],{"trials":5502,"activeCount":83},[],{"trials":5504,"activeCount":83},[],{"trials":5506,"activeCount":83},[],{"trials":5508,"activeCount":83},[],{"intervention":5510,"totalTrials":480,"cells":5511},"MEDI7219",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5526,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5513,"activeCount":83},[],{"trials":5515,"activeCount":83},[5516],{"nctId":5517,"briefTitle":5518,"status":167,"phases":5519,"primaryCompletion":5520,"completion":5520,"start":5521,"enrollment":5522,"conditions":5523,"interventions":5524},"NCT03362593","A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses",[72],"2020-05-11","2017-12-04",186,[1639],[5510,5525],"Formulation without Active Drug",{"trials":5527,"activeCount":83},[],{"trials":5529,"activeCount":83},[],{"trials":5531,"activeCount":83},[],{"trials":5533,"activeCount":83},[],{"intervention":5525,"totalTrials":480,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5544,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5537,"activeCount":83},[],{"trials":5539,"activeCount":83},[5540],{"nctId":5517,"briefTitle":5518,"status":167,"phases":5541,"primaryCompletion":5520,"completion":5520,"start":5521,"enrollment":5522,"conditions":5542,"interventions":5543},[72],[1639],[5510,5525],{"trials":5545,"activeCount":83},[],{"trials":5547,"activeCount":83},[],{"trials":5549,"activeCount":83},[],{"trials":5551,"activeCount":83},[],{"intervention":5553,"totalTrials":480,"cells":5554},"cotadutide multidose pen",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5567,"PHASE3":5569,"PHASE4":5571,"NA":5573},{"trials":5556,"activeCount":83},[],{"trials":5558,"activeCount":83},[5559],{"nctId":5560,"briefTitle":5561,"status":89,"phases":5562,"primaryCompletion":5563,"completion":5563,"start":5564,"enrollment":4080,"conditions":5565,"interventions":5566},"NCT04091373","A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide",[72],"2020-03-06","2019-09-27",[33],[5553,5553,5553],{"trials":5568,"activeCount":83},[],{"trials":5570,"activeCount":83},[],{"trials":5572,"activeCount":83},[],{"trials":5574,"activeCount":83},[],{"intervention":5576,"totalTrials":480,"cells":5577},"MEDI-546",{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5589,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5579,"activeCount":83},[],{"trials":5581,"activeCount":83},[5582],{"nctId":5583,"briefTitle":5584,"status":89,"phases":5585,"primaryCompletion":939,"completion":5586,"start":961,"enrollment":16,"conditions":5587,"interventions":5588},"NCT00930683","A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma",[72],"2011-07",[2210],[5576,5576,5576,5576,5576,5576,5576,5576,5576],{"trials":5590,"activeCount":83},[],{"trials":5592,"activeCount":83},[],{"trials":5594,"activeCount":83},[],{"trials":5596,"activeCount":83},[],{"intervention":5598,"totalTrials":480,"cells":5599},"MEDI3726 Post-Chemo",{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5615,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5601,"activeCount":83},[],{"trials":5603,"activeCount":83},[5604],{"nctId":5605,"briefTitle":5606,"status":89,"phases":5607,"primaryCompletion":5608,"completion":5608,"start":5609,"enrollment":19,"conditions":5610,"interventions":5612},"NCT02991911","A Phase 1\u002F1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer",[72],"2019-09-30","2017-01-06",[5611],"Metastatic Castration Resistant Prostate Cancer",[5598,5613,5614],"MEDI3726 Pre-Chemo","MEDI3726 & Enzalutamide Combo",{"trials":5616,"activeCount":83},[],{"trials":5618,"activeCount":83},[],{"trials":5620,"activeCount":83},[],{"trials":5622,"activeCount":83},[],{"intervention":5613,"totalTrials":480,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5633,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":83},[],{"trials":5628,"activeCount":83},[5629],{"nctId":5605,"briefTitle":5606,"status":89,"phases":5630,"primaryCompletion":5608,"completion":5608,"start":5609,"enrollment":19,"conditions":5631,"interventions":5632},[72],[5611],[5598,5613,5614],{"trials":5634,"activeCount":83},[],{"trials":5636,"activeCount":83},[],{"trials":5638,"activeCount":83},[],{"trials":5640,"activeCount":83},[],{"intervention":5614,"totalTrials":480,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5651,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5644,"activeCount":83},[],{"trials":5646,"activeCount":83},[5647],{"nctId":5605,"briefTitle":5606,"status":89,"phases":5648,"primaryCompletion":5608,"completion":5608,"start":5609,"enrollment":19,"conditions":5649,"interventions":5650},[72],[5611],[5598,5613,5614],{"trials":5652,"activeCount":83},[],{"trials":5654,"activeCount":83},[],{"trials":5656,"activeCount":83},[],{"trials":5658,"activeCount":83},[],{"intervention":5660,"totalTrials":480,"cells":5661},"MEDI7836 Dose 1",{"EARLY_PHASE1":5662,"PHASE1":5664,"PHASE2":5678,"PHASE3":5680,"PHASE4":5682,"NA":5684},{"trials":5663,"activeCount":83},[],{"trials":5665,"activeCount":83},[5666],{"nctId":5667,"briefTitle":5668,"status":89,"phases":5669,"primaryCompletion":823,"completion":5670,"start":4647,"enrollment":5671,"conditions":5672,"interventions":5674},"NCT02388347","A Study to Assess the Safety of MEDI7836 in Healthy Adults.",[72],"2016-04",79,[5673],"Healthy Adults",[5660,5675,5676,5677],"MEDI7836 Dose 2","MEDI7836 Dose 3","MEDI7836 Dose 4",{"trials":5679,"activeCount":83},[],{"trials":5681,"activeCount":83},[],{"trials":5683,"activeCount":83},[],{"trials":5685,"activeCount":83},[],{"intervention":5675,"totalTrials":480,"cells":5687},{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5696,"PHASE3":5698,"PHASE4":5700,"NA":5702},{"trials":5689,"activeCount":83},[],{"trials":5691,"activeCount":83},[5692],{"nctId":5667,"briefTitle":5668,"status":89,"phases":5693,"primaryCompletion":823,"completion":5670,"start":4647,"enrollment":5671,"conditions":5694,"interventions":5695},[72],[5673],[5660,5675,5676,5677],{"trials":5697,"activeCount":83},[],{"trials":5699,"activeCount":83},[],{"trials":5701,"activeCount":83},[],{"trials":5703,"activeCount":83},[],{"intervention":5676,"totalTrials":480,"cells":5705},{"EARLY_PHASE1":5706,"PHASE1":5708,"PHASE2":5714,"PHASE3":5716,"PHASE4":5718,"NA":5720},{"trials":5707,"activeCount":83},[],{"trials":5709,"activeCount":83},[5710],{"nctId":5667,"briefTitle":5668,"status":89,"phases":5711,"primaryCompletion":823,"completion":5670,"start":4647,"enrollment":5671,"conditions":5712,"interventions":5713},[72],[5673],[5660,5675,5676,5677],{"trials":5715,"activeCount":83},[],{"trials":5717,"activeCount":83},[],{"trials":5719,"activeCount":83},[],{"trials":5721,"activeCount":83},[],{"intervention":5677,"totalTrials":480,"cells":5723},{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5725,"activeCount":83},[],{"trials":5727,"activeCount":83},[5728],{"nctId":5667,"briefTitle":5668,"status":89,"phases":5729,"primaryCompletion":823,"completion":5670,"start":4647,"enrollment":5671,"conditions":5730,"interventions":5731},[72],[5673],[5660,5675,5676,5677],{"trials":5733,"activeCount":83},[],{"trials":5735,"activeCount":83},[],{"trials":5737,"activeCount":83},[],{"trials":5739,"activeCount":83},[],{"intervention":5741,"totalTrials":480,"cells":5742},"MEDI-570 0.03 MG",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5763},{"trials":5744,"activeCount":83},[],{"trials":5746,"activeCount":83},[5747],{"nctId":5748,"briefTitle":5749,"status":167,"phases":5750,"primaryCompletion":5751,"completion":5751,"start":939,"enrollment":1938,"conditions":5752,"interventions":5753},"NCT01127321","A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus",[72],"2012-07",[2330],[5741,5754,5755,5756],"MEDI-570 0.1 MG","MEDI-570 0.3 MG","MEDI-570 1 MG",{"trials":5758,"activeCount":83},[],{"trials":5760,"activeCount":83},[],{"trials":5762,"activeCount":83},[],{"trials":5764,"activeCount":83},[],{"intervention":5754,"totalTrials":480,"cells":5766},{"EARLY_PHASE1":5767,"PHASE1":5769,"PHASE2":5775,"PHASE3":5777,"PHASE4":5779,"NA":5781},{"trials":5768,"activeCount":83},[],{"trials":5770,"activeCount":83},[5771],{"nctId":5748,"briefTitle":5749,"status":167,"phases":5772,"primaryCompletion":5751,"completion":5751,"start":939,"enrollment":1938,"conditions":5773,"interventions":5774},[72],[2330],[5741,5754,5755,5756],{"trials":5776,"activeCount":83},[],{"trials":5778,"activeCount":83},[],{"trials":5780,"activeCount":83},[],{"trials":5782,"activeCount":83},[],{"intervention":5755,"totalTrials":480,"cells":5784},{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5793,"PHASE3":5795,"PHASE4":5797,"NA":5799},{"trials":5786,"activeCount":83},[],{"trials":5788,"activeCount":83},[5789],{"nctId":5748,"briefTitle":5749,"status":167,"phases":5790,"primaryCompletion":5751,"completion":5751,"start":939,"enrollment":1938,"conditions":5791,"interventions":5792},[72],[2330],[5741,5754,5755,5756],{"trials":5794,"activeCount":83},[],{"trials":5796,"activeCount":83},[],{"trials":5798,"activeCount":83},[],{"trials":5800,"activeCount":83},[],{"intervention":5756,"totalTrials":480,"cells":5802},{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5811,"PHASE3":5813,"PHASE4":5815,"NA":5817},{"trials":5804,"activeCount":83},[],{"trials":5806,"activeCount":83},[5807],{"nctId":5748,"briefTitle":5749,"status":167,"phases":5808,"primaryCompletion":5751,"completion":5751,"start":939,"enrollment":1938,"conditions":5809,"interventions":5810},[72],[2330],[5741,5754,5755,5756],{"trials":5812,"activeCount":83},[],{"trials":5814,"activeCount":83},[],{"trials":5816,"activeCount":83},[],{"trials":5818,"activeCount":83},[],{"intervention":5820,"totalTrials":480,"cells":5821},"MEDI3506",{"EARLY_PHASE1":5822,"PHASE1":5824,"PHASE2":5837,"PHASE3":5839,"PHASE4":5841,"NA":5843},{"trials":5823,"activeCount":83},[],{"trials":5825,"activeCount":83},[5826],{"nctId":5827,"briefTitle":5828,"status":89,"phases":5829,"primaryCompletion":5608,"completion":5608,"start":5830,"enrollment":5831,"conditions":5832,"interventions":5836},"NCT03096795","Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants",[72],"2017-05-15",88,[5833,5834,5835],"Part I (SAD) - Healthy Participants","Part II (MAD) - Chronic Obstructive Pulmonary Disease","Part III (J-SD) - Healthy Japanese Participants",[5820],{"trials":5838,"activeCount":83},[],{"trials":5840,"activeCount":83},[],{"trials":5842,"activeCount":83},[],{"trials":5844,"activeCount":83},[],{"intervention":2495,"totalTrials":480,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5855,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5848,"activeCount":83},[],{"trials":5850,"activeCount":83},[5851],{"nctId":2485,"briefTitle":2486,"status":167,"phases":5852,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":28,"conditions":5853,"interventions":5854},[72],[2491,2492,2493],[2495,2496,2478],{"trials":5856,"activeCount":83},[],{"trials":5858,"activeCount":83},[],{"trials":5860,"activeCount":83},[],{"trials":5862,"activeCount":83},[],{"intervention":2496,"totalTrials":480,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5873,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5866,"activeCount":83},[],{"trials":5868,"activeCount":83},[5869],{"nctId":2485,"briefTitle":2486,"status":167,"phases":5870,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":28,"conditions":5871,"interventions":5872},[72],[2491,2492,2493],[2495,2496,2478],{"trials":5874,"activeCount":83},[],{"trials":5876,"activeCount":83},[],{"trials":5878,"activeCount":83},[],{"trials":5880,"activeCount":83},[],{"intervention":96,"totalTrials":480,"cells":5882},{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5891,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5884,"activeCount":83},[],{"trials":5886,"activeCount":83},[5887],{"nctId":87,"briefTitle":88,"status":89,"phases":5888,"primaryCompletion":91,"completion":91,"start":92,"enrollment":93,"conditions":5889,"interventions":5890},[72],[27],[96,60],{"trials":5892,"activeCount":83},[],{"trials":5894,"activeCount":83},[],{"trials":5896,"activeCount":83},[],{"trials":5898,"activeCount":83},[],{"intervention":5900,"totalTrials":480,"cells":5901},"MEDI7814, 1 MG\u002FKG",{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5917,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5903,"activeCount":83},[],{"trials":5905,"activeCount":83},[5906],{"nctId":5907,"briefTitle":5908,"status":89,"phases":5909,"primaryCompletion":5910,"completion":5910,"start":3179,"enrollment":5911,"conditions":5912,"interventions":5913},"NCT01544361","A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers",[72],"2012-09",125,[1629],[5900,5914,5915,5916],"MEDI7814, 3 MG\u002FKG","MEDI7814, 10 MG\u002FKG","MEDI7814, 20 MG\u002FKG",{"trials":5918,"activeCount":83},[],{"trials":5920,"activeCount":83},[],{"trials":5922,"activeCount":83},[],{"trials":5924,"activeCount":83},[],{"intervention":5914,"totalTrials":480,"cells":5926},{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5928,"activeCount":83},[],{"trials":5930,"activeCount":83},[5931],{"nctId":5907,"briefTitle":5908,"status":89,"phases":5932,"primaryCompletion":5910,"completion":5910,"start":3179,"enrollment":5911,"conditions":5933,"interventions":5934},[72],[1629],[5900,5914,5915,5916],{"trials":5936,"activeCount":83},[],{"trials":5938,"activeCount":83},[],{"trials":5940,"activeCount":83},[],{"trials":5942,"activeCount":83},[],{"intervention":5915,"totalTrials":480,"cells":5944},{"EARLY_PHASE1":5945,"PHASE1":5947,"PHASE2":5953,"PHASE3":5955,"PHASE4":5957,"NA":5959},{"trials":5946,"activeCount":83},[],{"trials":5948,"activeCount":83},[5949],{"nctId":5907,"briefTitle":5908,"status":89,"phases":5950,"primaryCompletion":5910,"completion":5910,"start":3179,"enrollment":5911,"conditions":5951,"interventions":5952},[72],[1629],[5900,5914,5915,5916],{"trials":5954,"activeCount":83},[],{"trials":5956,"activeCount":83},[],{"trials":5958,"activeCount":83},[],{"trials":5960,"activeCount":83},[],{"intervention":5916,"totalTrials":480,"cells":5962},{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5971,"PHASE3":5973,"PHASE4":5975,"NA":5977},{"trials":5964,"activeCount":83},[],{"trials":5966,"activeCount":83},[5967],{"nctId":5907,"briefTitle":5908,"status":89,"phases":5968,"primaryCompletion":5910,"completion":5910,"start":3179,"enrollment":5911,"conditions":5969,"interventions":5970},[72],[1629],[5900,5914,5915,5916],{"trials":5972,"activeCount":83},[],{"trials":5974,"activeCount":83},[],{"trials":5976,"activeCount":83},[],{"trials":5978,"activeCount":83},[],{"intervention":298,"totalTrials":480,"cells":5980},{"EARLY_PHASE1":5981,"PHASE1":5983,"PHASE2":5989,"PHASE3":5991,"PHASE4":5993,"NA":5995},{"trials":5982,"activeCount":83},[],{"trials":5984,"activeCount":83},[5985],{"nctId":288,"briefTitle":289,"status":89,"phases":5986,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":5987,"interventions":5988},[72],[27,296],[298,188,299,300],{"trials":5990,"activeCount":83},[],{"trials":5992,"activeCount":83},[],{"trials":5994,"activeCount":83},[],{"trials":5996,"activeCount":83},[],{"intervention":5998,"totalTrials":480,"cells":5999},"MEDI6383",{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6020},{"trials":6001,"activeCount":83},[],{"trials":6003,"activeCount":83},[6004],{"nctId":6005,"briefTitle":6006,"status":89,"phases":6007,"primaryCompletion":6008,"completion":6008,"start":6009,"enrollment":160,"conditions":6010,"interventions":6012},"NCT02221960","A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors",[72],"2017-07-03","2014-09-15",[6011],"Recurrent or Metastatic Solid Tumors",[5998,6013],"MEDI6383 and MEDI4736",{"trials":6015,"activeCount":83},[],{"trials":6017,"activeCount":83},[],{"trials":6019,"activeCount":83},[],{"trials":6021,"activeCount":83},[],{"intervention":6013,"totalTrials":480,"cells":6023},{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6032,"PHASE3":6034,"PHASE4":6036,"NA":6038},{"trials":6025,"activeCount":83},[],{"trials":6027,"activeCount":83},[6028],{"nctId":6005,"briefTitle":6006,"status":89,"phases":6029,"primaryCompletion":6008,"completion":6008,"start":6009,"enrollment":160,"conditions":6030,"interventions":6031},[72],[6011],[5998,6013],{"trials":6033,"activeCount":83},[],{"trials":6035,"activeCount":83},[],{"trials":6037,"activeCount":83},[],{"trials":6039,"activeCount":83},[],{"intervention":118,"totalTrials":480,"cells":6041},{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6050,"PHASE3":6052,"PHASE4":6054,"NA":6056},{"trials":6043,"activeCount":83},[],{"trials":6045,"activeCount":83},[6046],{"nctId":109,"briefTitle":110,"status":89,"phases":6047,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":6048,"interventions":6049},[72],[116],[60,118,119],{"trials":6051,"activeCount":83},[],{"trials":6053,"activeCount":83},[],{"trials":6055,"activeCount":83},[],{"trials":6057,"activeCount":83},[],{"intervention":119,"totalTrials":480,"cells":6059},{"EARLY_PHASE1":6060,"PHASE1":6062,"PHASE2":6068,"PHASE3":6070,"PHASE4":6072,"NA":6074},{"trials":6061,"activeCount":83},[],{"trials":6063,"activeCount":83},[6064],{"nctId":109,"briefTitle":110,"status":89,"phases":6065,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":6066,"interventions":6067},[72],[116],[60,118,119],{"trials":6069,"activeCount":83},[],{"trials":6071,"activeCount":83},[],{"trials":6073,"activeCount":83},[],{"trials":6075,"activeCount":83},[],{"intervention":6077,"totalTrials":480,"cells":6078},"MEDI4920 3 mg",{"EARLY_PHASE1":6079,"PHASE1":6081,"PHASE2":6098,"PHASE3":6100,"PHASE4":6102,"NA":6104},{"trials":6080,"activeCount":83},[],{"trials":6082,"activeCount":83},[6083],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6086,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6089,"interventions":6091},"NCT02151110","Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults",[72],"2014-05-27",59,[6090],"Healthy Volunteer",[6077,6092,6093,6094,6095,6096,6097],"MEDI4920 10 mg","MEDI4920 30 mg","MEDI4920 100 mg","MEDI4920 300 mg","MEDI4920 1000 mg","MEDI4920 3000 mg",{"trials":6099,"activeCount":83},[],{"trials":6101,"activeCount":83},[],{"trials":6103,"activeCount":83},[],{"trials":6105,"activeCount":83},[],{"intervention":6092,"totalTrials":480,"cells":6107},{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6116,"PHASE3":6118,"PHASE4":6120,"NA":6122},{"trials":6109,"activeCount":83},[],{"trials":6111,"activeCount":83},[6112],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6113,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6114,"interventions":6115},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6117,"activeCount":83},[],{"trials":6119,"activeCount":83},[],{"trials":6121,"activeCount":83},[],{"trials":6123,"activeCount":83},[],{"intervention":6093,"totalTrials":480,"cells":6125},{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6134,"PHASE3":6136,"PHASE4":6138,"NA":6140},{"trials":6127,"activeCount":83},[],{"trials":6129,"activeCount":83},[6130],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6131,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6132,"interventions":6133},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6135,"activeCount":83},[],{"trials":6137,"activeCount":83},[],{"trials":6139,"activeCount":83},[],{"trials":6141,"activeCount":83},[],{"intervention":6094,"totalTrials":480,"cells":6143},{"EARLY_PHASE1":6144,"PHASE1":6146,"PHASE2":6152,"PHASE3":6154,"PHASE4":6156,"NA":6158},{"trials":6145,"activeCount":83},[],{"trials":6147,"activeCount":83},[6148],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6149,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6150,"interventions":6151},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6153,"activeCount":83},[],{"trials":6155,"activeCount":83},[],{"trials":6157,"activeCount":83},[],{"trials":6159,"activeCount":83},[],{"intervention":6095,"totalTrials":480,"cells":6161},{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6170,"PHASE3":6172,"PHASE4":6174,"NA":6176},{"trials":6163,"activeCount":83},[],{"trials":6165,"activeCount":83},[6166],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6167,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6168,"interventions":6169},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6171,"activeCount":83},[],{"trials":6173,"activeCount":83},[],{"trials":6175,"activeCount":83},[],{"trials":6177,"activeCount":83},[],{"intervention":6096,"totalTrials":480,"cells":6179},{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6188,"PHASE3":6190,"PHASE4":6192,"NA":6194},{"trials":6181,"activeCount":83},[],{"trials":6183,"activeCount":83},[6184],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6185,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6186,"interventions":6187},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6189,"activeCount":83},[],{"trials":6191,"activeCount":83},[],{"trials":6193,"activeCount":83},[],{"trials":6195,"activeCount":83},[],{"intervention":6097,"totalTrials":480,"cells":6197},{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6206,"PHASE3":6208,"PHASE4":6210,"NA":6212},{"trials":6199,"activeCount":83},[],{"trials":6201,"activeCount":83},[6202],{"nctId":6084,"briefTitle":6085,"status":89,"phases":6203,"primaryCompletion":4714,"completion":4714,"start":6087,"enrollment":6088,"conditions":6204,"interventions":6205},[72],[6090],[6077,6092,6093,6094,6095,6096,6097],{"trials":6207,"activeCount":83},[],{"trials":6209,"activeCount":83},[],{"trials":6211,"activeCount":83},[],{"trials":6213,"activeCount":83},[],{"intervention":6215,"totalTrials":480,"cells":6216},"MEDI6570",{"EARLY_PHASE1":6217,"PHASE1":6219,"PHASE2":6230,"PHASE3":6232,"PHASE4":6234,"NA":6236},{"trials":6218,"activeCount":83},[],{"trials":6220,"activeCount":83},[6221],{"nctId":6222,"briefTitle":6223,"status":89,"phases":6224,"primaryCompletion":6225,"completion":6225,"start":6226,"enrollment":5831,"conditions":6227,"interventions":6228},"NCT03654313","Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus",[72],"2020-07-21","2018-09-28",[4362,4363],[6215,6229],"Part B Placebo",{"trials":6231,"activeCount":83},[],{"trials":6233,"activeCount":83},[],{"trials":6235,"activeCount":83},[],{"trials":6237,"activeCount":83},[],{"intervention":6229,"totalTrials":480,"cells":6239},{"EARLY_PHASE1":6240,"PHASE1":6242,"PHASE2":6248,"PHASE3":6250,"PHASE4":6252,"NA":6254},{"trials":6241,"activeCount":83},[],{"trials":6243,"activeCount":83},[6244],{"nctId":6222,"briefTitle":6223,"status":89,"phases":6245,"primaryCompletion":6225,"completion":6225,"start":6226,"enrollment":5831,"conditions":6246,"interventions":6247},[72],[4362,4363],[6215,6229],{"trials":6249,"activeCount":83},[],{"trials":6251,"activeCount":83},[],{"trials":6253,"activeCount":83},[],{"trials":6255,"activeCount":83},[],{"intervention":1227,"totalTrials":480,"cells":6257},{"EARLY_PHASE1":6258,"PHASE1":6260,"PHASE2":6266,"PHASE3":6268,"PHASE4":6270,"NA":6272},{"trials":6259,"activeCount":83},[],{"trials":6261,"activeCount":83},[6262],{"nctId":1218,"briefTitle":1219,"status":89,"phases":6263,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":6264,"interventions":6265},[72],[1225],[1211,1211,1211,1211,1227,1211],{"trials":6267,"activeCount":83},[],{"trials":6269,"activeCount":83},[],{"trials":6271,"activeCount":83},[],{"trials":6273,"activeCount":83},[],{"intervention":140,"totalTrials":480,"cells":6275},{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6284,"PHASE3":6286,"PHASE4":6288,"NA":6290},{"trials":6277,"activeCount":83},[],{"trials":6279,"activeCount":83},[6280],{"nctId":132,"briefTitle":133,"status":89,"phases":6281,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":6282,"interventions":6283},[72],[27],[140,141,142],{"trials":6285,"activeCount":83},[],{"trials":6287,"activeCount":83},[],{"trials":6289,"activeCount":83},[],{"trials":6291,"activeCount":83},[],{"intervention":6293,"totalTrials":480,"cells":6294},"MEDI9314",{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6308,"PHASE3":6310,"PHASE4":6312,"NA":6314},{"trials":6296,"activeCount":83},[],{"trials":6298,"activeCount":83},[6299],{"nctId":6300,"briefTitle":6301,"status":89,"phases":6302,"primaryCompletion":6303,"completion":6304,"start":6305,"enrollment":1938,"conditions":6306,"interventions":6307},"NCT02669667","Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects",[72],"2016-11-17","2017-06-12","2016-02-18",[1628,1629],[6293],{"trials":6309,"activeCount":83},[],{"trials":6311,"activeCount":83},[],{"trials":6313,"activeCount":83},[],{"trials":6315,"activeCount":83},[],{"intervention":6317,"totalTrials":480,"cells":6318},"MEDI2338",{"EARLY_PHASE1":6319,"PHASE1":6321,"PHASE2":6329,"PHASE3":6331,"PHASE4":6333,"NA":6335},{"trials":6320,"activeCount":83},[],{"trials":6322,"activeCount":83},[6323],{"nctId":6324,"briefTitle":6325,"status":89,"phases":6326,"primaryCompletion":3178,"completion":3802,"start":5150,"enrollment":1087,"conditions":6327,"interventions":6328},"NCT01322594","A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease",[72],[3448],[6317,6317,6317,6317,6317],{"trials":6330,"activeCount":83},[],{"trials":6332,"activeCount":83},[],{"trials":6334,"activeCount":83},[],{"trials":6336,"activeCount":83},[],{"intervention":6338,"totalTrials":480,"cells":6339},"MEDI0639",{"EARLY_PHASE1":6340,"PHASE1":6342,"PHASE2":6352,"PHASE3":6354,"PHASE4":6356,"NA":6358},{"trials":6341,"activeCount":83},[],{"trials":6343,"activeCount":83},[6344],{"nctId":6345,"briefTitle":6346,"status":89,"phases":6347,"primaryCompletion":6348,"completion":6348,"start":6349,"enrollment":126,"conditions":6350,"interventions":6351},"NCT01577745","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",[72],"2015-12","2012-04",[106],[6338],{"trials":6353,"activeCount":83},[],{"trials":6355,"activeCount":83},[],{"trials":6357,"activeCount":83},[],{"trials":6359,"activeCount":83},[],{"intervention":6361,"totalTrials":480,"cells":6362},"MEDI5884 Dose 1",{"EARLY_PHASE1":6363,"PHASE1":6365,"PHASE2":6379,"PHASE3":6381,"PHASE4":6383,"NA":6385},{"trials":6364,"activeCount":83},[],{"trials":6366,"activeCount":83},[6367],{"nctId":6368,"briefTitle":6369,"status":89,"phases":6370,"primaryCompletion":6371,"completion":6371,"start":6372,"enrollment":6373,"conditions":6374,"interventions":6375},"NCT03001297","Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884",[72],"2018-08-10","2017-01-17",64,[1639],[6361,6376,6377,6378],"MEDI5884 Dose 2","MEDI5884 Dose 3","MEDI5884 Dose 4",{"trials":6380,"activeCount":83},[],{"trials":6382,"activeCount":83},[],{"trials":6384,"activeCount":83},[],{"trials":6386,"activeCount":83},[],{"intervention":6376,"totalTrials":480,"cells":6388},{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6397,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6390,"activeCount":83},[],{"trials":6392,"activeCount":83},[6393],{"nctId":6368,"briefTitle":6369,"status":89,"phases":6394,"primaryCompletion":6371,"completion":6371,"start":6372,"enrollment":6373,"conditions":6395,"interventions":6396},[72],[1639],[6361,6376,6377,6378],{"trials":6398,"activeCount":83},[],{"trials":6400,"activeCount":83},[],{"trials":6402,"activeCount":83},[],{"trials":6404,"activeCount":83},[],{"intervention":6377,"totalTrials":480,"cells":6406},{"EARLY_PHASE1":6407,"PHASE1":6409,"PHASE2":6415,"PHASE3":6417,"PHASE4":6419,"NA":6421},{"trials":6408,"activeCount":83},[],{"trials":6410,"activeCount":83},[6411],{"nctId":6368,"briefTitle":6369,"status":89,"phases":6412,"primaryCompletion":6371,"completion":6371,"start":6372,"enrollment":6373,"conditions":6413,"interventions":6414},[72],[1639],[6361,6376,6377,6378],{"trials":6416,"activeCount":83},[],{"trials":6418,"activeCount":83},[],{"trials":6420,"activeCount":83},[],{"trials":6422,"activeCount":83},[],{"intervention":6378,"totalTrials":480,"cells":6424},{"EARLY_PHASE1":6425,"PHASE1":6427,"PHASE2":6433,"PHASE3":6435,"PHASE4":6437,"NA":6439},{"trials":6426,"activeCount":83},[],{"trials":6428,"activeCount":83},[6429],{"nctId":6368,"briefTitle":6369,"status":89,"phases":6430,"primaryCompletion":6371,"completion":6371,"start":6372,"enrollment":6373,"conditions":6431,"interventions":6432},[72],[1639],[6361,6376,6377,6378],{"trials":6434,"activeCount":83},[],{"trials":6436,"activeCount":83},[],{"trials":6438,"activeCount":83},[],{"trials":6440,"activeCount":83},[],{"intervention":6442,"totalTrials":480,"cells":6443},"MEDI8897 Intravenous",{"EARLY_PHASE1":6444,"PHASE1":6446,"PHASE2":6456,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6445,"activeCount":83},[],{"trials":6447,"activeCount":83},[6448],{"nctId":6449,"briefTitle":6450,"status":89,"phases":6451,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":6452,"conditions":6453,"interventions":6454},"NCT02114268","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults",[72],342,[30],[6442,6442,6442,6455,6455],"MEDI8897 Intramuscular",{"trials":6457,"activeCount":83},[],{"trials":6459,"activeCount":83},[],{"trials":6461,"activeCount":83},[],{"trials":6463,"activeCount":83},[],{"intervention":6455,"totalTrials":480,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6474,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":83},[],{"trials":6469,"activeCount":83},[6470],{"nctId":6449,"briefTitle":6450,"status":89,"phases":6471,"primaryCompletion":824,"completion":824,"start":2065,"enrollment":6452,"conditions":6472,"interventions":6473},[72],[30],[6442,6442,6442,6455,6455],{"trials":6475,"activeCount":83},[],{"trials":6477,"activeCount":83},[],{"trials":6479,"activeCount":83},[],{"trials":6481,"activeCount":83},[],{"intervention":6483,"totalTrials":480,"cells":6484},"ACP-501",{"EARLY_PHASE1":6485,"PHASE1":6487,"PHASE2":6495,"PHASE3":6497,"PHASE4":6499,"NA":6501},{"trials":6486,"activeCount":83},[],{"trials":6488,"activeCount":83},[6489],{"nctId":6490,"briefTitle":6491,"status":89,"phases":6492,"primaryCompletion":5910,"completion":5910,"start":2206,"enrollment":79,"conditions":6493,"interventions":6494},"NCT01554800","Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease",[72],[2447,4362],[6483],{"trials":6496,"activeCount":83},[],{"trials":6498,"activeCount":83},[],{"trials":6500,"activeCount":83},[],{"trials":6502,"activeCount":83},[],{"intervention":6504,"totalTrials":480,"cells":6505},"MEDI-551 30 MG-IV",{"EARLY_PHASE1":6506,"PHASE1":6508,"PHASE2":6524,"PHASE3":6526,"PHASE4":6528,"NA":6530},{"trials":6507,"activeCount":83},[],{"trials":6509,"activeCount":83},[6510],{"nctId":6511,"briefTitle":6512,"status":89,"phases":6513,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":1851,"conditions":6517,"interventions":6519},"NCT01585766","Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",[72],"2015-01-02","2016-06-20","2012-04-24",[6518],"Multiple Sclerosis, Relapsing Forms",[6504,6520,6521,6522,6523],"MEDI-551 60 MG-SC","MEDI-551 100 MG-IV","MEDI-551 300 MG-SC","MEDI-551 600 MG-IV",{"trials":6525,"activeCount":83},[],{"trials":6527,"activeCount":83},[],{"trials":6529,"activeCount":83},[],{"trials":6531,"activeCount":83},[],{"intervention":6520,"totalTrials":480,"cells":6533},{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6542,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6535,"activeCount":83},[],{"trials":6537,"activeCount":83},[6538],{"nctId":6511,"briefTitle":6512,"status":89,"phases":6539,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":1851,"conditions":6540,"interventions":6541},[72],[6518],[6504,6520,6521,6522,6523],{"trials":6543,"activeCount":83},[],{"trials":6545,"activeCount":83},[],{"trials":6547,"activeCount":83},[],{"trials":6549,"activeCount":83},[],{"intervention":6521,"totalTrials":480,"cells":6551},{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6560,"PHASE3":6562,"PHASE4":6564,"NA":6566},{"trials":6553,"activeCount":83},[],{"trials":6555,"activeCount":83},[6556],{"nctId":6511,"briefTitle":6512,"status":89,"phases":6557,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":1851,"conditions":6558,"interventions":6559},[72],[6518],[6504,6520,6521,6522,6523],{"trials":6561,"activeCount":83},[],{"trials":6563,"activeCount":83},[],{"trials":6565,"activeCount":83},[],{"trials":6567,"activeCount":83},[],{"intervention":6522,"totalTrials":480,"cells":6569},{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6578,"PHASE3":6580,"PHASE4":6582,"NA":6584},{"trials":6571,"activeCount":83},[],{"trials":6573,"activeCount":83},[6574],{"nctId":6511,"briefTitle":6512,"status":89,"phases":6575,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":1851,"conditions":6576,"interventions":6577},[72],[6518],[6504,6520,6521,6522,6523],{"trials":6579,"activeCount":83},[],{"trials":6581,"activeCount":83},[],{"trials":6583,"activeCount":83},[],{"trials":6585,"activeCount":83},[],{"intervention":6523,"totalTrials":480,"cells":6587},{"EARLY_PHASE1":6588,"PHASE1":6590,"PHASE2":6596,"PHASE3":6598,"PHASE4":6600,"NA":6602},{"trials":6589,"activeCount":83},[],{"trials":6591,"activeCount":83},[6592],{"nctId":6511,"briefTitle":6512,"status":89,"phases":6593,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":1851,"conditions":6594,"interventions":6595},[72],[6518],[6504,6520,6521,6522,6523],{"trials":6597,"activeCount":83},[],{"trials":6599,"activeCount":83},[],{"trials":6601,"activeCount":83},[],{"trials":6603,"activeCount":83},[],{"intervention":2758,"totalTrials":480,"cells":6605},{"EARLY_PHASE1":6606,"PHASE1":6608,"PHASE2":6614,"PHASE3":6616,"PHASE4":6618,"NA":6620},{"trials":6607,"activeCount":83},[],{"trials":6609,"activeCount":83},[6610],{"nctId":2750,"briefTitle":2751,"status":167,"phases":6611,"primaryCompletion":2753,"completion":2753,"start":2754,"enrollment":2505,"conditions":6612,"interventions":6613},[72],[2756],[2758,2743,2759],{"trials":6615,"activeCount":83},[],{"trials":6617,"activeCount":83},[],{"trials":6619,"activeCount":83},[],{"trials":6621,"activeCount":83},[],{"intervention":2759,"totalTrials":480,"cells":6623},{"EARLY_PHASE1":6624,"PHASE1":6626,"PHASE2":6632,"PHASE3":6634,"PHASE4":6636,"NA":6638},{"trials":6625,"activeCount":83},[],{"trials":6627,"activeCount":83},[6628],{"nctId":2750,"briefTitle":2751,"status":167,"phases":6629,"primaryCompletion":2753,"completion":2753,"start":2754,"enrollment":2505,"conditions":6630,"interventions":6631},[72],[2756],[2758,2743,2759],{"trials":6633,"activeCount":83},[],{"trials":6635,"activeCount":83},[],{"trials":6637,"activeCount":83},[],{"trials":6639,"activeCount":83},[],{"intervention":6641,"totalTrials":480,"cells":6642},"MEDI9929, 140 mg",{"EARLY_PHASE1":6643,"PHASE1":6645,"PHASE2":6656,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6644,"activeCount":83},[],{"trials":6646,"activeCount":83},[6647],{"nctId":6648,"briefTitle":6649,"status":89,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":6653,"conditions":6654,"interventions":6655},"NCT02512900","A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma",[72],"2016-05-17","2015-09-10",21,[21],[6641],{"trials":6657,"activeCount":83},[],{"trials":6659,"activeCount":83},[],{"trials":6661,"activeCount":83},[],{"trials":6663,"activeCount":83},[],{"intervention":6665,"totalTrials":480,"cells":6666},"Omalizumab",{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6686,"PHASE3":6688,"PHASE4":6690,"NA":6692},{"trials":6668,"activeCount":83},[],{"trials":6670,"activeCount":83},[6671],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6674,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6676,"interventions":6679},"NCT01544348","A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU\u002FmL",[72],295,[6677,4240,6678,1639],"Allergic Asthma","Allergic Rhinitis",[6665,6680,6681,6682,6683,6684,6685],"MEDI4212 5 mg Subcutaneous","MEDI4212 15 mg Subcutaneous","MEDI4212 60 mg Subcutaneous","MEDI4212 150 mg Subcutaneous","MEDI4212 300 mg Subcutaneous","MEDI4212 300 mg Intravenous",{"trials":6687,"activeCount":83},[],{"trials":6689,"activeCount":83},[],{"trials":6691,"activeCount":83},[],{"trials":6693,"activeCount":83},[],{"intervention":6680,"totalTrials":480,"cells":6695},{"EARLY_PHASE1":6696,"PHASE1":6698,"PHASE2":6704,"PHASE3":6706,"PHASE4":6708,"NA":6710},{"trials":6697,"activeCount":83},[],{"trials":6699,"activeCount":83},[6700],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6701,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6702,"interventions":6703},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6705,"activeCount":83},[],{"trials":6707,"activeCount":83},[],{"trials":6709,"activeCount":83},[],{"trials":6711,"activeCount":83},[],{"intervention":6681,"totalTrials":480,"cells":6713},{"EARLY_PHASE1":6714,"PHASE1":6716,"PHASE2":6722,"PHASE3":6724,"PHASE4":6726,"NA":6728},{"trials":6715,"activeCount":83},[],{"trials":6717,"activeCount":83},[6718],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6719,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6720,"interventions":6721},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6723,"activeCount":83},[],{"trials":6725,"activeCount":83},[],{"trials":6727,"activeCount":83},[],{"trials":6729,"activeCount":83},[],{"intervention":6682,"totalTrials":480,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6740,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6733,"activeCount":83},[],{"trials":6735,"activeCount":83},[6736],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6737,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6738,"interventions":6739},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6741,"activeCount":83},[],{"trials":6743,"activeCount":83},[],{"trials":6745,"activeCount":83},[],{"trials":6747,"activeCount":83},[],{"intervention":6683,"totalTrials":480,"cells":6749},{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6758,"PHASE3":6760,"PHASE4":6762,"NA":6764},{"trials":6751,"activeCount":83},[],{"trials":6753,"activeCount":83},[6754],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6755,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6756,"interventions":6757},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6759,"activeCount":83},[],{"trials":6761,"activeCount":83},[],{"trials":6763,"activeCount":83},[],{"trials":6765,"activeCount":83},[],{"intervention":6684,"totalTrials":480,"cells":6767},{"EARLY_PHASE1":6768,"PHASE1":6770,"PHASE2":6776,"PHASE3":6778,"PHASE4":6780,"NA":6782},{"trials":6769,"activeCount":83},[],{"trials":6771,"activeCount":83},[6772],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6773,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6774,"interventions":6775},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6777,"activeCount":83},[],{"trials":6779,"activeCount":83},[],{"trials":6781,"activeCount":83},[],{"trials":6783,"activeCount":83},[],{"intervention":6685,"totalTrials":480,"cells":6785},{"EARLY_PHASE1":6786,"PHASE1":6788,"PHASE2":6794,"PHASE3":6796,"PHASE4":6798,"NA":6800},{"trials":6787,"activeCount":83},[],{"trials":6789,"activeCount":83},[6790],{"nctId":6672,"briefTitle":6673,"status":89,"phases":6791,"primaryCompletion":3628,"completion":3628,"start":3179,"enrollment":6675,"conditions":6792,"interventions":6793},[72],[6677,4240,6678,1639],[6665,6680,6681,6682,6683,6684,6685],{"trials":6795,"activeCount":83},[],{"trials":6797,"activeCount":83},[],{"trials":6799,"activeCount":83},[],{"trials":6801,"activeCount":83},[],{"intervention":6803,"totalTrials":480,"cells":6804},"CAT-354",{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6817,"PHASE3":6819,"PHASE4":6821,"NA":6823},{"trials":6806,"activeCount":83},[],{"trials":6808,"activeCount":83},[6809],{"nctId":6810,"briefTitle":6811,"status":89,"phases":6812,"primaryCompletion":939,"completion":293,"start":6813,"enrollment":2288,"conditions":6814,"interventions":6815},"NCT01093040","A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects",[72],"2010-04",[15],[6803,6803,6816],"CAT 354",{"trials":6818,"activeCount":83},[],{"trials":6820,"activeCount":83},[],{"trials":6822,"activeCount":83},[],{"trials":6824,"activeCount":83},[],{"intervention":6816,"totalTrials":480,"cells":6826},{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6835,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6828,"activeCount":83},[],{"trials":6830,"activeCount":83},[6831],{"nctId":6810,"briefTitle":6811,"status":89,"phases":6832,"primaryCompletion":939,"completion":293,"start":6813,"enrollment":2288,"conditions":6833,"interventions":6834},[72],[15],[6803,6803,6816],{"trials":6836,"activeCount":83},[],{"trials":6838,"activeCount":83},[],{"trials":6840,"activeCount":83},[],{"trials":6842,"activeCount":83},[],{"intervention":6844,"totalTrials":480,"cells":6845},"MEDI3902 - Dose 1",{"EARLY_PHASE1":6846,"PHASE1":6848,"PHASE2":6862,"PHASE3":6864,"PHASE4":6866,"NA":6868},{"trials":6847,"activeCount":83},[],{"trials":6849,"activeCount":83},[6850],{"nctId":6851,"briefTitle":6852,"status":89,"phases":6853,"primaryCompletion":6854,"completion":6854,"start":6855,"enrollment":1851,"conditions":6856,"interventions":6858},"NCT02255760","Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults",[72],"2015-04-20","2014-09-04",[6857],"MEDI3902 for Prevention of P. Aeruginosa Pneumonia",[6844,6859,6860,6861],"MEDI3902 - Dose 2","MEDI3902 - Dose 3","MEDI3902 - Dose 4",{"trials":6863,"activeCount":83},[],{"trials":6865,"activeCount":83},[],{"trials":6867,"activeCount":83},[],{"trials":6869,"activeCount":83},[],{"intervention":6859,"totalTrials":480,"cells":6871},{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6880,"PHASE3":6882,"PHASE4":6884,"NA":6886},{"trials":6873,"activeCount":83},[],{"trials":6875,"activeCount":83},[6876],{"nctId":6851,"briefTitle":6852,"status":89,"phases":6877,"primaryCompletion":6854,"completion":6854,"start":6855,"enrollment":1851,"conditions":6878,"interventions":6879},[72],[6857],[6844,6859,6860,6861],{"trials":6881,"activeCount":83},[],{"trials":6883,"activeCount":83},[],{"trials":6885,"activeCount":83},[],{"trials":6887,"activeCount":83},[],{"intervention":6860,"totalTrials":480,"cells":6889},{"EARLY_PHASE1":6890,"PHASE1":6892,"PHASE2":6898,"PHASE3":6900,"PHASE4":6902,"NA":6904},{"trials":6891,"activeCount":83},[],{"trials":6893,"activeCount":83},[6894],{"nctId":6851,"briefTitle":6852,"status":89,"phases":6895,"primaryCompletion":6854,"completion":6854,"start":6855,"enrollment":1851,"conditions":6896,"interventions":6897},[72],[6857],[6844,6859,6860,6861],{"trials":6899,"activeCount":83},[],{"trials":6901,"activeCount":83},[],{"trials":6903,"activeCount":83},[],{"trials":6905,"activeCount":83},[],{"intervention":6861,"totalTrials":480,"cells":6907},{"EARLY_PHASE1":6908,"PHASE1":6910,"PHASE2":6916,"PHASE3":6918,"PHASE4":6920,"NA":6922},{"trials":6909,"activeCount":83},[],{"trials":6911,"activeCount":83},[6912],{"nctId":6851,"briefTitle":6852,"status":89,"phases":6913,"primaryCompletion":6854,"completion":6854,"start":6855,"enrollment":1851,"conditions":6914,"interventions":6915},[72],[6857],[6844,6859,6860,6861],{"trials":6917,"activeCount":83},[],{"trials":6919,"activeCount":83},[],{"trials":6921,"activeCount":83},[],{"trials":6923,"activeCount":83},[],{"intervention":6925,"totalTrials":480,"cells":6926},"MEDI4276",{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6941,"PHASE3":6943,"PHASE4":6945,"NA":6947},{"trials":6928,"activeCount":83},[],{"trials":6930,"activeCount":83},[6931],{"nctId":6932,"briefTitle":6933,"status":89,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":6937,"conditions":6938,"interventions":6940},"NCT02576548","A Phase 1\u002F2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.",[72],"2018-05-23","2015-09-23",47,[6939],"HER2 Expressing Breast or Gastric\u002FStomach Cancers",[6925],{"trials":6942,"activeCount":83},[],{"trials":6944,"activeCount":83},[],{"trials":6946,"activeCount":83},[],{"trials":6948,"activeCount":83},[],{"intervention":6950,"totalTrials":480,"cells":6951},"AMP-224",{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6963,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6953,"activeCount":83},[],{"trials":6955,"activeCount":83},[6956],{"nctId":6957,"briefTitle":6958,"status":89,"phases":6959,"primaryCompletion":6960,"completion":2011,"start":5150,"enrollment":1938,"conditions":6961,"interventions":6962},"NCT01352884","Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer",[72],"2013-11",[24],[6950,6950],{"trials":6964,"activeCount":83},[],{"trials":6966,"activeCount":83},[],{"trials":6968,"activeCount":83},[],{"trials":6970,"activeCount":83},[],{"intervention":6972,"totalTrials":480,"cells":6973},"MEDI8897 10 mg",{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6989,"PHASE3":6991,"PHASE4":6993,"NA":6995},{"trials":6975,"activeCount":83},[],{"trials":6977,"activeCount":83},[6978],{"nctId":6979,"briefTitle":6980,"status":89,"phases":6981,"primaryCompletion":6982,"completion":6982,"start":6983,"enrollment":6984,"conditions":6985,"interventions":6986},"NCT02290340","A Phase 1b\u002F2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants",[72],"2016-09-28","2015-01-13",151,[2094],[6972,6987,6988],"MEDI8897 25 mg","MEDI8897 50 mg",{"trials":6990,"activeCount":83},[],{"trials":6992,"activeCount":83},[],{"trials":6994,"activeCount":83},[],{"trials":6996,"activeCount":83},[],{"intervention":6987,"totalTrials":480,"cells":6998},{"EARLY_PHASE1":6999,"PHASE1":7001,"PHASE2":7007,"PHASE3":7009,"PHASE4":7011,"NA":7013},{"trials":7000,"activeCount":83},[],{"trials":7002,"activeCount":83},[7003],{"nctId":6979,"briefTitle":6980,"status":89,"phases":7004,"primaryCompletion":6982,"completion":6982,"start":6983,"enrollment":6984,"conditions":7005,"interventions":7006},[72],[2094],[6972,6987,6988],{"trials":7008,"activeCount":83},[],{"trials":7010,"activeCount":83},[],{"trials":7012,"activeCount":83},[],{"trials":7014,"activeCount":83},[],{"intervention":6988,"totalTrials":480,"cells":7016},{"EARLY_PHASE1":7017,"PHASE1":7019,"PHASE2":7025,"PHASE3":7027,"PHASE4":7029,"NA":7031},{"trials":7018,"activeCount":83},[],{"trials":7020,"activeCount":83},[7021],{"nctId":6979,"briefTitle":6980,"status":89,"phases":7022,"primaryCompletion":6982,"completion":6982,"start":6983,"enrollment":6984,"conditions":7023,"interventions":7024},[72],[2094],[6972,6987,6988],{"trials":7026,"activeCount":83},[],{"trials":7028,"activeCount":83},[],{"trials":7030,"activeCount":83},[],{"trials":7032,"activeCount":83},[],{"intervention":362,"totalTrials":480,"cells":7034},{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7043,"PHASE3":7045,"PHASE4":7047,"NA":7049},{"trials":7036,"activeCount":83},[],{"trials":7038,"activeCount":83},[7039],{"nctId":353,"briefTitle":354,"status":89,"phases":7040,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":7041,"interventions":7042},[72],[360],[362,363,338],{"trials":7044,"activeCount":83},[],{"trials":7046,"activeCount":83},[],{"trials":7048,"activeCount":83},[],{"trials":7050,"activeCount":83},[],{"intervention":363,"totalTrials":480,"cells":7052},{"EARLY_PHASE1":7053,"PHASE1":7055,"PHASE2":7061,"PHASE3":7063,"PHASE4":7065,"NA":7067},{"trials":7054,"activeCount":83},[],{"trials":7056,"activeCount":83},[7057],{"nctId":353,"briefTitle":354,"status":89,"phases":7058,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":7059,"interventions":7060},[72],[360],[362,363,338],{"trials":7062,"activeCount":83},[],{"trials":7064,"activeCount":83},[],{"trials":7066,"activeCount":83},[],{"trials":7068,"activeCount":83},[],{"intervention":152,"totalTrials":480,"cells":7070},{"EARLY_PHASE1":7071,"PHASE1":7073,"PHASE2":7079,"PHASE3":7081,"PHASE4":7083,"NA":7085},{"trials":7072,"activeCount":83},[],{"trials":7074,"activeCount":83},[7075],{"nctId":144,"briefTitle":145,"status":89,"phases":7076,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":7077,"interventions":7078},[72],[106,24],[152,60],{"trials":7080,"activeCount":83},[],{"trials":7082,"activeCount":83},[],{"trials":7084,"activeCount":83},[],{"trials":7086,"activeCount":83},[],{"intervention":7088,"totalTrials":480,"cells":7089},"Dose Escalation, MEDI2228, ADC",{"EARLY_PHASE1":7090,"PHASE1":7092,"PHASE2":7104,"PHASE3":7106,"PHASE4":7108,"NA":7110},{"trials":7091,"activeCount":83},[],{"trials":7093,"activeCount":83},[7094],{"nctId":7095,"briefTitle":7096,"status":89,"phases":7097,"primaryCompletion":7098,"completion":7098,"start":443,"enrollment":7099,"conditions":7100,"interventions":7102},"NCT03489525","MEDI2228 in Subjects With Relapsed\u002FRefractory Multiple Myeloma",[72],"2022-03-21",107,[7101],"Relapsed\u002FRefractory Multiple Myeloma",[7088,7103],"Dose Expansion, MEDI2228, ADC",{"trials":7105,"activeCount":83},[],{"trials":7107,"activeCount":83},[],{"trials":7109,"activeCount":83},[],{"trials":7111,"activeCount":83},[],{"intervention":7103,"totalTrials":480,"cells":7113},{"EARLY_PHASE1":7114,"PHASE1":7116,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7115,"activeCount":83},[],{"trials":7117,"activeCount":83},[7118],{"nctId":7095,"briefTitle":7096,"status":89,"phases":7119,"primaryCompletion":7098,"completion":7098,"start":443,"enrollment":7099,"conditions":7120,"interventions":7121},[72],[7101],[7088,7103],{"trials":7123,"activeCount":83},[],{"trials":7125,"activeCount":83},[],{"trials":7127,"activeCount":83},[],{"trials":7129,"activeCount":83},[],{"intervention":7131,"totalTrials":480,"cells":7132},"100mg Mavrilimumab",{"EARLY_PHASE1":7133,"PHASE1":7135,"PHASE2":7144,"PHASE3":7146,"PHASE4":7148,"NA":7150},{"trials":7134,"activeCount":83},[],{"trials":7136,"activeCount":83},[7137],{"nctId":7138,"briefTitle":7139,"status":89,"phases":7140,"primaryCompletion":5273,"completion":5273,"start":5328,"enrollment":160,"conditions":7141,"interventions":7142},"NCT02213315","A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects",[72],[1639],[7131,7143],"150mg mavrilimumab",{"trials":7145,"activeCount":83},[],{"trials":7147,"activeCount":83},[],{"trials":7149,"activeCount":83},[],{"trials":7151,"activeCount":83},[],{"intervention":7143,"totalTrials":480,"cells":7153},{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7162,"PHASE3":7164,"PHASE4":7166,"NA":7168},{"trials":7155,"activeCount":83},[],{"trials":7157,"activeCount":83},[7158],{"nctId":7138,"briefTitle":7139,"status":89,"phases":7159,"primaryCompletion":5273,"completion":5273,"start":5328,"enrollment":160,"conditions":7160,"interventions":7161},[72],[1639],[7131,7143],{"trials":7163,"activeCount":83},[],{"trials":7165,"activeCount":83},[],{"trials":7167,"activeCount":83},[],{"trials":7169,"activeCount":83},[],{"intervention":1667,"totalTrials":480,"cells":7171},{"EARLY_PHASE1":7172,"PHASE1":7174,"PHASE2":7180,"PHASE3":7182,"PHASE4":7184,"NA":7186},{"trials":7173,"activeCount":83},[],{"trials":7175,"activeCount":83},[7176],{"nctId":1660,"briefTitle":1661,"status":89,"phases":7177,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":22,"conditions":7178,"interventions":7179},[72],[1639],[1615,1667,1668],{"trials":7181,"activeCount":83},[],{"trials":7183,"activeCount":83},[],{"trials":7185,"activeCount":83},[],{"trials":7187,"activeCount":83},[],{"intervention":1668,"totalTrials":480,"cells":7189},{"EARLY_PHASE1":7190,"PHASE1":7192,"PHASE2":7198,"PHASE3":7200,"PHASE4":7202,"NA":7204},{"trials":7191,"activeCount":83},[],{"trials":7193,"activeCount":83},[7194],{"nctId":1660,"briefTitle":1661,"status":89,"phases":7195,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":22,"conditions":7196,"interventions":7197},[72],[1639],[1615,1667,1668],{"trials":7199,"activeCount":83},[],{"trials":7201,"activeCount":83},[],{"trials":7203,"activeCount":83},[],{"trials":7205,"activeCount":83},[],{"intervention":374,"totalTrials":480,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7216,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7209,"activeCount":83},[],{"trials":7211,"activeCount":83},[7212],{"nctId":365,"briefTitle":366,"status":89,"phases":7213,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":7214,"interventions":7215},[72],[372],[337,338,374],{"trials":7217,"activeCount":83},[],{"trials":7219,"activeCount":83},[],{"trials":7221,"activeCount":83},[],{"trials":7223,"activeCount":83},[],{"intervention":7225,"totalTrials":480,"cells":7226},"MEDI5083 monotherapy",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7241,"PHASE3":7243,"PHASE4":7245,"NA":7247},{"trials":7228,"activeCount":83},[],{"trials":7230,"activeCount":83},[7231],{"nctId":7232,"briefTitle":7233,"status":89,"phases":7234,"primaryCompletion":7235,"completion":7235,"start":7236,"enrollment":160,"conditions":7237,"interventions":7238},"NCT03089645","MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and\u002For Docetaxel.",[72],"2020-06-23","2017-03-21",[27],[7225,7239,7240],"MEID5083 with Durvalumab or Tremelimumab","Medi5083 with Durvalumab and Docetaxel",{"trials":7242,"activeCount":83},[],{"trials":7244,"activeCount":83},[],{"trials":7246,"activeCount":83},[],{"trials":7248,"activeCount":83},[],{"intervention":7239,"totalTrials":480,"cells":7250},{"EARLY_PHASE1":7251,"PHASE1":7253,"PHASE2":7259,"PHASE3":7261,"PHASE4":7263,"NA":7265},{"trials":7252,"activeCount":83},[],{"trials":7254,"activeCount":83},[7255],{"nctId":7232,"briefTitle":7233,"status":89,"phases":7256,"primaryCompletion":7235,"completion":7235,"start":7236,"enrollment":160,"conditions":7257,"interventions":7258},[72],[27],[7225,7239,7240],{"trials":7260,"activeCount":83},[],{"trials":7262,"activeCount":83},[],{"trials":7264,"activeCount":83},[],{"trials":7266,"activeCount":83},[],{"intervention":7240,"totalTrials":480,"cells":7268},{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7277,"PHASE3":7279,"PHASE4":7281,"NA":7283},{"trials":7270,"activeCount":83},[],{"trials":7272,"activeCount":83},[7273],{"nctId":7232,"briefTitle":7233,"status":89,"phases":7274,"primaryCompletion":7235,"completion":7235,"start":7236,"enrollment":160,"conditions":7275,"interventions":7276},[72],[27],[7225,7239,7240],{"trials":7278,"activeCount":83},[],{"trials":7280,"activeCount":83},[],{"trials":7282,"activeCount":83},[],{"trials":7284,"activeCount":83},[],{"intervention":163,"totalTrials":480,"cells":7286},{"EARLY_PHASE1":7287,"PHASE1":7289,"PHASE2":7295,"PHASE3":7297,"PHASE4":7299,"NA":7301},{"trials":7288,"activeCount":83},[],{"trials":7290,"activeCount":83},[7291],{"nctId":154,"briefTitle":155,"status":89,"phases":7292,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":7293,"interventions":7294},[72],[27],[163,60],{"trials":7296,"activeCount":83},[],{"trials":7298,"activeCount":83},[],{"trials":7300,"activeCount":83},[],{"trials":7302,"activeCount":83},[],{"intervention":175,"totalTrials":480,"cells":7304},{"EARLY_PHASE1":7305,"PHASE1":7307,"PHASE2":7313,"PHASE3":7315,"PHASE4":7317,"NA":7319},{"trials":7306,"activeCount":83},[],{"trials":7308,"activeCount":83},[7309],{"nctId":165,"briefTitle":166,"status":167,"phases":7310,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":7311,"interventions":7312},[72],[106,173,24],[175,141],{"trials":7314,"activeCount":83},[],{"trials":7316,"activeCount":83},[],{"trials":7318,"activeCount":83},[],{"trials":7320,"activeCount":83},[],{"intervention":7322,"totalTrials":480,"cells":7323},"MEDI-547",{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7340},{"trials":7325,"activeCount":83},[],{"trials":7327,"activeCount":83},[7328],{"nctId":7329,"briefTitle":7330,"status":167,"phases":7331,"primaryCompletion":4014,"completion":937,"start":963,"enrollment":420,"conditions":7332,"interventions":7333},"NCT00796055","Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors",[72],[24],[7322],{"trials":7335,"activeCount":83},[],{"trials":7337,"activeCount":83},[],{"trials":7339,"activeCount":83},[],{"trials":7341,"activeCount":83},[],{"intervention":1854,"totalTrials":480,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7345,"activeCount":83},[],{"trials":7347,"activeCount":83},[7348],{"nctId":1846,"briefTitle":1847,"status":89,"phases":7349,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":7350,"interventions":7351},[72],[446],[1854,337],{"trials":7353,"activeCount":83},[],{"trials":7355,"activeCount":83},[],{"trials":7357,"activeCount":83},[],{"trials":7359,"activeCount":83},[],{"intervention":7361,"totalTrials":480,"cells":7362},"MEDI-565",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7375,"PHASE3":7377,"PHASE4":7379,"NA":7381},{"trials":7364,"activeCount":83},[],{"trials":7366,"activeCount":83},[7367],{"nctId":7368,"briefTitle":7369,"status":89,"phases":7370,"primaryCompletion":1958,"completion":1958,"start":938,"enrollment":7371,"conditions":7372,"interventions":7374},"NCT01284231","A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas",[72],78,[7373],"Gastrointestinal Adenocarcinomas",[7361,7361,7361,7361],{"trials":7376,"activeCount":83},[],{"trials":7378,"activeCount":83},[],{"trials":7380,"activeCount":83},[],{"trials":7382,"activeCount":83},[],{"intervention":1152,"totalTrials":1799,"cells":7384},{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7398,"PHASE3":7400,"PHASE4":7432,"NA":7449},{"trials":7386,"activeCount":83},[],{"trials":7388,"activeCount":83},[7389],{"nctId":7390,"briefTitle":7391,"status":89,"phases":7392,"primaryCompletion":7393,"completion":7394,"start":7395,"enrollment":1139,"conditions":7396,"interventions":7397},"NCT00112112","Safety Study to Evaluate FluMist in Immunocompromised Children",[72],"2008-03-01","2008-05-01","2005-08-01",[24],[1152],{"trials":7399,"activeCount":83},[],{"trials":7401,"activeCount":83},[7402,7408,7412,7420,7426],{"nctId":7403,"briefTitle":7404,"status":89,"phases":7405,"primaryCompletion":1930,"completion":1919,"start":1137,"enrollment":1078,"conditions":7406,"interventions":7407},"NCT00192491","Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children",[74],[18],[1152,1152],{"nctId":1143,"briefTitle":1144,"status":89,"phases":7409,"completion":1146,"start":1147,"enrollment":1148,"conditions":7410,"interventions":7411},[74],[15],[1034,1151,1152],{"nctId":7413,"briefTitle":7414,"status":89,"phases":7415,"completion":7416,"start":7417,"enrollment":750,"conditions":7418,"interventions":7419},"NCT00325481","Study To Evaluate the Safety of Bivalent Vaccine",[74],"2006-12","2006-06",[15],[1152],{"nctId":7421,"briefTitle":7422,"status":89,"phases":7423,"completion":1146,"start":1797,"enrollment":750,"conditions":7424,"interventions":7425},"NCT00192127","Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults",[74],[18],[1152],{"nctId":7427,"briefTitle":7422,"status":89,"phases":7428,"completion":1066,"start":7429,"enrollment":750,"conditions":7430,"interventions":7431},"NCT00125944",[74],"2005-07",[15,18],[1152],{"trials":7433,"activeCount":83},[7434,7442],{"nctId":7435,"briefTitle":7436,"status":89,"phases":7437,"primaryCompletion":7438,"completion":7438,"start":1486,"enrollment":7439,"conditions":7440,"interventions":7441},"NCT00192218","Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program",[75],"2005-04",3022,[18],[1152],{"nctId":7443,"briefTitle":7444,"status":89,"phases":7445,"primaryCompletion":1486,"completion":1910,"start":1796,"enrollment":7446,"conditions":7447,"interventions":7448},"NCT00192140","Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age",[75],345,[18],[1152],{"trials":7450,"activeCount":83},[7451,7458],{"nctId":7452,"briefTitle":7453,"status":89,"phases":7454,"primaryCompletion":4299,"completion":937,"start":4079,"enrollment":7455,"conditions":7456,"interventions":7457},"NCT00113880","A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults",[],63061,[15],[1152,1152,1152],{"nctId":7459,"briefTitle":7460,"status":89,"phases":7461,"primaryCompletion":2607,"completion":2607,"start":846,"enrollment":7462,"conditions":7463,"interventions":7464},"NCT00569894","A Post Marking Study to Evaluate the Safety of FluMist in Children",[],29296,[15],[7465,1090],"FLuMist",{"intervention":1345,"totalTrials":31,"cells":7467},{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7480,"PHASE3":7503,"PHASE4":7526,"NA":7528},{"trials":7469,"activeCount":83},[],{"trials":7471,"activeCount":83},[7472],{"nctId":7473,"briefTitle":7474,"status":89,"phases":7475,"primaryCompletion":1910,"completion":1910,"start":7476,"enrollment":1087,"conditions":7477,"interventions":7479},"NCT00192504","Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection",[72],"2004-03",[7478],"Respiratory Syncytial Virus Prophylaxis",[1345,1345,1345],{"trials":7481,"activeCount":83},[7482,7486,7490,7499],{"nctId":1338,"briefTitle":1339,"status":89,"phases":7483,"primaryCompletion":792,"completion":792,"start":848,"enrollment":1341,"conditions":7484,"interventions":7485},[73],[1343],[1345,1346],{"nctId":4541,"briefTitle":4542,"status":89,"phases":7487,"primaryCompletion":3953,"completion":3953,"start":1067,"enrollment":2173,"conditions":7488,"interventions":7489},[72,73],[4545],[1358,4532],{"nctId":7491,"briefTitle":7492,"status":167,"phases":7493,"primaryCompletion":7494,"completion":7494,"start":7495,"enrollment":25,"conditions":7496,"interventions":7498},"NCT00435227","A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness",[73],"2008-05-31","2007-03-20",[7497],"Participants Less Than 12 Months of Age With RSV Illness",[1345],{"nctId":4667,"briefTitle":4668,"status":89,"phases":7500,"primaryCompletion":4670,"completion":4670,"start":1929,"enrollment":4671,"conditions":7501,"interventions":7502},[73],[30,4673,4674],[4658,4676,1345],{"trials":7504,"activeCount":83},[7505,7509,7517],{"nctId":1350,"briefTitle":1351,"status":89,"phases":7506,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":1355,"conditions":7507,"interventions":7508},[74],[30],[1358,1329],{"nctId":7510,"briefTitle":7511,"status":1977,"phases":7512,"primaryCompletion":7513,"completion":3802,"start":293,"enrollment":83,"conditions":7514,"interventions":7516},"NCT00628303","A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants",[74],"2011-02",[7515],"Wheezing",[1345],{"nctId":7518,"briefTitle":7519,"status":89,"phases":7520,"primaryCompletion":7521,"completion":7521,"start":7522,"enrollment":7523,"conditions":7524,"interventions":7525},"NCT00121108","MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States",[74],"2010-12-27","2004-11-15",2127,[15],[1345],{"trials":7527,"activeCount":83},[],{"trials":7529,"activeCount":83},[7530],{"nctId":7531,"briefTitle":7532,"status":89,"phases":7533,"primaryCompletion":7534,"completion":7534,"start":7535,"enrollment":4648,"conditions":7536,"interventions":7538},"NCT00421304","A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness",[76],"2009-09-17","2007-01-10",[7537],"RSV Illness in ≤12 Months of Participants",[1345],{"intervention":1090,"totalTrials":273,"cells":7540},{"EARLY_PHASE1":7541,"PHASE1":7543,"PHASE2":7545,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7542,"activeCount":83},[],{"trials":7544,"activeCount":83},[],{"trials":7546,"activeCount":83},[7547,7551],{"nctId":3237,"briefTitle":3238,"status":89,"phases":7548,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":3240,"conditions":7549,"interventions":7550},[73],[18],[3228,3243,1090],{"nctId":1082,"briefTitle":1083,"status":89,"phases":7552,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":7553,"interventions":7554},[73],[18],[1034,1090],{"trials":7556,"activeCount":83},[],{"trials":7558,"activeCount":83},[],{"trials":7560,"activeCount":83},[7561],{"nctId":7459,"briefTitle":7460,"status":89,"phases":7562,"primaryCompletion":2607,"completion":2607,"start":846,"enrollment":7462,"conditions":7563,"interventions":7564},[],[15],[7465,1090],{"intervention":7566,"totalTrials":273,"cells":7567},"MEDI-534",{"EARLY_PHASE1":7568,"PHASE1":7570,"PHASE2":7587,"PHASE3":7589,"PHASE4":7591,"NA":7593},{"trials":7569,"activeCount":83},[],{"trials":7571,"activeCount":83},[7572,7581],{"nctId":7573,"briefTitle":7574,"status":89,"phases":7575,"primaryCompletion":7576,"completion":6813,"start":3282,"enrollment":1223,"conditions":7577,"interventions":7580},"NCT00493285","Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to \u003C 24 Months of Age",[72],"2009-11",[7578,30,7579],"Respiratory Viral Infections","Parainfluenza Virus 3, Human",[7566,7566,7566],{"nctId":7582,"briefTitle":7583,"status":89,"phases":7584,"completion":3059,"start":7417,"enrollment":1047,"conditions":7585,"interventions":7586},"NCT00345670","Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children",[72],[15],[7566,7566,7566],{"trials":7588,"activeCount":83},[],{"trials":7590,"activeCount":83},[],{"trials":7592,"activeCount":83},[],{"trials":7594,"activeCount":83},[7595],{"nctId":7596,"briefTitle":7597,"status":89,"phases":7598,"completion":1485,"start":7438,"enrollment":1047,"conditions":7599,"interventions":7601},"NCT00111878","Study to Evaluate MEDI-534 in Healthy Adults",[],[30,7600],"Parainfluenza Infections",[7566],{"intervention":7603,"totalTrials":480,"cells":7604},"Influenza vaccination",{"EARLY_PHASE1":7605,"PHASE1":7607,"PHASE2":7609,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7606,"activeCount":83},[],{"trials":7608,"activeCount":83},[],{"trials":7610,"activeCount":83},[],{"trials":7612,"activeCount":83},[],{"trials":7614,"activeCount":83},[],{"trials":7616,"activeCount":83},[7617],{"nctId":7618,"briefTitle":7619,"status":89,"phases":7620,"primaryCompletion":5150,"completion":2607,"start":1899,"enrollment":7621,"conditions":7622,"interventions":7623},"NCT00639418","A Study to Describe Pediatric Influenza Vaccine Coverage",[],147494,[15],[7603],{"intervention":7625,"totalTrials":480,"cells":7626},"No Intervention",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7628,"activeCount":83},[],{"trials":7630,"activeCount":83},[],{"trials":7632,"activeCount":83},[],{"trials":7634,"activeCount":83},[],{"trials":7636,"activeCount":83},[],{"trials":7638,"activeCount":83},[7639],{"nctId":7640,"briefTitle":7641,"status":89,"phases":7642,"primaryCompletion":962,"completion":962,"start":846,"enrollment":7643,"conditions":7644,"interventions":7646},"NCT00626808","A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children",[],321697,[21,7515,7645],"Immunosuppression",[7625],{"intervention":7648,"totalTrials":480,"cells":7649},"Choice of TIV or FluMist with baseline advertisement",{"EARLY_PHASE1":7650,"PHASE1":7652,"PHASE2":7654,"PHASE3":7656,"PHASE4":7658,"NA":7660},{"trials":7651,"activeCount":83},[],{"trials":7653,"activeCount":83},[],{"trials":7655,"activeCount":83},[],{"trials":7657,"activeCount":83},[],{"trials":7659,"activeCount":83},[],{"trials":7661,"activeCount":83},[7662],{"nctId":7663,"briefTitle":7664,"status":89,"phases":7665,"primaryCompletion":7666,"completion":791,"start":4299,"enrollment":7667,"conditions":7668,"interventions":7669},"NCT00808808","Assessing Choice in the Employer Setting (ACES) Study",[],"2008-11",4411,[15],[7648,7670],"Control - Usual care offering TIV only with baseline advertisement",{"intervention":7670,"totalTrials":480,"cells":7672},{"EARLY_PHASE1":7673,"PHASE1":7675,"PHASE2":7677,"PHASE3":7679,"PHASE4":7681,"NA":7683},{"trials":7674,"activeCount":83},[],{"trials":7676,"activeCount":83},[],{"trials":7678,"activeCount":83},[],{"trials":7680,"activeCount":83},[],{"trials":7682,"activeCount":83},[],{"trials":7684,"activeCount":83},[7685],{"nctId":7663,"briefTitle":7664,"status":89,"phases":7686,"primaryCompletion":7666,"completion":791,"start":4299,"enrollment":7667,"conditions":7687,"interventions":7688},[],[15],[7648,7670]]